

22-11-2019

09:45 - 11:25 **Type: Opening session** **Hall 406**
Title: Opening Ceremony
 Chair: Josep Tabernero, ES; Ravindran Kanesvaran, SG

09:45 - 09:50 **Singapore Cultural Dance performance**

09:50 - 10:00 **Welcome address by the ESMO President**
J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES

10:00 - 10:10 **Welcome address by the Senior Minister of State, Ministry of Transport & Ministry of Health**
P.M. Lam, Singapore, SG

10:10 - 10:15 **Welcome address by the President of the Singapore Society of Oncology**
S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG

10:15 - 10:35 **Presentation of Token of Appreciation to the endorsing National Oncology Societies**
J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES

10:35 - 10:45 **Scientific address**
R. Dent¹, I. Chau², ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

10:45 - 11:05 **Keynote 1 - Cancer burden in the Asia-Pacific region**
E. Weiderpass, International Agency for Research on Cancer, Lyon, FR

11:05 - 11:25 **Keynote 2 - Innate immunity, inflammation and cancer: The long journey to bedside**
A. Mantovani, Humanitas University, Milan, IT

11:40 - 12:20 **Type: Mini Oral session** **Room 311**
Title: Mini Oral session - Sarcoma
 Chair: Tom Wei-Wu Chen, TW; Silvia Stacchiotti, IT; Aisha Miah, GB

11:40 - 11:40 **Session DOI**

11:40 - 11:45 **4030 - The efficacy of eribulin methylate for patients with taxane-resistant cutaneous angiosarcoma: Final results from a multi-center, prospective, observational study**
Y. Fujisawa¹, K. Yoshino², T. Fujimura³, Y. Yamamoto⁴, H. Uchi⁵, H. Hata⁶, A. Otsuka⁷, T.

Miyagi⁸, T. Funakoshi⁹, S. Matsushita¹⁰, ¹University of Tsukuba, Tsukuba, JP, ²Komagome Hospital, Tokyo, JP, ³Tohoku University, Sendai, JP, ⁴Wakayama Medical University, Wakayama, JP, ⁵Kyushu University, Hakata, JP, ⁶Hokkaido University, Sapporo, JP, ⁷Kyoto University-Graduate school of medicine, Kyoto, JP, ⁸Ryukyu University, Naha, JP, ⁹Keio University, Tokyo, JP, ¹⁰National Hospital Organization Kagoshima Medical Center, Kagoshima, JP

11:45 - 11:50 **4040 - A phase II single arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classical Kaposi Sarcoma (CKS)**

A. Zer¹, O. Icht¹, O. Jacobi¹, E. Fenig¹, S. Shamai², O. Merimsky², R. Shapira³, H. Bernstine⁴, R. Weitzen⁵, O. Vornikova⁶, E. Ben-Ami⁵, G. Bar-Sela⁶, S. Stemmer¹, M. Lotem⁷, ¹Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, ²Tel Aviv Sourasky Medical Center, Tel Aviv, IL, ³Ella Institute for Immuno-Oncology and melanoma, Sheba medical center, Tel Aviv, IL, ⁴Rabin Medical Center, Beilinson Campus, Petah Tikva, IL, ⁵Chaim Sheba Medical Center, Ramat Gan, IL, ⁶HaEmek Medical Center, Afula, IL, ⁷Hadassah Ein Kerem, Jerusalem, IL

11:50 - 12:00 **Discussion led by moderators**

T.W.-W. Chen¹, S. Stacchiotti², A. Miah³, ¹NTU - National Taiwan University - College of Medicine, Taipei City, TW, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³The Royal Marsden Hospital - NHS Foundation Trust, London, GB

12:00 - 12:05 **4050 - Neutrophil-lymphocyte and platelet-lymphocyte ratios as robust prognostic markers in sarcomas: A population-based analysis of 3746 sarcoma patients from Hong Kong**

S.C.S. Kwan¹, C. Wong², C. Ho², Y.Z. Zhang³, T. Tse⁴, Y.-M. Lau⁴, L. Leung⁵, T. Tan⁴, H. Loong⁶, ¹Chinese CHUK - University of Hong Kong, Shatin, HK, ²The University of Hong Kong, Hong Kong, HK, ³Chinese University of Hong Kong, Sha Tin, HK, ⁴The Chinese University of Hong Kong, Sha Tin, HK, ⁵The Chinese University of Hong Kong, Hong Kong, HK, ⁶The Chinese University of Hong Kong, Shatin, HK

12:05 - 12:10 **4060 - VEGFR2 Polymorphisms as Novel Biomarker of Anti-angiogenic Therapy for Pediatric and Young Adult Sarcoma**

Q. Bao¹, Y. Hu², J. Wen², Y. Shen², W. Zhang², ¹Jiangshan City People's Hospital, Jiangshan City, CN, ²ruijin hospital, shanghai, CN

12:10 - 12:20 **Discussion led by moderators**

T.W.-W. Chen¹, S. Stacchiotti², A. Miah³, ¹NTU - National Taiwan University - College of Medicine, Taipei City, TW, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³The Royal Marsden Hospital - NHS Foundation Trust, London, GB

11:45 - 12:30 **Type: Challenge Your Expert session** **Hall 404**
Title: Optimal sequence and treatment choice in osimertinib failure
 Chair: Myung-Ju Ahn, KR

11:45 - 11:45 **Session DOI**

11:45 - 12:00 **Optimal sequence and treatment choice in osimertinib failure**
T.S.K. Mok, Prince of Wales Hospital, Hong Kong, CN

12:00 - 12:30 **Discussion**

11:45 - 12:30 **Type: Challenge Your Expert session** **Hall 407**
Title: Surgical management of ovarian cancer
 Chair: Amita Maheshwari, IN

11:45 - 11:45 **Session DOI**

11:45 - 12:00 **Surgical Management of Ovarian Cancer**
C. Marth, Innsbruck Medical University, Innsbruck, AT

12:00 - 12:30 **Discussion**
A. Maheshwari, Tata Memorial Hospital Centre, Mumbai, IN

11:45 - 12:30 **Type: Challenge Your Expert session** **Room**
Title: Locally advanced nasopharyngeal carcinoma (LA NPC): Asian and **324**
European perspectives
 Chair: Pierre Blanchard, FR; Anthony Chan, HK

11:45 - 11:45 **Session DOI**

11:45 - 12:15 **Locally advanced nasopharyngeal carcinoma (LA NPC): Asian and European perspectives**
A. Chan¹, P. Blanchard², ¹Prince of Wales Hospital, Shatin, HK, ²Institut Gustave Roussy, Villejuif, FR

12:15 - 12:30 **Discussion**

11:45 - 12:30 **Type: Challenge Your Expert session** **Summit**
Title: Immunotherapy in GU cancers: Focus on kidney and bladder **2**
cancers
 Chair: Cora Sternberg, US

11:45 - 11:45 **Session DOI**

11:45 - 11:55 **Kidney**
Y.L. Su, Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, TW

11:55 - 12:05 **Bladder**
R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

12:05 - 12:30 **Discussion**

12:45 - 14:15 **Type: Industry Satellite Symposium** **Hall**
Title: AstraZeneca - Changing the course for the lung cancer patient: A **405**
new direction
 Chair: Mei-Kim Ang, SG

12:45 - 12:50 **Introduction**
M.-K. Ang, NCCS - National Cancer Centre Singapore, Singapore, SG

12:50 - 13:35 **Charting the course for the stage III NSCLC patient**
N. Reinmuth, Asklepios-Fachklinikum, Gauting, DE

13:35 - 14:10 **Navigating the waters of ES-SCLC**
M.-J. Ahn, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

14:10 - 14:15 **Conclusions**
M.-K. Ang, NCCS - National Cancer Centre Singapore, Singapore, SG

12:45 - 14:15	<p>Type: Industry Satellite Symposium Title: AstraZeneca - PARP inhibitors as targeted therapy for personalised medicine Chair: John Chia, SG; Byoung-Gie Kim, KR</p>	Hall 404
12:45 - 12:50	<p>Introduction <u>B.-G. Kim</u>, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR</p>	
12:50 - 13:15	<p>PARPi maintenance: A new paradigm in the management of frontline ovarian cancer <u>S. Dawood</u>, Dubai Hospital Pacemaker & EP Clinics, Dubai, AE</p>	
13:15 - 13:30	<p>What's new in metastatic pancreatic cancer management? <u>T. Golan</u>, Chaim Sheba Medical Center, Ramat Gan, IL</p>	
13:30 - 13:45	<p>Recent advances in metastatic prostate cancer management <u>S. Sandhu</u>, Peter MacCallum Cancer Centre, Melbourne, AU</p>	
13:45 - 14:00	<p>Expert Opinion on 'PARP inhibitors as targeted therapy for personalized medicine' - Panel Discussion <u>J. Chia</u>, NCCS - National Cancer Centre Singapore, Singapore, SG</p>	
14:00 - 14:10	Q&A	
14:10 - 14:15	<p>Closing <u>B.-G. Kim</u>, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR</p>	

12:45 - 14:15	Type: ESMO Colloquium Title: ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC Chair: Ross Soo, SG; Marina Garassino, IT	Hall 407
12:45 - 12:45	Session DOI	
12:45 - 12:50	Introduction <u>R. Soo</u> , National University Hospital, 119047, Singapore, SG	
12:50 - 13:15	Immune-Check Points Inhibitors (ICI) in non-oncogenic addicted mNSCLC <u>M. Garassino</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	
13:15 - 13:40	EGFR mutant mNSCLC: Single agent or in combination? <u>F. Barlesi</u> , Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR	
13:40 - 14:05	Future development for the use of biomarkers <u>R. Soo</u> , National University Hospital, 119047, Singapore, SG	
14:05 - 14:10	Conclusion	

12:45 - 14:15	Type: Industry Satellite Symposium Title: Pfizer - From clinical trials to practice: Changing the trajectory for metastatic breast cancer patients Chair: Yen Shen Lu, TW; Yoon Sim Yap, SG	Room 324
12:45 - 12:48	Introduction of Speaker <u>Y.S. Lu</u> , National Taiwan University Hospital, Taipei, TW	
12:48 - 13:28	From clinical trials to practice: Changing the trajectory for metastatic breast cancer patients <u>R. Finn</u> , Geffen School of Medicine at UCLA, Los Angeles, US	
13:28 - 13:30	Introduction of Speaker <u>Y.S. Yap</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
13:30 - 13:45	Presentation of real world outcomes in ER+ HER2- mBC <u>S. Rajappa</u> , 2. Basavatkaram Indo American Cancer Hospital, Hyderabad, IN	
13:45 - 14:05	Panel discussion on management of mBC in Asian patients <u>S. Rajappa</u> , 2. Basavatkaram Indo American Cancer Hospital, Hyderabad, IN	
14:05 - 14:15	Q&A	

12:45 - 14:15 **Type: Industry Satellite Symposium** **Summit 2**
Title: Roche - Precision oncology in Asia: A new dawn or a false hope?
 Chair: David SP Tan, SG

12:45 - 12:50 **Introduction**
D.S. Tan, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

12:50 - 13:10 **The clinical significance of comprehensive genomic profiling**
S. Ikeda, Tokyo Medical and Dental University, Tokyo, JP

13:10 - 13:30 **Generating meaningful evidence with novel trial designs and real-world data**
R. Dienstmann, Vall d'Hebron University Hospital, Barcelona, ES

13:30 - 13:45 **South Korea's journey with precision oncology**
T.-Y. Kim, SNUH-Seoul National University Hospital, Seoul, KR

13:45 - 14:00 **Singapore's journey with precision oncology**
D.S. Tan, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

14:00 - 14:15 **Q&A and closing remarks**
D.S. Tan, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

12:45 - 14:15 **Type: Industry Satellite Symposium** **Room**
Title: MSD - A quantum leap in treatment of NSCLC and HNSCC with IO **311**
 Chair: Daniel Shao Weng Tan, SG

12:45 - 12:50 **Welcome, introductions and objectives of the session**
D.S.W. Tan, National Cancer Center Singapore, Singapore, SG

12:50 - 13:25 **The landscape and role of IO-Chemo combination in NSCLC treatment**
T. Mitsudomi, Kindai University - Faculty of Medicine, Osaka, JP

13:25 - 14:00 **Is immuno-oncology going to replace chemotherapy in advanced HNSCC?**
E. Cohen¹, D. Rischin², ¹Moore's Cancer Center at UC San Diego Health, La Jolla, US,
²Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, AU

14:00 - 14:15 **Q&A**
D.S.W. Tan, National Cancer Center Singapore, Singapore, SG

14:30 - 16:00 **Type: Educational session** **Hall 405**
Title: Integrating new treatment paradigms in breast cancer care in 2019
Chair: Yoon-Sim Yap, SG

14:30 - 14:30 **Session DOI**

14:30 - 14:55 **HER2-positive breast cancer: Escalation and de-escalation strategies in the neo/adjuvant setting, who and when**
A. Eniu, The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO

14:55 - 15:20 **Triple negative advanced breast cancer: Immunotherapy incorporation, who and when**
G. Curigliano, Istituto Europeo di Oncologia, Milan, IT

15:20 - 15:45 **HR-positive advanced breast cancer: CDK4 inhibitors, who and when**
S. Goel, Peter MacCallum Cancer Centre, Melbourne, AU

15:45 - 16:00 **Discussion**

14:30 - 16:00 **Type: Multidisciplinary tumour board** **Hall 404**
Title: Contemporary issues in cervical cancer management
 Chair: Mansoor Raza Mirza, DK

14:30 - 14:30 **Session DOI**

14:30 - 14:45 **Primary and secondary prevention**
S. Ahsan, OMI Hospital, Karachi, PK

14:45 - 14:55 **Presentation of case/condition**
T. Sadaf, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKM), Lahore, PK

14:55 - 15:10 **Surgical management: When and how?**
K. Fujiwara, Saitama Medical University Internatl Medical Centre, Saitama, JP

15:10 - 15:30 **Is there a role of neoadjuvant chemotherapy? EORTC and Indian trial presentations**
S. Gupta¹, G. Kenter², ¹Tata Memorial Hospital Centre, Mumbai, IN, ²Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL

15:30 - 16:00 **Discussion**
K. Fujiwara¹, M.R. Mirza², ¹Saitama Medical University Internatl Medical Centre, Saitama, JP, ²Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK

14:30 - 16:00 **Type: Proffered Paper session** **Hall 406**
Title: Proffered paper session - Thoracic cancers
 Chair: Myung-Ju Ahn, KR; Sanjay Popat, GB; Pilar Garrido Lopez, ES

14:30 - 14:30 **Session DOI**

14:30 - 14:42 **LBA15 - Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia**
M. Nishio¹, J.H. Ji², K. Hotta³, C.-H. Chiu⁴, J.-S. Lee⁵, K. Azuma⁶, S.-W. Kim⁷, S.-Y. Wu⁸, M. Dvorkin⁹, D. Trukhin¹⁰, L. Havel¹¹, M.J. Hochmair¹², M. Özgüroğlu¹³, J. Bar¹⁴, Y. Chen¹⁵, J.W. Goldman¹⁶, N. Byrne¹⁷, P.J. Laud¹⁸, N. Shire¹⁹, L. Paz-Ares²⁰, ¹The Cancer Institute Hospital of JFCR, Tokyo, JP, ²Samsung Changwon Hospital, Changwon, KR, ³Okayama, okayama, JP, ⁴Taipei Veterans General Hospital, Taipei City, TW, ⁵Seoul National University Bundang Hospital, Gyeonggi-do, KR, ⁶Kurume University Hospital, Fukuoka, JP, ⁷Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁸National Cheng Kung University Hospital, Tainan City, TW, ⁹BHI of Omsk Region Clinical Oncology Dispensary, Omsk, RU, ¹⁰Odessa National Medical University, Odessa, UA, ¹¹Thomayer Hospital, Charles University, Prague, CZ, ¹²Otto Wagner Hospital,

Sanatoriumstrasse 2, 1140, Vienna, AT, ¹³Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Fatih/İstanbul, TR, ¹⁴Sheba Medical Center, Ramat Gan, IL, ¹⁵Cancer & Hematology Centers of Western Michigan, Grand Rapids, US, ¹⁶David Geffen School of Medicine at UCLA, Los Angeles, US, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸University of Sheffield, Sheffield, GB, ¹⁹AstraZeneca, Gaithersburg, US, ²⁰University Hospital 12 De Octubre, Madrid, ES

14:42 - 14:54

4740 - Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

B.C. Cho¹, K.H. Lee², M.-J. Ahn³, S. Lucien Geater⁴, T.V. Ngoc⁵, C.-C. Wang⁶, E.K. Cho⁷, J.S. Lee⁸, V. Sriuranpong⁹, Q. Bui¹⁰, S. Clarke¹¹, S. Kuyama¹², K. Nakagawa¹³, F. Liu¹⁴, D. Clemett¹⁵, U. Scheuring¹⁶, S. Peters¹⁷, N. Rizvi¹⁸, ¹Yonsei University, Seoul, KR, ²Chungbuk National University Hospital, Cheongju, KR, ³Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Hat yai Hospital - Prince of Songkla University, Songkla, TH, ⁵Cho Ray Hospital, Ho Chi Minh, VN, ⁶Chang Gung Memorial Hospital, Kaoshiung, Kaoshiung, TW, ⁷Gachon University, Incheon, KR, ⁸Seoul National University Bundang Hospital, Seoul, KR, ⁹King Chulalongkorn Memorial Hospital, Bangkok, TH, ¹⁰Hanoi Oncology Hospital, Hanoi, VN, ¹¹Royal North Shore Hospital, St Leonards, AU, ¹²Chugoku Chuo Hospital, Fukuyama, JP, ¹³Kindai University Hospital, Osaka, JP, ¹⁴AstraZeneca, Gaithersburg, US, ¹⁵AstraZeneca, Macclesfield, GB, ¹⁶AstraZeneca UK, Melbourn, GB, ¹⁷Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ¹⁸Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

14:54 - 15:09

Invited Discussant LBA15 and 4740

S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB

15:09 - 15:21

4750 - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

Y.-L. Wu¹, T.S.K. Mok², J.-Y. Han³, M.-J. Ahn⁴, A. Delmonte⁵, S. Ramalingam⁶, S.-W. Kim⁷, F. Shepherd⁸, J. Laskin⁹, Y. He¹⁰, H. Akamatsu¹¹, W. Theelen¹², W.-C. Su¹³, T. John¹⁴, M. Sebastian¹⁵, H. Mann¹⁶, M. Miranda¹⁶, G. Laus¹⁷, Y. Rukazenzov¹⁸, V. Papadimitrakopoulou¹⁹, ¹Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ²Prince of Wales Hospital, Hong Kong, CN, ³National Cancer Center, Goyang, KR, ⁴Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, ⁶Emory University Winship Cancer Institute, Atlanta, US, ⁷Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁸Princess Margaret Cancer Center, Toronto, CA, ⁹BC Cancer Agency - Vancouver, Vancouver, CA, ¹⁰Daping Hospital, Chongqing, CN, ¹¹Wakayama Medical University, Wakayama, JP, ¹²Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, ¹³National Cheng Kung University Hospital, Tainan, TW, ¹⁴Austin Health, Melbourne, AU, ¹⁵Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ¹⁶AstraZeneca, Cambridge, GB, ¹⁷AstraZeneca UK, Melbourn, GB, ¹⁸Astrazeneca, Macclesfield, GB, ¹⁹MD Anderson

Cancer Center, Houston, US

15:21 - 15:33

LBA16 - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

B.C. Cho¹, Y. Ohe², C. Zhou³, T. Reungwetwattana⁴, Y. Cheng⁵, B. Chewaskulyong⁶, K.H. Lee⁷, D. Planchard⁸, J. Vansteenkiste⁹, J. Gray¹⁰, R. Shah¹¹, P.K. Cheema¹², M. Tiseo¹³, T. John¹⁴, R. Hodge¹⁵, Y. Rukazenzov¹⁶, J.-C. Soria¹⁷, M.-C. Lin¹⁸, F. Imamura¹⁹, S. Ramalingam²⁰, ¹Yonsei University, Seoul, KR, ²National Cancer Center Hospital, Tokyo, JP, ³Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ⁴Ramathibodi Hospital, Bangkok, TH, ⁵Jilin Province Cancer Hospital, Changchun, CN, ⁶Maharaj Nakorn Chiang Mai Hospital Faculty of Medicine, Chiang Mai, TH, ⁷Chungbuk National University Hospital, Cheongju, KR, ⁸Institut Gustave Roussy, Villejuif, FR, ⁹University Hospitals Leuven, Leuven, BE, ¹⁰H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ¹¹Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, GB, ¹²William Osler Health System, University of Toronto, Toronto, CA, ¹³University Hospital of Parma, Parma, IT, ¹⁴Austin Health, Melbourne, AU, ¹⁵AstraZeneca, Cambridge, GB, ¹⁶Astrazeneca, Macclesfield, GB, ¹⁷17. Early Oncology, Research & Development, AstraZeneca, Gaithersburg, Maryland / Université Paris-Sud, Villejuif / Orsay, FR, ¹⁸18. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung, TW, ¹⁹Osaka International Cancer Institute, Osaka, JP, ²⁰Emory University Winship Cancer Institute, Atlanta, US

15:33 - 15:45

LBA17 - Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA

T. Reungwetwattana¹, J. Gray², A. Markovets³, N. Nogami⁴, J.S. Lee⁵, B.C. Cho⁶, B. Chewaskulyong⁷, M. Majem⁸, N. Peled⁹, K. Vishwanathan³, A. Todd¹⁰, Y. Rukazenzov¹¹, M. Johnson¹⁰, C. Barrett³, J. Chmielecki³, R. Hartmaier³, S. Ramalingam¹², ¹Ramathibodi Hospital, Bangkok, TH, ²H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ³AstraZeneca, Boston, US, ⁴Shikoku Cancer Center, Matsuyama, JP, ⁵Seoul National University Bundang Hospital, Seoul, KR, ⁶Yonsei University, Seoul, KR, ⁷Maharaj Nakorn Chiang Mai Hospital Faculty of Medicine, Chiang Mai, TH, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁹Ben-Gurion University, Beer Sheva, IL, ¹⁰AstraZeneca, Cambridge, GB, ¹¹Astrazeneca, Macclesfield, GB, ¹²Emory University Winship Cancer Institute, Atlanta, US

15:45 - 16:00

Invited Discussant 4750, LBA16 and LBA17

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

14:30 - 16:00 **Type: Educational session** **Hall 407**
Title: Precision medicine in advanced gastrointestinal cancer
Chair: Tae Won Kim, KR; Fortunato Ciardiello, IT

14:30 - 14:30 **Session DOI**

14:30 - 14:50 **Clinical applications of circulating tumour DNA in advanced setting**
F. Ciardiello, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT

14:50 - 15:10 **Targeted treatment in gastroesophageal cancer: The present and the future**
S. Lorenzen, Rechts der Isar Hospital, TUM, Munich, DE

15:10 - 15:30 **Precision medicine in metastatic colorectal cancer**
T.W. Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

15:30 - 16:00 **Discussion**

14:30 - 16:00 **Type: Collaborative session** **Room**
Title: ESMO - JSMO Collaborative Session: Guideline harmonisations **324**
and international consensus
 Chair: George Pentheroudakis, GR; Takayuki Yoshino, JP

14:30 - 14:30 **Session DOI**

14:30 - 14:35 **Introduction**

G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR

14:35 - 14:55 **Overview of the (ESMO Clinical Practice) Guidelines adaptation initiative**

G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR

14:55 - 15:15 **Outcome of the Consensus Conference on agnostic treatments**

T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP

15:15 - 15:35 **Harmonisation and international consensus? Differences in evaluation of an agnostic approach between agencies (EMA, FDA, PMDA)**

F. Pignatti, European Medicines Agency (EMA), London, GB

15:35 - 15:55 **Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer**

K. Muro, Aichi Cancer Center Hospital, Nagoya, JP

15:55 - 16:00 **Conclusions**

T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP

14:30 - 15:20 **Type: Mini Oral session** **Summit 2**
Title: Mini Oral session - Genitourinary tumours
 Chair: Arun Azad, AU; Manuela Schmidinger, AT; Ben Tran, AU

14:30 - 14:30 **Session DOI**

14:30 - 14:35 **LBA8 - PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations**

S. Sandhu¹, M. Hussain², J. Mateo³, K. Fizazi⁴, F. Saad⁵, N. Shore⁶, K. Chi⁷, O. Sartor⁸, N. Agarwal⁹, D. Olmos¹⁰, A. Thiery-Vuillemin¹¹, P. Twardowski¹², N. Mehra¹³, C. Goessl¹⁴, J. Kang¹⁵, J. Burgents¹⁶, W. Wu¹⁵, A. Kohlmann¹⁷, C. Adelman¹⁸, J. De Bono¹⁹,
 1Peter MacCallum Cancer Centre, Melbourne, AU, 2Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, US, 3Vall d'Hebron University Hospital, Barcelona, ES, 4Institut Gustave Roussy, Villejuif, FR, 5Centre Hospitalier de l'Université de Montréal/CRCHUM, Montreal, CA, 6Carolina Urologic Research Center, Myrtle Beach, US, 7BC Cancer Agency, Vancouver, CA,

⁸Tulane University, New Orleans, US, ⁹Huntsman Cancer Institute, University of Utah (NCI-CCC), Salt Lake City, US, ¹⁰Spanish National Cancer Research Centre (CNIO), & Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Madrid, ES, ¹¹CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ¹²Providence John Wayne Cancer Institute, Santa Monica, US, ¹³Radboud University Medical Center, Nijmegen, NL, ¹⁴BN ImmunoTherapeutics, Inc., Mountain View, US, ¹⁵AstraZeneca, Gaithersburg, US, ¹⁶Merck & Co., Inc. - Upper Gwynedd Site, North Wales, US, ¹⁷AstraZeneca UK, Royston, GB, ¹⁸AstraZeneca, Cambridge, GB, ¹⁹The Institute of Cancer Research and Royal Marsden, London, GB

14:35 - 14:40 **Discussion led by moderator**

A. Azad, Monash Medical Centre, Clayton, AU

14:40 - 14:45 **LBA9 - Real-world assessment of clinical effectiveness and safety of pazopanib in patients with advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: A prospective, observational study (PARACHUTE)**

R. Kanessvaran¹, B. Biswas², P. Danchaivijitr³, C.S. Lim⁴, B. Karabulut⁵, Y.F. Wong⁶, H. Coskun⁷, C.-H. Chang⁸, I. Cicin⁹, S. Ingles¹⁰, K. Slimane¹¹, M. Erman¹², ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Tata Medical Center, Kolkata, IN, ³Siriraj Hospital, Mahidol University, Bangkok, TH, ⁴Hospital Sultan Ismail, Johor, MY, ⁵Ege University Medical Faculty, Izmir, TR, ⁶National Cancer Institute, Putrajaya, MY, ⁷Akdeniz University Medical Oncology, Antalya, TR, ⁸China Medical university Hospital, Taichung, TW, ⁹Trakya University, Edirne, TR, ¹⁰Novartis Pharma AG, Basel, CH, ¹¹Novartis, Magny Le Hongre, FR, ¹²Hacettepe University, Ankara, TR

14:45 - 14:50 **2080 - Association between kidney function, proteinuria and the risk of kidney cancer: A nationwide cohort study involving 10 million participants**

J. Park¹, D.W. Shin², K. Han³, S. Chun², ¹Eulji University Hospital, Daejeon, KR, ²Samsung Medical Center, Seoul, KR, ³The Catholic University of Korea, Seoul, KR

14:50 - 15:00 **Discussion led by moderator**

M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

15:00 - 15:05 **2090 - A novel risk-based approach simulating oncologic surveillance according to smoking status after radical nephroureterectomy with upper tract urothelial carcinoma**

K. Shigeta, E. Kikuchi, T. Abe, M. Hagiwara, K. Ogihara, N. Tanaka, T. Takeda, K. Matsumoto, R. Mizuno, M. Oya, Keio University School of Medicine, Tokyo, JP

15:05 - 15:10 **2100 - High incidence and mortality of transitional cell carcinoma in Thai kidney transplant patients**

S. Laowalert¹, N. Prasongsook², T. Ativitasvas², W. Liwlompaisan¹, P. Thanak¹, N. Techawathanawanna¹, R. Khunprakant¹, V. Mavichak¹, ¹Kidney Transplantation Institute, Praram 9 hospital, Bangkok, TH, ²Cancer center, Praram 9 hospital, Bangkok, TH

15:10 - 15:20 **Discussion led by moderator**

B. Tran, Peter MacCallum Cancer Centre, Melbourne, AU

14:30 - 16:00 **Type: Educational session** **Room 326**
Title: Improving cancer care in Asia
 Chair: Gouri Shankar Bhattacharyya, IN; Soe Aung, MM

14:30 - 14:30 **Session DOI**

14:30 - 14:50 **Challenges in implementing National Cancer Control Plans in LMCs**
A. Ilbawi, WHO - World Health Organization, Geneva, CH

14:50 - 15:10 **Population-based cancer registries in Asia**
G.S. Bhattacharyya, G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center,, Kolkata, IN

15:10 - 15:30 **Using cancer registries for drug development**
G.B. Kanakasetty, Curie Centre Of Oncology-Hcg Hospital Koramangala, Bangalore, IN

15:30 - 15:50 **How to measure and improve quality of cancer care in Asia**
S. Aung, Myanmar Center of Chemotherapy, Yangon, MM

15:50 - 16:00 **Discussion**

15:00 - 16:00 **Type: Mini Oral session** **Room 311**
Title: Mini Oral session - Developmental and precision medicine
 Chair: Noboru Yamamoto, JP; Fabrice André, FR

15:00 - 15:00 **Session DOI**

15:00 - 15:05 **3630 - Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)**
D.H. Lee¹, V. Subbiah², J. Gainor³, M. Taylor⁴, V. Zhu⁵, R. Doebele⁶, G. Lopes⁷, C. Baik⁸, E. Garralda⁹, S. Gadgeel¹⁰, D.-W. Kim¹¹, C. Turner¹², M. Palmer¹², S. Miller¹³, G. Curigliano¹⁴, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Massachusetts General Hospital, Boston, US, ⁴OHSU Knight Cancer Institute - Northwest Portland, Portland, US, ⁵UC Irvine, Orange, US, ⁶University of Colorado, Aurora, US, ⁷University of Miami Sylvester Comprehensive Cancer Center, Miami, US, ⁸University of Washington/Seattle Cancer Care Alliance, Seattle, US, ⁹Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ¹⁰University of Michigan, Ann Arbor, US, ¹¹Seoul National University Hospital, Seoul, KR, ¹²Blueprint Medicines Corporation,

Cambridge, US, ¹³Blueprint Medicines, Cambridge, US, ¹⁴Istituto Europeo di Oncologia, Milan, IT

- 15:05 - 15:10 **3640 - Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC**
L. Mezquita¹, D. Planchard¹, M. Dorta Suarez¹, M. Aldea¹, C. Naltet¹, V. Lamberts¹, M. Grecea¹, P. Martin-Romano¹, F. De Kievit², C. Jovelet¹, L. Lacroix¹, J. Remon Masip³, P. Lavaud¹, A. Gazzah¹, C. Morris², K. Howarth², E. Green², G. Vassal¹, C. Massard⁴, B. Besse¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Inivata Ltd, Cambridge, GB, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR
- 15:10 - 15:15 **3650 - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer**
D. Hyman¹, D.S.W. Tan², C. Van Tilburg³, C. Albert⁴, B. Georger⁵, A. Farago⁶, T. Laetsch⁷, S. Kummar⁸, F. Doz⁹, U. Lassen¹⁰, S. Dubois¹¹, R. Mcdermott¹², L. Mascarenhas¹³, J. Berlin¹⁴, E. Rudzinski¹⁵, S. Nanda¹⁶, B. Childs¹⁶, A. Drilon¹⁷, D. Hong¹⁸, ¹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, ²National Cancer Center Singapore, Singapore, SG, ³Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, DE, ⁴University of Washington, Fred Hutchinson Cancer Research Center, Seattle, US, ⁵Université Paris-Sud, Université Paris-Saclay, Villejuif, FR, ⁶Massachusetts General Hospital Cancer Center, Boston, US, ⁷Southwestern Medical Center/Children's Health, Dallas, US, ⁸Stanford University, Palo Alto, US, ⁹Paris Descartes University, Paris, FR, ¹⁰Rigshospitalet, Copenhagen, DK, ¹¹Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, US, ¹²St. Vincent's University Hospital and Cancer Trials Ireland, Dublin, IE, ¹³University of Southern California, Keck School of Medicine, Los Angeles, US, ¹⁴Vanderbilt University, Nashville, US, ¹⁵Seattle Children's Hospital and University of Washington Medical Center, Seattle, US, ¹⁶Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, ¹⁷Memorial Sloan Kettering Cancer Center, New York, US, ¹⁸MD Anderson Cancer Center, Houston, US
- 15:15 - 15:30 **Discussion led by moderators**
N. Yamamoto¹, F. André², ¹National Cancer Center Hospital, Tokyo, JP, ²Gustave Roussy - Cancer Campus, Villejuif, FR
- 15:30 - 15:35 **610 - Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours**
D.-Y. Oh¹, E. Hamilton², D. Hanna³, M. Beeram⁴, K.-W. Lee⁵, Y.-K. Kang⁶, J. Chaves⁷, J.-Y. Lee⁸, R. Goodwin⁹, C. Vaklavas¹⁰, S.-Y. Rha¹¹, E. Elimova¹², J. Mayordomo¹³, C. Ferrario¹⁴, M. Cobleigh¹⁵, A. Fortenberry¹⁶, G. Rowse¹⁷, T. Gray¹⁷, R. Lai¹⁶, F. Meric Bernstam¹⁸, ¹Seoul National University Hospital, Seoul, KR, ²Sarah Cannon Research Institute and Tennessee Oncology, Nashville Tennessee, US, ³USC Norris Comprehensive Cancer Center, Los Angeles, US, ⁴The START Center for Cancer Care, San Antonio Texas, US, ⁵National University of Seoul Bundang Hospital, Bundang, KR, ⁶Asan Medical Center, Bundang, KR, ⁷Northwest Medical Specialties, Tacoma Washington, US, ⁸Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR,

⁹University of Ottawa Cancer Centre, Ottawa Ontario, US, ¹⁰University of Alabama Cancer Center, Birmingham Alabama, US, ¹¹Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ¹²Princess Margaret Cancer Centre, Toronto Ontario, CA, ¹³University of Colorado Cancer Center, Denver Colorado, US, ¹⁴Jewish General Hospital, Montreal Quebec, CA, ¹⁵Rush University Medical Center, Chicago Illinois, US, ¹⁶Zymeworks Inc, Vancouver, CA, ¹⁷Zymeworks Inc., Vancouver, CA, ¹⁸The University of Texas MD Anderson Cancer Center, Houston Texas, US

15:35 - 15:40

620 - Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study

L. Cummings¹, K. Park², E. Felip³, R. Veillon⁴, A. Cortot⁵, J. Mazieres⁶, H. Sakai⁷, S. Viteri⁸, Y.-M. Chen⁹, J.-Y. Han¹⁰, T.-W. Jang¹¹, M. Morise¹², T. Sakamoto¹³, T. Tokito¹⁴, B.C. Cho¹⁵, R. Bruns¹⁶, J. Scheele¹⁶, J. Straub¹⁶, X. Le¹⁷, P. Paik¹⁸, N. Reinmuth¹⁹, ¹Bioscript, Macclesfield, GB, ²Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Hopital Universitaire de Bordeaux, Pessac, FR, ⁵Lille University Hospital, Univ. Lille, Lille, FR, ⁶CHU de Toulouse-Hopital Larrey, Toulouse, FR, ⁷Saitama Cancer Center, Saitama, JP, ⁸Dr Rosell Oncology Institute, Dexeus University Hospital, QuironSalud Group, Barcelona, ES, ⁹Taipei Veterans General Hospital, Taipei, TW, ¹⁰Research Institute, National Cancer Center, Gyeonggi-do, KR, ¹¹Kosin University Gospel Hospital, Busan, KR, ¹²Nagoya University, Graduate School of Medicine, Nagoya, JP, ¹³Tottori University Hospital, Tottori, JP, ¹⁴Kurume University Hospital, Fukuoka-Ken, JP, ¹⁵Yonsei University, Seoul, KR, ¹⁶Merck KGaA, Darmstadt, DE, ¹⁷MD Anderson Cancer Center, The University of Texas, Houston, US, ¹⁸Memorial Sloan Kettering Cancer Center, New York, US, ¹⁹Asklepios-Fachklinikum, Gauting, DE

15:40 - 15:45

630 - NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib

Y. Goto¹, J. Cadranel², B.A. Weinberg³, M. Duruisseaux⁴, S.V. Liu⁵, K. Tolba⁶, E. Branden⁷, R.C. Doebele⁸, C. Heining⁹, R.F. Schlenk¹⁰, J.J. Laskin¹¹, P.K. Cheema¹², M.R. Jones¹³, D. Trombetta¹⁴, L.A. Muscarella¹⁵, A. Cseh¹⁶, F. Solca¹⁷, D.J. Renouf¹¹, ¹National Cancer Center Hospital, Tokyo, JP, ²Hôpital Tenon APHP and Sorbonne Université, Paris, FR, ³Georgetown University Medical Center, Washington, US, ⁴Hospices Civils de Lyon Cancer Institute, Lyon, FR, ⁵Georgetown University, Washington, US, ⁶Oregon Health and Science University, Portland, US, ⁷Gävle Hospital, Gävle, SE, ⁸University of Colorado Cancer Center, Aurora, US, ⁹National Center for Tumor Diseases Dresden, Dresden, DE, ¹⁰Heidelberg University Hospital and German Cancer Research Center, Heidelberg, DE, ¹¹University of British Columbia, BC Cancer, Vancouver, CA, ¹²University of Toronto, Toronto, CA, ¹³QIAGEN Inc., Redwood City, US, ¹⁴Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, IT, ¹⁵Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ¹⁶Boehringer Ingelheim, Vienna, AT, ¹⁷Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, AT

15:45 - 16:00

Discussion led by moderators

N. Yamamoto¹, F. André², ¹National Cancer Center Hospital, Tokyo, JP, ²Gustave Roussy - Cancer Campus, Villejuif, FR

16:00 - 16:30	Type: Young Oncologist session Title: Meet your mentor Chair: Fatima Cardoso, PT; Florian Lordick, DE; Jyoti Bajpai, IN; John Haanen, NL; Marina Garassino, IT	Exhibition area
16:30 - 18:00	Type: Educational session Title: Precision immunotherapy Chair: Han Chong Toh, SG; Emanuela Romano, FR	Hall 405

16:30 - 16:30	Session DOI	
16:30 - 16:45	Basic concepts arguing for the use of neoadjuvant immunotherapy <u>M. Teng</u> , QIMR Berghofer Medical Research Institute, Brisbane, AU	
16:45 - 17:00	Precision medicine in cellular therapies: How can we identify patients who would benefit most <u>A. Gros</u> , Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES	
17:00 - 17:15	New biomarkers for checkpoint inhibitor therapy <u>J. Desai</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
17:15 - 17:30	Basic concepts in overcoming adaptive immune resistance <u>J. Haanen</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL	
17:30 - 18:00	Discussion	

16:30 - 18:00	Type: Proffered Paper session Title: Mixed Proffered paper session - Gastrointestinal tumours & Head and neck cancers Chair: Sjoukje Oosting, NL; Anthony T C Chan, HK; Takayuki Yoshino, JP; Sylvie Lorenzen, DE	Hall 404
----------------------	---	-----------------

16:30 - 16:30	Session DOI	
16:30 - 16:45	LBA7 - Randomised efficacy and safety results for atezolizumab (Atezo) &#x0002B; bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC) <u>C.-H. Hsu</u> ¹ , M. Lee ² , K.-H. Lee ³ , K. Numata ⁴ , S. Stein ⁵ , W. Verret ⁶ , S. Hack ⁶ , J. Spahn ⁶ , B. Liu ⁶ , C. Huang ⁷ , R. He ⁸ , B.-Y. Ryoo ⁹ , ¹ National Taiwan University Hospital, Taipei City, TW, ² University of North Carolina at Chapel Hill, Chapel Hill, US, ³ Seoul National University Hospital, Seoul, KR, ⁴ Yokohama City University Medical Center, Yokohama, JP, ⁵ Yale School of Medicine, New Haven, US, ⁶ Genentech, Inc., South San Francisco, US, ⁷ Roche Product Development, Shanghai, CN, ⁸ Georgetown University Medical Center,	

Washington, US, ⁹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

16:45 - 16:55 **Invited Discussant LBA7**

S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG

16:55 - 17:10 **2860 - Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis**

N. Ngamphaiboon¹, K. Tanaka², R.-L. Hong³, W.Z. Wan Ishak⁴, C.-J. Yen⁵, V. Sriuranpong⁶, S. Takahashi⁷, V. Srimuninnimit⁸, S.-P. Yeh⁹, N. Oridate¹⁰, M.-H. Yang¹¹, N. Nohata¹², Y. Koh¹³, A. Roy¹⁴, B. Gumuscu¹⁵, R. Swaby¹⁶, M. Tahara¹⁷, ¹ramathibodi, prayathia, TH, ²Kinki University School of Medicine, Osaka, JP, ³National Taiwan University Hospital, Taipei City, TW, ⁴University Malaya, Kuala Lumpur, MY, ⁵National Cheng Kung University, Tainan, TW, ⁶Chulalongkorn University Faculty of Medicine, Pathumwan, TH, ⁷Cancer Institute Hospital of JFCR, Tokyo, JP, ⁸Siriraj Piyamaharajkarun Hospital, TH, ⁹China Medical University Hospital, Taichung, TW, ¹⁰Yokohama City University Graduate School of Medicine, Yokohama, JP, ¹¹Taipei Veterans General Hospital, Taipei, TW, ¹²MSD k.k., Tokyo, JP, ¹³Shizuoka Cancer Center, Shizuoka, JP, ¹⁴Merck & Co., Inc., Kenilworth, US, ¹⁵Merck, North Wales, US, ¹⁶Merck & Co Inc, North Wales, US, ¹⁷National Cancer Center Hospital East, Kashiwa, JP

17:10 - 17:20 **Invited Discussant 2860**

B. Ma, The Chinese University of Hong Kong, Shatin, HK

17:20 - 17:35 **2870 - Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal cancer (NPC) to adjuvant therapy**

E. Hui¹, W.F. Li², B.B.Y. Ma³, F. Mo³, W.K.J. Lam³, K.C.A. Chan³, Q.H. Ai³, A.D. King³, C.H. Wong³, R. Guo², D.M.C. Poon³, M. Tong³, L. Li³, T.K.H. Lau³, K.C.W. Wong³, D.C.M. Lam³, Y.M.D. Lo³, J. Ma², A.T.C. Chan³, ¹The Chinese University of Hong Kong, Shatin, HK, ²Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, CN, ³State Key Laboratory of Translational Oncology, Sir YK Pao Cancer Center, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, HK

17:35 - 17:45 **Invited Discussant 2870**

M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

16:30 - 18:00 **Type: Educational session** **Hall 407**
Title: Tumour agnostic drug development
 Chair: Chia-Chi Lin, TW; Christian Dittrich, AT

16:30 - 16:30 **Session DOI**

16:30 - 16:50 **Challenges of different genomic platforms used to select patients**

C.-C. Lin, National Taiwan University Hospital, Taipei City, TW

16:50 - 17:10 **Basket trial design in tumour agnostic drug development**

C. Dittrich, Angewandte Krebsforschung - Institution für Translationale Forschung Wien (ACR-ITR VIENNA), Vienna, AT

17:10 - 17:30 **Targeted therapy with TRK inhibitors in tumours with NTRK fusion**

D.S.W. Tan, National Cancer Center Singapore, Singapore, SG

17:30 - 17:50 **Basket trials in rare cancer in Japan (and an overview of Asia)**

K. Yonemori, National Cancer Center Hospital, Tokyo, JP

17:50 - 18:00 **Discussion**

16:30 - 18:00	<p>Type: Collaborative session Title: ESMO - CSCO Collaborative Session: Drug prioritisation and support of biomarkers Chair: Jin Li, CN; E.G. Elisabeth De Vries, NL</p>	Room 324
16:30 - 16:30	Session DOI	
16:30 - 16:35	<p>Introduction E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL</p>	
16:35 - 16:55	<p>ESMO Magnitude of Clinical Benefit Scale (MCBS): Present status and online tools E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL</p>	
16:55 - 17:15	<p>Precision medicine and ESMO Scale for Clinical Actionability of molecular Target (ESCAT) biomarkers F. André, Gustave Roussy - Cancer Campus, Villejuif, FR</p>	
17:15 - 17:35	<p>Landscape of phase I oncology studies in China Z. Li, Sun Yat-sen University Cancer Center, Guangzhou, CN</p>	
17:35 - 17:55	<p>Development of biomarker driven clinical studies in China X. Zhang, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN</p>	
17:55 - 18:00	<p>Conclusions J. Li, Merck Serono Pharmaceutical R&D Co, Beijing, CN</p>	

16:30 - 18:00	Type: Multidisciplinary tumour board Title: The multi-modality approach to sarcomas: Balancing cure and quality of life Chair: Anastasia Constantinidou, CY	Summit 2
16:30 - 16:30	Session DOI	
16:30 - 16:32	Introduction <u>A. Constantinidou</u> , Bank of Cyprus Oncology Centre, Nicosia, CY	
16:32 - 16:47	Localized disease: Retroperitoneal <u>A. Miah</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
16:47 - 17:02	Locally advanced disease <u>M. Endo</u> , Kyushu University - Graduate School of Medical Sciences - Faculty of medical Sciences, Fukuoka, JP	
17:02 - 17:17	Oligo metastatic (focusing on lung metastases) <u>A. Constantinidou</u> , Bank of Cyprus Oncology Centre, Nicosia, CY	
17:17 - 17:32	Multi-focal metastatic <u>F. Gracieux Jr.</u> , Philippine General Hospital, Manila, PH	
17:32 - 17:57	Panel discussion	
17:57 - 18:00	Conclusions	

16:30 - 18:00 **Type: Special Session** **Room 311**
Title: Biosimilars use in oncology: Clarifying concepts
 Chair: Josep Tabernero, ES

16:30 - 16:30 **Session DOI**

16:30 - 16:35 **Welcoming remarks**

J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES

16:35 - 16:55 **Biosimilars use in clinical practice (Example of the EU)**

R. Giuliani, The Christie NHS Foundation Trust, Manchester, GB

16:55 - 17:15 **Clarifying immunogenicity, switching & extrapolation in oncology biosimilars**

G.S. Bhattacharyya, G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center,, Kolkata, IN

17:15 - 17:35 **Do biosimilars really save cost in practice?**

P. Basumatary, Singapore, SG

17:35 - 17:55 **Panel discussion**

17:55 - 18:00 **Concluding remarks**

J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES

16:30 - 17:30 **Type: Mini Oral session** **Room 326**
Title: Mini Oral session - Supportive and palliative care
 Chair: Matti Aapro, CH; Masanori Mori, JP; Kiley Loh, SG

16:30 - 16:30 **Session DOI**

16:30 - 16:35 **4190 - Olanzapine combined with 5-HT3 RA plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in cancer patients: A systematic review and meta-analysis of randomized controlled trials**

J.-G. Zhou¹, S.-H. Jin², H. Ma³, ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²Zunyi Medical College Affiliated Stematological Hospital, Zunyi City, CN, ³Zunyi Medical College Affiliated Hospital, Zunyi City, CN

16:35 - 16:40 **4200 - Role of cardioprotective therapies for prevention of cardiotoxicity in breast cancer: A systematic review and meta-analysis**

Y.C. Kong¹, M. Sener², S. Subramaniam³, N. Bhoo-Pathy⁴, ¹National Clinical Research Centre, Kuala Lumpur, MY, ²Erasmus University Medical Centre, Rotterdam, NL, ³Ministry of Health, Setia Alam, MY, ⁴University Malaya Medical Center, Kuala Lumpur,

MY

- 16:40 - 16:50 **Discussion led by moderator**
M. Aapro, Clinique de Genolier, Genolier, CH
- 16:50 - 16:55 **4210 - Effects of an educational program on knowledge and quality of life for Korean breast cancer survivors: A prospective cohort study**
J. Cheon, J. Bae, Y. Choi, B.K. Ko, J.S. Kim, C.R. Kim, J.H. Kim, S.-J. Koh, Ulsan University Hospital, Ulsan, KR
- 16:55 - 17:00 **4220 - Needs of cancer patients in an Asian setting**
N. Bhoo-Pathy¹, Y.C. Kong², R.S. Bustamam³, A. Matin Mellor Bin⁴, H. Zaharah⁵, N.A. Taib¹, G.F. Ho¹, C.H. Yip⁴, ¹University Malaya Medical Center, Kuala Lumpur, MY, ²University of Malaya, Kuala Lumpur, MY, ³Kuala Lumpur Hospital, Kuala Lumpur, MY, ⁴Sime Darby Medical Centre Subang Jaya, Subang Jaya, MY, ⁵National Cancer Institute, Putrajaya, MY
- 17:00 - 17:10 **Discussion led by moderator**
K. Loh, Singapore Society of Oncology, Singapore, SG
- 17:10 - 17:15 **3510 - The FAFA (FAn on FAcE) trial: A randomized clinical trial on the effect of a fan blowing air on the face to relieve dyspnea in Filipino patients with terminal cancer**
F.I. Ting, C.E. Barbon, S. Estreller, H.M.J. Strebhel, University of the Philippines - Philippine General Hospital, Manila, PH
- 17:15 - 17:20 **3520 - Parenting experiences of cancer patients with minor children and their conversations about the possibility of death: A cross-sectional web-based survey for the online cancer community**
Y. Usui¹, K. Kosugi¹, Y. Nishiguchi², T. Miura¹, D. Fujisawa³, Y. Uehara¹, T. Kawaguchi⁴, K. Izumi⁵, J. Takehana⁵, Y. Matsumoto¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²General Incorporated Association Cancer Parents, Tokyo, JP, ³Keio University School of Medicine, Tokyo, JP, ⁴Tokyo University of Pharmacy and Life Sciences, Hachioji, JP, ⁵Medilead Inc, Tokyo, JP
- 17:20 - 17:30 **Discussion led by moderator**
M. Mori, Seirei Christopher University, Hamamatsu, JP

23-11-2019

08:00 - 08:45 **Type: Challenge Your Expert session** **Hall 404**
Title: Immunotherapy in gastroesophageal cancers: Present and future
 Chair: Kei Muro, JP

08:00 - 08:00 **Session DOI**

08:00 - 08:15 **Immunotherapy in gastroesophageal cancers: Present and future**
F. Lordick, Uniklinikum Leipzig - Gefaessmedizinisches Zentrum, Leipzig, DE

08:15 - 08:45 **Discussion**

08:00 - 08:45 **Type: Challenge Your Expert session** **Hall 407**
Title: To use or not to use: Genomics assays in guiding adjuvant treatment of HR positive breast cancer
 Chair: Soo Chin Lee, SG; Giuseppe Curigliano, IT

08:00 - 08:00 **Session DOI**

08:00 - 08:15 **To use or not to use: Genomics assays in guiding adjuvant treatment of HR positive breast cancer**
F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT

08:15 - 08:45 **Discussion**

08:00 - 08:45 **Type: Challenge Your Expert session** **Room 324**
Title: How to manage toxicity of immunotherapy
 Chair: Mohamad Farid Harunal Rashid, SG

08:00 - 08:00 **Session DOI**

08:00 - 08:15 **How to manage toxicity of immunotherapy**
J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

08:15 - 08:45 **Discussion**

08:00 - 08:45 **Type: Challenge Your Expert session** **Summit 2**
Title: Management of irAEs in patients from Asia

Chair: Emanuela Romano, FR

08:00 - 08:00 **Session DOI**

08:00 - 08:25 **Management of irAEs in patients from Asia**

H.-F. Kao, National Taiwan University Hospital, New Taipei city, TW

08:25 - 08:45 **Discussion**

E. Romano, Institut Curie, Paris, FR

09:00 - 10:30 **Type: Proffered Paper session** **Hall 405**
Title: Proffered paper session - Breast cancer

Chair: Rebecca Dent, SG

09:00 - 09:00 **Session DOI**

09:00 - 09:12 **250 - Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial)**

D. Hinerfeld¹, S. Chumsri², K. Asleh³, H.A. Brauer⁴, J. Kachergus², S. Lanttia⁵, H. Lindman⁶, T. Nielsen³, H. Joensuu⁷, A. Thompson², ¹NanoString Technologies, Seattle, US, ²Mayo Clinic, Jacksonville, US, ³The University of British Columbia, Vancouver, CA, ⁴Nanostring Technologies, Seattle, CA, ⁵University of Helsinki, Helsinki, FI, ⁶Uppsala University, Uppsala, SE, ⁷Helsinki University Central Hospital (HUCH), Helsinki, FI

09:12 - 09:24 **LBA6 - First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer**

B. Xu¹, Q. Zhang², T. Sun³, W. Li⁴, Y. Teng⁵, X. Hu⁶, I. Bondarenko⁷, H. Adamchuk⁸, Y. Li⁹, B. Shan⁹, J. Cheng⁹, T. Peng⁹, X. Wang⁹, Y. Chen⁹, W. Jiang⁹, S. Liu⁹, X. Zhang⁹, E. Liu⁹, A. Luk¹⁰, Q. Wang⁹, ¹Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ²Harbin Medical University Cancer Hospital, Harbin, CN, ³Liaoning Cancer Hospital and Institution,, Shenyang, CN, ⁴The first Bethune Hospital of Jilin University, Shengyang, CN, ⁵The first hospital of China Medical University, Shengyang, Shengyang, CN, ⁶Fudan University Shanghai Cancer Center, Shanghai, CN, ⁷CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipo, UA, ⁸CI Kryvyi Rih Oncological Dispensary of DRC, Dnipropetrovsk, UA, ⁹Shanghai Henlius Biotech, Inc., Shanghai, CN, ¹⁰Shanghai Henlius Biopharm, Shanghai, CN

09:24 - 09:34 **Invited Discussant 250 and LBA6**

S.-B. Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

- 09:34 - 09:46 **10 - Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study**
C. Huang¹, Y. Yang², A. Kwong³, S.-C. Chen⁴, L.-M. Tseng⁵, M.-C. Liu⁶, K. Shen⁷, S. Wang⁸, T.-Y. Ng⁹, Y. Feng¹⁰, G. Sun¹⁰, I. Yan¹⁰, Z. Shao¹¹, ¹National Taiwan University Hospital, New Taipei city, TW, ²Taichung Veterans General Hospital and School of Medicine, Taipei, TW, ³The University of Hong Kong, Hong Kong, HK, ⁴Chang Gung Medical Foundation, Taipei, TW, ⁵Taipei-Veterans General Hospital, Taipei, TW, ⁶Koo Foundation Sun Yat-Sen Cancer Center, Taipei, TW, ⁷Shanghai Jiaotong University School of Medicine, Shanghai, CN, ⁸Sun Yat-Sen University Cancer Center, Guangdong Sheng, CN, ⁹Tuen Mun Hospital, Tuen Mun, HK, ¹⁰Roche (China) Holding Ltd., Shanghai, CN, ¹¹Fudan University Shanghai Cancer Center, Shanghai, CN
- 09:46 - 09:56 **Invited Discussant 10**
G. Curigliano, Istituto Europeo di Oncologia, Milan, IT
- 09:56 - 10:08 **370 - Subgroup analysis of IMpassion130: Atezolizumab & nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries**
H. Iwata¹, S.-A. Im², J. Sohn³, K.H. Jung⁴, Y.-H. Im⁵, K.S. Lee⁶, K. Inoue⁷, K. Tamura⁸, A. Wong⁹, L. Emens¹⁰, C. Barrios¹¹, S. Adams¹², A. Schneeweiss¹³, V. Diéras¹⁴, E. Winer¹⁵, S. Chui¹⁶, V. Henschel¹⁷, H. Rugo¹⁸, S. Loi¹⁹, P. Schmid²⁰, ¹Aichi Cancer Center Hospital, Nagoya, JP, ²Seoul National University Hospital, Seoul, KR, ³Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ⁴Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁶National Cancer Center, Korea, Seoul, KP, ⁷Saitama Cancer Center, Saitama, JP, ⁸National Cancer Center Hospital (NCCH), Tokyo, JP, ⁹National University Cancer Institute, Singapore, SG, ¹⁰UPMC Hillman Cancer Center, Pittsburgh, US, ¹¹PUCRS-Pontifícia Universidade do Rio Grande do Sul, Porto Alegre, BR, ¹²New York University, New York, US, ¹³University Hospital Heidelberg, Heidelberg, DE, ¹⁴Centre Eugene Marquis, Rennes, FR, ¹⁵Harvard Medical School, Boston, US, ¹⁶Genentech, Inc., South San Francisco, US, ¹⁷F. Hoffmann-La Roche, Basel, CH, ¹⁸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ¹⁹Peter MacCallum Cancer Center, Melbourne, AU, ²⁰Barts Cancer Institute-Queen Mary University of London, London, GB
- 10:08 - 10:20 **380 - Talazoparib (TALA) vs physician's choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA**
K.-H. Lee¹, S.-B. Kim², J. Sohn³, A. Goodwin⁴, T. Usari⁵, S. Lanzaone⁵, Y.-H. Im⁶, ¹Seoul National University Hospital, Seoul, KR, ²Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ³Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ⁴Concord Clinical School, University of Sydney, Sydney, AU, ⁵Pfizer, Milan, IT, ⁶Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR
- 10:20 - 10:30 **Invited Discussant 370 and 380**
Y.S. Yap, NCCS - National Cancer Centre Singapore, Singapore, SG

09:00 - 10:30 **Type: Educational session** **Hall 404**
Title: Precision medicine for GU cancer
Chair: Arun Azad, AU; Cora Sternberg, US

09:00 - 09:00 **Session DOI**

09:00 - 09:25 **Precision Medicine in prostate cancer**
C. Sternberg, Weill Cornell Medicine - The Blenis Lab, New York, US

09:25 - 09:50 **Molecular dissection on bladder cancer**
B. Tran, Peter MacCallum Cancer Centre, Melbourne, AU

09:50 - 10:15 **mRCC treatment in 2019: current paradigms and future directions**
M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

10:15 - 10:30 **Discussion**

09:00 - 10:30 **Type: ESMO Clinical Practice Guidelines session** **Hall 407**
Title: ESMO Clinical Practice Guidelines session
 Chair: Andres Cervantes, ES; George Pentheroudakis, GR

09:00 - 09:00 **Session DOI**

09:00 - 09:05 **Introduction**

G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR

09:05 - 09:35 **Cervical cancer**

G. Kenter¹, S. Gupta², ¹Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ²Tata Memorial Hospital Centre, Mumbai, IN

09:35 - 09:45 **Questions and answers**

09:45 - 10:15 **Immunotherapy in advanced NSCLC**

C. Baldini¹, M.-J. Ahn², ¹Gustave Roussy, Villejuif, FR, ²Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

10:15 - 10:25 **Questions and answers**

10:25 - 10:30 **Conclusion**

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

09:00 - 10:00 **Type: Mini Oral session** **Room 324**
Title: Mini Oral session - Head and neck cancer
 Chair: Bhumsuk Keam, KR; Lisa Licitra, IT; Joseph Wee, SG

09:00 - 09:00 **Session DOI**

09:00 - 09:05 **2880 - Molecular profiling and treatment patterns of advanced salivary gland cancers in head and neck region**

V. Talreja¹, V. Patil², V. Noronha¹, A. Joshi¹, N. Menon³, A. Chougule¹, M. Menon¹, N. Mittal¹, K. Prabhash¹, ¹Tata Memorial Hospital, Mumbai, IN, ²Tata Memorial Hospital Centre, Mumbai, IN, ³Prince Aly Khan Hospital, Mumbai, IN

09:05 - 09:10 **2890 - Spectrum of mitochondrial genomic variation in parathyroid neoplasms by ultra-deep targeted DNA sequencing**

Y. Hu¹, X. Zhang¹, O. Wang¹, X. Xing¹, M. Cui¹, M. Wang¹, C. Song², Q. Liao¹, Y. Zhao¹, ¹PUMCH-Peking Union Medical College Hospital (East), Beijing, CN, ²Novogene Bioinformatics Institute, Beijing, CN

- 09:10 - 09:20 **Discussion led by moderator**
B. Keam, Seoul National University Hospital, Seoul, KR
- 09:20 - 09:25 **2900 - Long-term results of phase II trial of reduced modified clinical target volume in low-risk nasopharyngeal carcinoma treated with intensity modulated radiotherapy**
J. Miao¹, M. Di¹, Y. Cao², L. Wang¹, W. Xiao¹, M. Zhu¹, B. Chen¹, S. Huang¹, F. Han¹, X. Deng¹, Y. Xiang¹, M.L.K. Chua³, X. Guo¹, C. Zhao¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, CN, ³NCCS - National Cancer Centre Singapore, Singapore, SG
- 09:25 - 09:30 **2910 - Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta Indonesia**
S. Hutajulu¹, D. Howdon², K. Taroeno Hariadi¹, M. Hardianti¹, I. Purwanto¹, S. Indrasari¹, C. Herdini¹, B. Hariwiyanto¹, A. Ghozali¹, H. Kusumo¹, W. Dhamiyati¹, S. Danarti¹, I. Tan³, J. Kurnianda¹, M. Allsop², ¹Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID, ²University of Leeds, Leeds, GB, ³Maastricht University Medical Center, Maastricht, Maastricht, NL
- 09:30 - 09:40 **Discussion led by moderator**
J. Wee, NCCS - National Cancer Centre Singapore, Singapore, SG
- 09:40 - 09:45 **2920 - 90-day mortality in head and neck cancer after concurrent chemoradiotherapy**
S.-Y. Wu, Taipei Medical University - Municipal Wan Fang Hospital, Taipei, TW
- 09:45 - 09:50 **2930 - Survival outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting**
F. Pontes¹, I. Rego², I. Domingues³, L. Pinto⁴, R. Garcia², M. Teixeira³, L. Khoury², T. Serra², M. Mariano¹, G. Sousa³, ¹Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, ²Portuguese Oncology Institute of Coimbra, Coimbra, PT, ³Instituto Português Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, ⁴Centro Hospitalar e Universitário de Coimbra, Coimbra, PT
- 09:50 - 10:00 **Discussion led by moderator**
L. Licitra, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

09:00 - 10:30	Type: Collaborative session Title: ESMO - KSMO Collaborative Session: Going towards an agnostic treatment / approach Chair: Kyong Hwa Park, KR; Josep Tabernero, ES	Summit 2
09:00 - 09:00	Session DOI	
09:00 - 09:05	Introduction <u>K.H. Park</u> , Korea University Anam Hospital, Seoul, KR	
09:05 - 09:25	The concept of agnostic treatment and its impact in clinical trial design <u>A. Hollebecque</u> , Institut Gustave Roussy, Villejuif, FR	
09:25 - 09:45	ESMO recommendations for detecting MSI and TRK fusion (using NGS?) <u>C. Marchiò</u> , IRCCS - Istituto di Candiolo - FPO, Candiolo, IT	
09:45 - 10:05	Innovation of NGS driven basket trial (K-MASTER) <u>K.H. Park</u> , Korea University Anam Hospital, Seoul, KR	
10:05 - 10:25	DDR pathway with gBRCA mutation in Korean cancer patients <u>S.-A. Im</u> , Seoul National University Hospital, Seoul, KR	
10:25 - 10:30	Conclusions <u>J. Tabernero</u> , Vall d'Hebron University Hospital, Barcelona, ES	

09:00 - 10:30	Type: Educational session Title: The interface between histopathology, genomics and therapy Chair: Tom Wei-Wu Chen, TW; Silvia Stacchiotti, IT	Room 311
09:00 - 09:00	Session DOI	
09:00 - 09:15	New Insights in pathology: The WHO classification <u>A. Yoshida</u> , National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP	
09:15 - 09:30	Genomic-guided precision therapy for soft tissue sarcoma <u>T.W.-W. Chen</u> , NTU - National Taiwan University - College of Medicine, Taipei City, TW	
09:30 - 09:45	Surgical perspective on improved pathological classification of tumours <u>M. Teo</u> , SGH-Singapore General Hospital/Singhealth-Academia, Singapore, SG	
09:45 - 10:00	Medical oncology on improved pathological classification of tumours <u>S. Stacchiotti</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	
10:00 - 10:30	Discussion	

09:00 - 09:50	Type: Mini Oral session Title: Mini Oral session - Public policy Chair: Fatima Cardoso, PT; Gouri Shankar Bhattacharyya, IN; Alexandru Eniu, RO	Room 326
09:00 - 09:00	Session DOI	
09:00 - 09:05	3910 - Setting up breast services improvements and learning bridges in Kyrgyzstan: The SILK project <u>O. Pagani</u> ¹ , M. Del Grande ¹ , F. Peccatori ² , C. De Wolf ³ , G. Pruneri ⁴ , L. Mattei ⁵ , A. Richetti ¹ , S. Presilla ¹ , T. Sabyrbekova ⁶ , N. Bakirova ⁶ , T. Soldak ⁷ , D. Abdyldaev ⁸ , T. Abdyldaev ⁸ , I. Aliev ⁸ , R. Aralbaev ⁸ , S. Naizabekova ⁸ , B. Shaimurzaeva ⁸ , O. Shimkina ⁸ , R. Marti ⁹ , F. Cavalli ¹⁰ , ¹ IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH, ² European School of Oncology, Milan, IT, ³ Development et évaluation des politiques de santé (ADSAN), Onex, CH, ⁴ National Cancer Institute, Milan, IT, ⁵ Istituto Cantonale Patologia, Locarno, CH, ⁶ Public Foundation "Ergene", Bishkek, KG, ⁷ Resource & Policy Exchange, Inc, Delhi, NY, US, ⁸ National Center of Oncology and Haematology, Bishkek, KG, ⁹ Cancer League, Bern, CH, ¹⁰ European School of Oncology, Bellinzona, CH	
09:05 - 09:10	3920 - Treatment outcomes of colorectal cancer patients enrolled in a comprehensive benefits program of the National Health Insurance System in the Philippines: Data from the program pilot site <u>D.B. Sacdalan</u> ¹ , F.I. Ting ² , M.M. Tampo ² , H.I. Monroy ² , D. Sacdalan ¹ , ¹ Philippine General Hospital, Manila, PH, ² University of the Philippines - Philippine General Hospital, Manila, PH	
09:10 - 09:15	3930 - Timeliness of lung cancer treatment utilizing the rapid access lung cancer clinic in a regional Australian Hospital <u>N. Chau</u> , Epworth Healthcare, Melbourne, AU	
09:15 - 09:20	5370 - Evaluating medical oncology outcomes: An Asian lung cancer study L. Mery ¹ , F. Bray ¹ , P. Sripan ² , R. Soo ³ , H. Storm ⁴ , <u>R.A. Stahel</u> ⁵ , ¹ International Agency for Research on Cancer, Lyon, FR, ² Chang Mai University - Faculty of Medicine - Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, TH, ³ National University Hospital, 119047, Singapore, SG, ⁴ The Danish Cancer Society, Copenhagen, DK, ⁵ University Hospital Zürich, Zurich, CH	
09:20 - 09:45	Discussion led by moderators <u>F. Cardoso</u> ¹ , <u>G.S. Bhattacharyya</u> ² , ¹ Champalimaud Foundation Cancer Center, Lisbon, PT, ² G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center,, Kolkata, IN	

10:00 - 10:30	Type: Special Session Title: Introduction to ESMO Immuno-Oncology Technology (IOTECH) Chair: John Haanen, NL	Room 326
10:00 - 10:00	Session DOI	
10:00 - 10:30	Presentation of the journal and of selected manuscripts <u>J. Haanen</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL	
10:00 - 10:45	Type: Young Oncologist session Title: Vesalius talk: How to prevent and deal with burn out in oncology Chair: Guillem Argiles Martinez, ES; Alena Gros, ES; Ravindran Kanesvaran, SG	Exhibition area
11:00 - 12:30	Type: Proffered Paper session Title: Presidential session Chair: Josep Tabernero, ES; Ian Chau, GB	Hall 406
11:00 - 11:00	Session DOI	
11:00 - 11:15	LBA1 - Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial <u>R. Camidge</u> ¹ , <u>H.R. Kim</u> ² , <u>M.-J. Ahn</u> ³ , <u>J.C.-H. Yang</u> ⁴ , <u>J.-Y. Han</u> ⁵ , <u>M.J. Hochmair</u> ⁶ , <u>K.H. Lee</u> ⁷ , <u>A. Delmonte</u> ⁸ , <u>M.R. Garcia Campelo</u> ⁹ , <u>D.-W. Kim</u> ¹⁰ , <u>F. Griesinger</u> ¹¹ , <u>E. Felip</u> ¹² , <u>R. Califano</u> ¹³ , <u>A. Spira</u> ¹⁴ , <u>S. Gettinger</u> ¹⁵ , <u>M. Tiseo</u> ¹⁶ , <u>Q. Ni</u> ¹⁷ , <u>P. Zhang</u> ¹⁷ , <u>S. Popat</u> ¹⁸ , 1University Of Colorado Hospital, Aurora, US, 2Yonsei University Severance Hospital, Seoul, KR, 3Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, 4National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, 5National Cancer Center, Goyang, KR, 6Otto Wagner Hospital, Sanatoriumstrasse 2, 1140, Vienna, AT, 7Chungbuk National University Hospital, Cheongju, KR, 8Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, 9Complejo Hospitalario Universitario A Coruna Hospital Teresa Herrera-Materno Infantil, Coruna, ES, 10Seoul National University Hospital, Seoul, KR, 11Pius-Hospital Oldenburg, University of Oldenburg, Oldenburg, DE, 12Vall d'Hebron University Hospital, Barcelona, ES, 13The Christie NHS Foundation Trust, Manchester, GB, 14Virginia Cancer Specialists and US Oncology Research, The Woodlands, US, 15Yale Cancer Center, New Haven, US, 16University Hospital of Parma, Parma, IT, 17Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, US, 18Royal Marsden Hospital NHS Foundation Trust, London, GB	
11:15 - 11:25	Invited Discussant LBA1 <u>S.-H. Ou</u> , UCI Health Chao Family Comprehensive Cancer Center, Orange, US	

- 11:25 - 11:40 **LBA2 - TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI**
J.-Y. Han¹, L. Sequist², M.-J. Ahn³, B.C. Cho⁴, H. Yu⁵, S.-W. Kim⁶, J.C.-H. Yang⁷, J.S. Lee⁸, W.-C. Su⁹, D. Kowalski¹⁰, S. Orlov¹¹, M. Cantarini¹², R. Verheijen¹³, A. Mellempgaard¹³, P. Frewer¹³, X. Ou¹³, G. Oxnard¹⁴, ¹National Cancer Center, Goyang, KR, ²Massachusetts General Hospital, Boston, US, ³Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Yonsei University, Seoul, KR, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁷National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, ⁸Seoul National University Bundang Hospital, Seoul, KR, ⁹National Cheng Kung University Hospital, Tainan, TW, ¹⁰Oncology Centre and Institute, Wasaw, PL, ¹¹Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ¹²Sandigrey Clinical Limited, Sandiway, GB, ¹³AstraZeneca, Cambridge, GB, ¹⁴Dana Farber Cancer Institute, Boston, US
- 11:40 - 11:50 **Invited Discussant LBA2**
D. Planchard, Institut Gustave Roussy, Villejuif, FR
- 11:50 - 12:05 **LBA3 - IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)**
A.-L. Cheng¹, S. Qin², M. Ikeda³, P. Galle⁴, M. Ducreux⁵, A. Zhu⁶, T.-Y. Kim⁷, M. Kudo⁸, V. Breder⁹, P. Merle¹⁰, A. Kaseb¹¹, D. Li¹², W. Verret¹³, Z. Xu¹⁴, S. Hernandez¹⁵, J. Liu¹⁶, C. Huang¹⁷, S. Mulla¹⁸, H.Y. Lim¹⁹, R. Finn²⁰, ¹National Taiwan University Hospital, Taipei City, TW, ²Nanjing Bayi Hospital, Nanjing, CN, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Universitätsmedizin Mainz, Mainz, DE, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Massachusetts General Hospital, Boston, US, ⁷SNUH-Seoul National University Hospital, Seoul, KR, ⁸Kindai University - Faculty of Medicine, Osaka, JP, ⁹FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ¹⁰Hôpital de la Croix-Rousse, Lyon, FR, ¹¹The University of Texas MD Anderson Cancer Center, Houston, US, ¹²City of Hope, Duarte, US, ¹³Genentech, Inc., South San Francisco, US, ¹⁴Roche, Beijing, CN, ¹⁵Genentech, Inc. - Member of the Roche Group, South San Francisco, US, ¹⁶Shanghai Roche Pharmaceuticals Ltd., Shanghai, CN, ¹⁷Roche Product Development, Shanghai, CN, ¹⁸F. Hoffmann-La Roche, Ltd., Mississauga, CA, ¹⁹Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ²⁰Geffen School of Medicine at UCLA, Los Angeles, US
- 12:05 - 12:15 **Invited Discussant LBA3**
I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

12:45 - 14:15	Type: Industry Satellite Symposium Title: AstraZeneca - Evolving the treatment practice of advanced EGFRm NSCLC Chair: Seng-Weng Wong, SG	Hall 405
12:45 - 12:50	Opening by the Chairperson <u>S.-W. Wong</u> , The Cancer Centre, Singapore, SG	
12:50 - 13:10	Newly diagnosed advanced EGFRm NSCLC: What information will help improve our treatment decision?	
13:10 - 13:25	Planning the patient journey: How can we maximise all of the treatment opportunities? <u>R. Soo</u> , National University Hospital, 119047, Singapore, SG	
13:25 - 13:40	Exploring treatment options beyond progression <u>B.J. Solomon</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
13:40 - 13:55	Expert opinions on hot topics: A panel discussion <u>S.-W. Wong</u> , The Cancer Centre, Singapore, SG	
13:55 - 14:10	Your opportunity to question the panel further: Audience Q & A <u>S.-W. Wong</u> , The Cancer Centre, Singapore, SG	
14:10 - 14:15	Closing remarks <u>S.-W. Wong</u> , The Cancer Centre, Singapore, SG	

12:45 - 14:15	Type: Industry Satellite Symposium Title: Pfizer - Treating EGFR+ NSCLC in 2020: New approaches, optimal outcomes Chair: Hwai Loong Kong, AU	Hall 404
12:45 - 12:50	Opening and welcome remarks <u>H.L. Kong</u> , Icon Cancer Centre Midland, Midland, AU	
12:50 - 13:10	Upfront strategy: Third-generation EGFR TKI as first-line therapy <u>T. Reungwetwattana</u> , Ramathibodi Hospital, Bangkok, TH	
13:10 - 13:30	Sequencing strategy: First- or second-generation TKI followed by third-generation EGFR TKI <u>T.S.K. Mok</u> , Prince of Wales Hospital, Hong Kong, CN	
13:30 - 13:45	Combination strategy: EGFR TKI and chemotherapy/anti-angiogenic combinations <u>D.S.W. Tan</u> , National Cancer Center Singapore, Singapore, SG	
13:45 - 14:10	Expert panel interactive forum <u>H.L. Kong</u> ¹ , <u>T.S.K. Mok</u> ² , <u>T. Reungwetwattana</u> ³ , <u>D.S.W. Tan</u> ⁴ , ¹ Icon Cancer Centre Midland, Midland, AU, ² Prince of Wales Hospital, Hong Kong, CN, ³ Ramathibodi Hospital, Bangkok, TH, ⁴ National Cancer Center Singapore, Singapore, SG	
14:10 - 14:15	Closing remarks <u>H.L. Kong</u> , Icon Cancer Centre Midland, Midland, AU	

12:45 - 14:15 **Type: Industry Satellite Symposium** **Hall 407**
Title: MSD - Advances in immune-oncology: A Pan tumour perspective
 Chair: Ravindran Kanesvaran, SG

12:45 - 12:50 **Welcome, introductions and objectives of the session**
R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

12:50 - 13:15 **A deep dive in the treatment of mHCC with IO: An Asian perspective**
S. Chan, The Chinese University of Hong Kong, Shatin, HK

13:15 - 13:40 **Next generation approach in 1L RCC: IO-TKI combination**
B. Rini, Cleveland Clinic, Cleveland, US

13:40 - 14:05 **Conquering TNBC in Asia: An insider's view**
S.-C. Chen, Chang Gung Memorial Hospital-Taipei, New Taipei city, TW

14:05 - 14:15 **Q&A**
R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

12:45 - 14:15 **Type: Industry Satellite Symposium** **Room**
Title: Novartis - Evolving treatment landscape in ER+ breast cancer: **324**
Clinical practice
 Chair: Yen Shen Lu, TW

12:45 - 12:50 **Introduction**
Y.S. Lu, National Taiwan University Hospital, Taipei, TW

12:50 - 13:10 **Achieving success when treating young patients with breast cancer**
Y.S. Lu, National Taiwan University Hospital, Taipei, TW

13:10 - 13:30 **Treatment paradigm in the era of CDK 4/6 inhibitors - What's New in 2019 ?**
Y.S. Yap, NCCS - National Cancer Centre Singapore, Singapore, SG

13:30 - 13:50 **PI3K inhibitors in advanced breast cancer: What has changed?**
B. Pistilli, Institut Gustave Roussy, Villejuif, FR

13:50 - 14:10 **Panel discussion**

14:10 - 14:15 **Conclusions**
Y.S. Lu, National Taiwan University Hospital, Taipei, TW

12:45 - 14:15 **Type: Industry Satellite Symposium** **Summit**
Title: Merck Pfizer Alliance - Recent advances and future possibilities **2**
with immunotherapy in renal and urothelial cancers

Chair: Ian Davis, AU

12:45 - 12:50 **Introduction**
I. Davis, Monash University Eastern Health Clinical School, Box Hill, AU

12:50 - 13:10 **Selection and sequencing of therapies for RCC**
I. Davis, Monash University Eastern Health Clinical School, Box Hill, AU

13:10 - 13:30 **What is next on the horizon for RCC?**
Y.-C. Tsai, National Taiwan University Hospital, New Taipei city, TW

13:30 - 13:55 **The evolving IO treatment landscape in UC**
C. Sternberg, Weill Cornell Medicine - The Blenis Lab, New York, US

13:55 - 14:10 **Q&A**

14:10 - 14:15 **Conclusions**
I. Davis, Monash University Eastern Health Clinical School, Box Hill, AU

12:45 - 14:15	Type: Industry Satellite Symposium Title: Ipsen - Managing HCC today: How can we give our patients the best chance?	Room 311
----------------------	--	-----------------

12:45 - 13:05 **All Presentations**

13:05 - 13:10 **Welcome and introductions**

A.-L. Cheng¹, B.-Y. Ryoo², ¹National Taiwan University, Taipei, TW, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

13:10 - 13:30 **Filling in the gaps: What does the data mean for HCC management?**

A.-L. Cheng, National Taiwan University, Taipei, TW

13:30 - 13:50 **Looking ahead: What does the future hold for the management of HCC?**

T. Yau, Queen Mary Hospital, Hong Kong, HK

13:50 - 14:10 **Insights from real-life practice: Optimising the use of systemic treatments**

S. Chan, The Chinese University of Hong Kong, Hong Kong, HK

14:10 - 14:30 **Panel discussion**

14:30 - 14:35 **Meeting close**

B.-Y. Ryoo, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

12:45 - 13:15	Type: Young Oncologist session Title: Meet your mentor	Exhibition area
----------------------	---	------------------------

Chair: Caroline Robert, FR; Bhumsuk Keam, KR; Olivia Pagani, CH; Pasi Jänne, US

14:30 - 16:00 **Type: Educational session** **Hall 405**
Title: Immuno-oncology in specific populations
 Chair: Fabrice Barlesi, FR; Caicun Zhou, CN

14:30 - 14:30 **Session DOI**

14:30 - 14:55 **Clinical considerations (PS2, Elderly and Brain mets, autoimmuno diseases)**
C. Baldini, Gustave Roussy, Villejuif, FR

14:55 - 15:20 **Biological considerations (Hepatitis, HIV, TB)**
C. Zhou, Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN

15:20 - 15:45 **Patient populations receiving corticosteroids asking for vaccination: What are the recommendations?**
F. Barlesi, Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR

15:45 - 16:00 **Discussion**

14:30 - 16:00 **Type: Educational session** **Hall 404**
Title: Immuno-oncology
 Chair: Anthony Chan, HK; Lisa Licitra, IT

14:30 - 14:30 **Session DOI**

14:30 - 14:55 **Immune checkpoint inhibition and biomarkers in NPC**
B. Ma, The Chinese University of Hong Kong, Shatin, HK

14:55 - 15:20 **Immune checkpoint inhibition and biomarkers in HNSCC**
L. Licitra, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

15:20 - 15:45 **Beyond immune checkpoint inhibition**
S. Oosting, University Hospital Groningen (UMCG), Groningen, NL

15:45 - 16:00 **Discussion**

14:30 - 16:00 **Type: Multidisciplinary tumour board** **Hall 407**
Title: Management of young patients with residual disease after preoperative chemotherapy
 Chair: Olivia Pagani, CH

14:30 - 14:30 **Session DOI**

14:30 - 14:35 **Presentation of case/condition**

O. Pagani, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

14:35 - 14:50 **Surgical challenges**

P. Dubsky, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH

14:50 - 15:05 **Loco-regional radiotherapy: Shall we target the initial or residual disease burden?**

B. Chua, Peter MacCallum Cancer Center, Melbourne, AU

15:05 - 15:20 **Treatment side effects; balancing effectiveness and long-term sequaele**

A. Eniu, The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO

15:20 - 15:35 **Addressing residual disease in 2019**

S.-B. Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

15:35 - 16:00 **Discussion**

14:30 - 15:30 **Type: Mini Oral session** **Room 324**
Title: Mini Oral session - Gastrointestinal tumours
 Chair: Takayuki Yoshino, JP; Eiji Oki, JP; Sylvie Lorenzen, DE

14:30 - 14:30 **Session DOI**

14:30 - 14:35 **1240 - KEYNOTE-181: Pembrolizumab vs chemotherapy in patients (pts) with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy**

S.-B. Kim¹, T. Doi², K. Kato³, J. Chen⁴, M. Shah⁵, A. Adenis⁶, S. Luo⁷, S. Qin⁸, T. Kojima⁹, J.-P. Metges¹⁰, E. Francois¹¹, K. Muro¹², Y. Cheng¹³, Z. Li¹⁴, X. Yuan¹⁵, R. Wang¹⁶, Y. Cui¹⁶, P. Bhagia¹⁷, L. Shen¹⁸, ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²National Cancer Center Hospital East, Chiba, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, CN, ⁵Weill Cornell Medical College, New York Presbyterian Hospital, New York, US, ⁶Institut du Cancer de Montpellier, Montpellier, FR, ⁷Henan Cancer Hospital, Zhengzhou, CN, ⁸Jingling Hospital, Nanjing, CN, ⁹Asan Medical Center, University of

Ulsan College of Medicine, Seoul, KR, ¹⁰Centre Hospitalier Regional Universitaire (CHRU) de Brest - Hopital Morvan, Brest, FR, ¹¹CLCC Antoine Lacassagne, Nice, FR, ¹²Aichi Cancer Center Hospital, Nagoya, JP, ¹³Jilin Cancer Hospital, Jilin, CN, ¹⁴Shanghai Chest Hospital, Shanghai Jia Tong University, Shanghai, CN, ¹⁵Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Hubei, CN, ¹⁶MSD China, Shanghai, CN, ¹⁷MSD-Merck Sharp & Dohme, Kenilworth, US, ¹⁸Peking University Cancer Hospital and Institute, Beijing, CN

14:35 - 14:40

1250 - Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study

H.C. Chung¹, Y.-J. Bang², J. Tabernero³, E. Van Cutsem⁴, C. Fuchs⁵, L. Wyrwicz⁶, K.-W. Lee⁷, I. Kudaba⁸, M. Garrido⁹, H. Castro¹⁰, W. Mansoor¹¹, M. Braghiroli¹², E. Goekkurt¹³, J. Chao¹⁴, Z. Wainberg¹⁵, U. Kher¹⁶, S. Shah¹⁶, K. Shitara¹⁷, ¹Yonsei University, Seoul, KR, ²Seoul National University Hospital, Seoul, KR, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁵Yale Cancer Center, Smilow Cancer Hospital, New Haven, US, ⁶The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, ⁷Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, KR, ⁸Latvian Oncology Center Rakus Gailezers, Riga, LV, ⁹Pontificia Universidad Cat3lica de Chile, Santiago, CL, ¹⁰Grupo Medico Angeles, Guatemala City, GT, ¹¹The Christie Hospital NHS Trust, Manchester, GB, ¹²Institute of Cancer of S3o Paulo, University of S3o Paulo, S3o Paulo, BR, ¹³Hematology Oncology Practice Eppendorf, and University Cancer Center Hamburg, Hamburg, DE, ¹⁴City of Hope Comprehensive Cancer Center, Duarte, US, ¹⁵David Geffen School of Medicine at UCLA, Los Angeles, Los Angeles, US, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷National Cancer Center Hospital East, Kashiwa, JP

14:40 - 14:45

1260 - Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial

D.-Y. Oh¹, T. Golan², P. Hammel³, M. Reni⁴, E. Van Cutsem⁵, T. Macarulla⁶, M.J. Hall⁷, J. Oh Park⁸, D. Hochhauser⁹, D. Arnold¹⁰, A. Reinacher-Schick¹¹, G. Tortora¹², H. Alg3l¹³, E.M. O'Reilly¹⁴, D. Mcguinness¹⁵, K.Y. Cui¹⁶, K. Schlienger¹⁷, G.Y. Locker¹⁸, H.L. Kindler¹⁹, ¹Seoul National University Hospital, Seoul, KR, ²Chaim Sheba Medical Center, Ramat Gan, IL, ³Beaujon Hospital APHP, Clichy, FR, ⁴IRCCS Ospedale San Raffaele, Milan, IT, ⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁶Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁷Fox Chase Cancer Center, Philadelphia, US, ⁸Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁹UCL Cancer Institute/Paul O'Gorman Building, London, GB, ¹⁰Asklepios Klinik Altona, Hamburg, DE, ¹¹Katholisches Klinikum Bochum - St. Josef-Hospital, Bochum, DE, ¹²Fondazione Policlinico Universitario Agostino Gemelli -IRCCS Rome, Rome, IT, ¹³Klinikum rechts der Isar, Department of Internal Medicine II, Technische Universit3t M3nchen, Munich, DE, ¹⁴Memorial Sloan Kettering Cancer Center, New York, US, ¹⁵AstraZeneca, Cambridge, GB, ¹⁶AstraZeneca, Gaithersburg, US, ¹⁷Merck & Co, Rahway, US, ¹⁸AstraZeneca, Gaithersbury, US, ¹⁹The University of Chicago, Chicago, US

14:45 - 15:00

Discussion led by moderator

S. Lorenzen, Rechts der Isar Hospital, TUM, Munich, DE

- 15:00 - 15:05 **780 - Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients**
J. Galon¹, F. Hermitte², B. Mlecnik³, F. Marliot⁴, C. Bifulco⁵, A. Lugli⁶, I. Nagtegaal⁷, A. Hartmann⁸, M. Van Den Eynde⁹, M. Roehrl¹⁰, P. Ohashi¹¹, E. Zavadova¹², T. Torigoe¹³, P. Patel¹⁴, Y. Wang¹⁵, Y. Kawakami¹⁶, F. Marincola¹⁷, P. Ascierto¹⁸, B. Fox¹⁹, F. Pagès⁴,
¹Laboratory of Integrative Cancer Immunology, Paris, FR, ²HalioDx, Marseille, FR, ³INSERM, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, Paris, FR, ⁴AP-HP, Georges Pompidou European Hospital, Paris, FR, ⁵Providence Portland Medical Center, Portland, US, ⁶University of Bern, Bern, CH, ⁷Radboud University Medical Centre Nijmegen, Nijmegen, NL, ⁸University Erlangen-Nürnberg, Erlangen, DE, ⁹Cliniques Universitaires St. Luc, Brussels, BE, ¹⁰Memorial Sloan Kettering Cancer Center, New York, US, ¹¹University Health Network, Toronto, CA, ¹²VFN Charles University, Prague, CZ, ¹³Sapporo Medical University School of Medicine, Sapporo, JP, ¹⁴The Gujarat Cancer & Research Institute, Ahmedabad, IN, ¹⁵Health Science Center of Xi'an Jiaotong University, Xian, CN, ¹⁶Keio University School of Medicine, Tokyo, JP, ¹⁷Refuge Biotechnologies, Menlo Park, US, ¹⁸Instituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Naples, IT, ¹⁹Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US
- 15:05 - 15:10 **Discussion led by moderators**
T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP
- 15:10 - 15:15 **790 - A multicenter phase II study of neoadjuvant FOLFOXIRI followed by concurrent capecitabine and radiotherapy for high risk rectal cancer: A final report**
G. Lam¹, M. Tong², J. Lee³, S. Chu³, D. Ng⁴, D.C.M. Lam², C. Cho³, E. Hung³, L. Li², W.M. Ho², E. Hui⁵, A. Chan⁶, S. Hon⁷, T. Mak³, S. Ng³, J. Suen², F. Mo², B. Ma⁵, ¹Chinese University of Hong Kong, Hong Kong, HK, ²State Key Laboratory of Translational Oncology, Sir YK Pao Cancer Center, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, HK, ³Prince of Wales Hospital, Hong Kong, HK, ⁴North District Hospital, Hong Kong, HK, ⁵The Chinese University of Hong Kong, Shatin, HK, ⁶The Chinese University of Hong Kong, Hong Kong, HK, ⁷Alice Ho Miu Ling Nethersole Hospital, Hong Kong, HK
- 15:15 - 15:20 **Discussion led by moderators**
T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP
- 15:20 - 15:25 **1230 - Multiplatform analysis of HCC tumours**
J.-S. Lee¹, S. Yim², S. Lee³, ¹The M. D. Anderson Cancer Center, Houston, US, ²Korea University, Seoul, KR, ³MD Anderson Cancer Center, Houston, US
- 15:25 - 15:30 **Discussion led by moderator**
E. Oki, National Kyushu Cancer Center, Fukuoka, JP

14:30 - 16:00 **Type: Educational session** **Summit 2**
Title: Precision medicine in ovarian and endometrial cancer
 Chair: Mansoor Raza Mirza, DK; Sandro Pignata, IT; David SP Tan, SG

14:30 - 14:30 **Session DOI**

14:30 - 14:55 **Therapeutic genetic testing**
D.S. Tan, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

14:55 - 15:20 **Integrating PARP inhibition**
M.R. Mirza, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK

15:20 - 15:45 **Novel treatments - immunotherapy and beyond**
S. Pignata, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

15:45 - 16:00 **Discussion**

14:30 - 16:00 **Type: Educational session** **Room 311**
Title: New advances in frequent lymphomas
 Chair: Martin Dreyling, DE; Soon Thye Lim, SG

14:30 - 14:30 **Session DOI**

14:30 - 14:55 **Advances in the management of the NK-T cell lymphomas**
W.S. Kim, Samsung Medical Center (SMC), Seoul, KR

14:55 - 15:20 **What is new in the classification and management of DLBCL in 2019**
K. Izutsu, National Cancer Center Hospital, Tokyo, JP

15:20 - 15:45 **Novel management of follicular lymphoma based on biological insights and novel concepts**
M. Ladetto, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT

15:45 - 16:00 **Discussion**

14:30 - 16:00	Type: Educational session Title: Overcoming challenges in cancer research in Asia Chair: Fatima Cardoso, PT; Pierce Chow, SG	Room 326
14:30 - 14:30	Session DOI	
14:30 - 14:50	Harmonization of regulatory requirements for clinical and translational research and treatment approvals <u>C.J. Cairo</u> , Disease Prevention and Control Bureau, Metro Manila, PH	
14:50 - 15:10	Hurdles imposed by regulatory agencies: are they all needed? <u>B. Gyawali</u> , Queen's University, Kingston, CA	
15:10 - 15:30	Defining adequate endpoints and meaningful clinical benefit <u>F. Cardoso</u> , Champalimaud Foundation Cancer Center, Lisbon, PT	
15:30 - 15:50	How to conduct multinational academic trials in Asia <u>P. Chow</u> , National Cancer Centre Singapore, Singapore, SG	
15:50 - 16:00	Discussion	
16:00 - 16:30	Type: Young Oncologist session Title: Meet your mentor Chair: Takayuki Yoshino, JP; Karin Jordan, DE; Sanjay Popat, GB; Giuseppe Curigliano, IT	Exhibition area

16:15 - 17:45	Type: Special Session Title: Radiation oncology Chair: Françoise Mornex, FR; Melvin Lee Kiang Chua, SG	Room 311
16:15 - 16:15	Session DOI	
16:15 - 16:15	Breast cancer early stage: What is the place of radiation in case of breast conservative surgery	
16:15 - 16:25	Clinical case <u>G. Kusumawidjaja</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
16:25 - 17:00	Discussion and update of the topic <u>Y.-J. Kim</u> , National Cancer Center - Korea, Goyang, KR	
17:00 - 17:00	IO (RT-OI combination for stage III NSCLC)	
17:00 - 17:10	Clinical case <u>K. Chua</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
17:10 - 17:45	Discussion and update <u>J. Belderbos</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL	

16:30 - 18:00	Type: Educational session Title: Infectious disease and cancer therapy: Tips for daily practice of oncology Chair: Matti Aapro, CH	Hall 405
16:30 - 16:30	Session DOI	
16:30 - 16:55	Vaccinating your cancer patients - When to vaccinate your solid tumour patient and health care professionals <u>S. Cinieri</u> , Ospedale A. Perrino, Brindisi, IT	
16:55 - 17:20	Why to screen for hepatitis if immuno/chemotherapy is contemplated <u>W. Yeo</u> , The Chinese University of Hong Kong, Shatin, HK	
17:20 - 17:45	How to prevent reactivation of tuberculosis <u>T. Reungwetwattana</u> , Ramathibodi Hospital, Bangkok, TH	
17:45 - 18:00	Discussion	

16:30 - 18:00	Type: ESMO Clinical Practice Guidelines session Title: Pan Asia Adapted ESMO Guidelines: Adaptation of ESMO guidelines in Asia Chair: George Pentheroudakis, GR; Takayuki Yoshino, JP	Hall 404
16:30 - 16:30	Session DOI	
16:30 - 16:35	Welcome and introduction <u>T. Yoshino</u> , National Cancer Center Hospital East, Kashiwa, JP	
16:35 - 16:45	PAGA for hepatocellular carcinoma: Case presentation <u>Y.-Y. Su</u> , Tainan, TW	
16:45 - 17:00	PAGA for hepatocellular carcinoma: Review of adapted recommendations for HCC <u>L.T. Chen</u> , National Health Research Institutes - National Institute of Cancer Research, Tainan City, TW	
17:00 - 17:10	PAGA for early breast cancer: Case presentation <u>K.I. Suh</u> , Seoul, KR	
17:10 - 17:25	PAGA for early breast cancer: Review of adapted recommendations for early breast <u>Y.H. Park</u> , Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR	
17:25 - 17:35	PAGA for locally advanced lung cancer: Case presentation <u>H. Ahn</u> , Gachon University Gil Hospital, Incheon, KR	
17:35 - 17:50	PAGA for locally advanced lung cancer: Review of adapted recommendations for locally advanced lung cancer <u>K. Park</u> , Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR	
17:50 - 18:00	The way forward: Other ESMO guidelines to adapt in 2020 - Perspective and challenges <u>G. Pentheroudakis</u> , University Hospital of Ioannina, Ioannina, GR	
16:30 - 17:50	Type: Mini Oral session Title: Mini Oral session - Thoracic cancers Chair: Mei-Kim Ang, SG; Byoung Chul Cho, KR	Hall 407
16:30 - 16:30	Session DOI	

- 16:30 - 16:35 **LBA18 - Survival and treatment patterns in patients (pts) with locally advanced or metastatic NSCLC treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIS): Analysis of US insurance claims databases**
- R. Soo¹, T. Seto², J. Gray³, P. Karimi⁴, A. Taylor⁵, W. Sawyer⁶, E. Thiel⁷, E. Marchlewicz⁷, M. Brouillette⁷, ¹National University Hospital, 119047, Singapore, SG, ²NHO Kyushu Cancer Center, Fukuoka, JP, ³H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ⁴AstraZeneca USA, Gaithersburg, US, ⁵AMGEN Ltd, Uxbridge, GB, ⁶AstraZeneca, Cambridge, GB, ⁷IBM Watson Health, Cambridge, US
- 16:35 - 16:40 **LBA19 - Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations**
- T.S.K. Mok¹, Y. Cheng², X. Zhou³, K.H. Lee⁴, K. Nakagawa⁵, S. Niho⁶, R. Linke⁷, R. Rosell⁸, J. Corral⁹, M.R. Migliorino¹⁰, A. Pluzanski¹¹, K. Noonan¹², Y. Tang¹³, K. Wilner¹³, Y.-L. Wu¹⁴, ¹Prince of Wales Hospital, Hong Kong, CN, ²Jilin Provincial Cancer Hospital, Changchun, CN, ³First Affiliated Hospital of Third Military Medical University, Chongqing, CN, ⁴Chungbuk National University Hospital, Cheongju, KR, ⁵Kindai University Hospital, Osaka, JP, ⁶National Cancer Center Hospital East, Kashiwa, JP, ⁷SFJ Pharmaceuticals®, Pleasanton, US, ⁸Catalan Institute of Oncology, Barcelona, ES, ⁹Hospital Universitario Virgen del Rocio, Seville, ES, ¹⁰San Camillo-Forlanini Hospital, Rome, IT, ¹¹The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, PL, ¹²Pfizer Inc., Groton, US, ¹³Pfizer Oncology, La Jolla, US, ¹⁴Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN
- 16:40 - 16:45 **LBA20 - Keynote-407 China Extension study: Pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC**
- Y. Cheng¹, L. Zhang², J. Hu³, D. Wang⁴, C. Hu⁵, J. Zhou⁶, L. Wu⁷, L. Cao⁸, J. Liu⁹, H. Zhang¹⁰, H. Sun¹¹, Z. Wang¹², H. Gao¹³, J. Ge¹⁴, H. Wang¹⁵, Y. Tian¹⁴, B. Piperdi¹⁶, L. Paz-Ares¹⁷, ¹Jilin Province Cancer Hospital, Changchun, CN, ²Peking Union Medical College Hospital, Beijing, CN, ³Zhongshan Hospital Fudan University, Shanghai, CN, ⁴Chongqing Cancer Hospital, Chongqing, CN, ⁵Xiangya Hospital Central South University, Changsha, CN, ⁶The First Affiliated Hospital of Zhejiang University, Hangzhou, CN, ⁷Hunan Cancer Hospital, Changsha, CN, ⁸Anhui Provincial Hospital, Hefei, CN, ⁹The First Affiliated Hospital of Dalian Medical University, Dalian, CN, ¹⁰Tang Du Hospital, Xi'an, CN, ¹¹The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ¹²Beijing Cancer Hospital, Beijing, CN, ¹³Affiliated Hospital of Academy of Military Medical Sciences, Beijing, CN, ¹⁴MSD China, Shanghai, CN, ¹⁵MSD China, Beijing, CN, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Hospital Universitario 12 de Octubre, Madrid, ES
- 16:45 - 16:50 **4760 - A phase I study to evaluate safety and efficacy of BPI-7711 in EGFRm+/T790M+ advanced or recurrent NSCLC patients**
- Y. Shi¹, J. Fang², Y. Shu³, D. Wang⁴, H. Yu⁴, Y. Zhao⁵, L. Zhang⁶, B. Zhu⁷, X. Li⁸, G. Chen⁹, J. Shi¹⁰, R. Zheng¹¹, J. Huang¹², S. Yang¹, J. Long², W. Gao³, M. Greco¹³, G. Hu¹⁴, X. Li¹⁵, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²Beijing Cancer Hospital, Beijing, CN, ³Jiangsu Province Hospital, Nanjing, CN,

⁴Chongqing Cancer Hospital, Chongqing, CN, ⁵Henan Cancer Hospital, Zhengzhou, CN, ⁶Yantai Yuhuangding Hospital, Yantai, CN, ⁷The Second Affiliated Hospital of Army Medical University, PLA, Chongqing, CN, ⁸The first affiliated hospital of Zhengzhou University, Zhengzhou, CN, ⁹Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁰Shandong Linyi Tumor Hospital, Linyi, CN, ¹¹The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, ¹²The First Affiliated Hospital of Soochow University, Suzhou, CN, ¹³Beta Pharma, Princeton, US, ¹⁴Beta Pharma, Shanghai, CN, ¹⁵Betta Pharmaceuticals Co., Ltd. - Headquarters, Hangzhou, CN

16:50 - 16:55

4770 - Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study

K. Park¹, J. Zhou², D.-W. Kim³, A. Ahmad⁴, R. Soo⁵, R. Bruns⁶, J. Straub⁶, A. Johne⁶, J. Scheele⁶, J.C.-H. Yang⁷, Y.-L. Wu⁸, ¹Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ²First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, ³Seoul National University Hospital, Seoul, KR, ⁴Beacon International Specialist Centre Sdn Bhd, Selangor, MY, ⁵National University Hospital, 119047, Singapore, SG, ⁶Merck KGaA, Darmstadt, DE, ⁷National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, ⁸Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

16:55 - 17:00

4640 - Induction gefitinib followed by standard chemoradiotherapy in locally advanced (LA) non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations: The LOGIK0902/OLCSG0905 intergroup phase II study

S. Saeki¹, K. Hotta², M. Yamaguchi³, D. Harada⁴, A. Bessho⁵, K. Tanaka⁶, K. Inoue⁷, K. Gemba⁸, K. Inoue⁹, E. Ichihara¹⁰, J. Kishimoto⁶, T. Sasaki¹¹, Y. Shioyama¹², K. Katsui¹³, J. Sasaki¹⁴, K. Kiura¹⁰, K. Sugio¹⁵, ¹Kumamoto University, Kumamoto, JP, ²Okayama, Okayama, JP, ³National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ⁴National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ⁵Japanese Red Cross Okayama Hospital, Okayama, JP, ⁶Kyushu University Hospital, Fukuoka, JP, ⁷Kitakyushu Municipal Medical Center, Kitakyushu, JP, ⁸Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Fukuyama, JP, ⁹Ehime Prefectural Central Hospital, Matsuyama, JP, ¹⁰Okayama University Hospital, Okayama, JP, ¹¹Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ¹²Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ¹³Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JP, ¹⁴Kitasato University School of Medicine, Sagamihara, JP, ¹⁵Oita University, Yufu, JP

17:00 - 17:05

4780 - Phase II study of fruquintinib plus gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations

S. Lu¹, J. Zhou², X. Niu³, Y. Chen⁴, W. Su⁵, ¹Shanghai Chest hospital, Shanghai, CN, ²First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, ³Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ⁴Hutchison MediPharma Limited - Development Center (C), Shanghai, CN, ⁵Hutchison MediPharma Limited, Shanghai, CN

17:05 - 17:10

4790 - Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated

metastatic NSCLC (EGFR+ mNSCLC)

K. Yoh¹, S. Atagi², M. Reck³, E. Garon⁴, S. Ponce Aix⁵, D. Moro-Sibilot⁶, K. Winfree⁷, B. Frimodt-Moller⁸, A. Zimmermann⁹, C. Visseren-Grul¹⁰, K. Nakagawa¹¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, JP, ³Krankenhaus Grosshansdorf, Grosshansdorf, DE, ⁴UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ⁵University Hospital 12 De Octubre, Madrid, ES, ⁶CHU de Grenoble, Hopital Michallon, La Tronche, FR, ⁷No place of work provided Iran, Teheran, IR, ⁸Eli Lilly Denmark, Herlev, DK, ⁹Eli Lilly and Company, Indianapolis, US, ¹⁰Eli Lilly Netherlands, Utrecht, NL, ¹¹Kindai University Hospital, Osaka, JP

17:10 - 17:50 **Discussion led by moderators**

M.-K. Ang¹, B.C. Cho², ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Yonsei University, Seoul, KR

16:30 - 18:00	Type: Collaborative session Title: ESMO - AACR Collaborative Session: Challenges in the use of genomics platforms Chair: Daniel Shao Weng Tan, SG; Kenna R. Mills Shaw, US	Room 324
----------------------	--	---------------------------

16:30 - 16:30 **Session DOI**

16:30 - 16:50 **Overview of the ESMO Precision Medicine Working Group accomplishments in 2018/19**

F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

16:50 - 17:10 **Building a scalable genomic medicine programme: MSK IMPACT experience**

M. Berger, Memorial Sloan Kettering Cancer Center, New York, US

17:10 - 17:30 **Disparity and diversity in Asia: Obstacle or opportunity for precision oncology?**

D.S.W. Tan, National Cancer Center Singapore, Singapore, SG

17:30 - 17:50 **Pragmatic considerations for implementing molecular profiling**

K.R. Mills Shaw, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

17:50 - 18:00 **Panel discussion**

16:30 - 18:00	Type: Young Oncologist session Title: YO Case presentations Chair: Guillem Argiles Martinez, ES; Fortunato Ciardiello, IT	Summit 2
----------------------	---	-----------------

16:30 - 16:30 **Session DOI**

- 16:30 - 16:35 **Introduction**
- 16:35 - 16:40 **YO1 - Is metastatic breast cancer curable?**
S. Gandhi, S. Hingmire, D. Kelkar, S. Pingle, S. Joshi, Deenanath Mangeshkar Hospital & Research Centre, Pune, IN
- 16:40 - 16:45 **Q&A and discussion led by the Chairs**
- 16:45 - 16:50 **YO2 - Paraneoplastic encephalitis in a gastrointestinal stromal tumor**
L.I. Catedral¹, J.J. Torres², M. Ando¹, H.N. Tan¹, R. Velasco, Jr.¹, J. Tan¹, ¹University of the Philippines - Philippine General Hospital, Manila, PH, ²Department of Medicine, Manila, PH
- 16:50 - 16:55 **Q&A and discussion led by the Chairs**
- 16:55 - 17:00 **YO3 - Squamous cell carcinoma of renal parenchyma in a 30 year old female with renal calculi**
N. Abu Bakar¹, S. Mokhtar², M. Nik Eezamuddeen³, A.B. Peter³, T. Charng Chee², R. Malek², ¹University of Malaya Faculty of Medicine, Kuala Lumpur, MY, ²Hospital Selayang, SELANGOR, MY, ³University technology Mara, Sungai buloh, Sungai Buloh, MY
- 17:00 - 17:05 **Q&A and discussion led by the Chairs**
- 17:05 - 17:10 **YO4 - pelvic nut carcinoma**
K. Bajaj, Tata Memorial Hospital, Mumbai, IN
- 17:10 - 17:15 **Q&A and discussion led by the Chairs**
- 17:15 - 17:20 **YO5 - Molecular and clonal evolution in recurrent metastatic gliosarcoma**
A. Tan¹, K. Anderson², J. Parkinson³, M. Back³, M. Kastelan³, A. Newey³, J. Brewer³, H. Wheeler³, R. Verhaak², M. Khasraw⁴, ¹RNSH - Royal North Shore Hospital, St Leonards, AU, ²Jackson Laboratory for Genomic Medicine, Farmington, US, ³Royal North Shore Hospital, St Leonards, AU, ⁴Duke University Medical Center, Durham, US
- 17:20 - 17:25 **Q&A and discussion led by the Chairs**

17:25 - 17:30 **YO7 - Intracranial Extra-skeletal Myxoid Chondrosarcoma with EWSR1 gene fusion**
V. Selvaraj, D.K. Gudipudi, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN

17:30 - 17:35 **Q&A and discussion led by the Chairs**

16:30 - 18:00 Type: Special Session **Room 326**
Title: Rare cancers: What is different between Asia and Europe?
 Chair: Paolo G. Casali, IT

16:30 - 16:30 **Session DOI**

16:30 - 16:45 **Rare Cancers Europe**
P.G. Casali, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

16:45 - 17:05 **Epidemiological differences in survival across rare cancers**
A. Trama¹, T. Matsuda², ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²National Cancer Center Hospital, Tokyo, JP

17:05 - 17:25 **Biological/clinical differences in nasopharyngeal carcinoma**
A. Chan¹, L. Licitra², ¹Prince of Wales Hospital, Shatin, HK, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

17:25 - 17:45 **Pathologic diagnosis: Improving accuracy in Asia and Europe**
B. Rekh¹, A.P. Dei Tos², ¹Tata Memorial Hospital, Mumbai, IN, ²Istituto Oncologico Veneto IRCCS, Padova, IT

17:45 - 18:00 **Rare Cancers Asia**
A. Kawai, National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP

18:00 - 19:00 **Type: Special Session** **Room 311**
Title: Radiation oncology
 Chair: Françoise Mornex, FR; Melvin Lee Kiang Chua, SG

18:00 - 18:00 **Session DOI**

18:00 - 18:00 **Oligometastatic disease: How can RTX help improving disease control?**

18:00 - 18:10 **Clinical case**

H. Sun, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences,, Guangzhou, CN

18:10 - 18:40 **Discussion of the topic**

Y.C. Ahn, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

18:40 - 19:00 **Should additional combination or RT-CT be used or is Radiation alone to be recommended? Issues with Concurrent TKIs? SBRT/IO? /Current trials?**

J. Belderbos, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

18:00 - 19:00 **Type: Poster Display** **Exhibition area**
Title: Poster display session

18:00 - 18:00 **Breast cancer, early stage**

18:00 - 18:00 **4P - Impact of chemotherapy and radiotherapy on tissue expander or implant removal in breast cancer patients**

S. Jung, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

18:00 - 18:00 **5P - Long-term prognostic effect of hormone receptor subtype on breast cancer**

K.-T. Hwang, Boramae Medical Center, Seoul, KR

18:00 - 18:00 **6P - Effect of apparent diffusion coefficient in predicting pathologic responses in patients with breast cancer treated with neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel**

Y. Mizuno, Yokkaichi Municipal Hospital, Yokkaichi, JP

18:00 - 18:00 **7P - Current diagnostic strategy for mammographic microcalcification without specific ultrasound abnormality**

N. Sato, Okazaki City Hospital, Okazaki, JP

- 18:00 - 18:00 **8P - Comparison of standard uptake value of 18F-FDG-PET-CT with tumour-infiltrating lymphocytes in breast cancer ≥1cm**
S. Park, E.K. Min, S.J. Bae, C. Cha, D. Kim, J. Lee, Y.J. Cha, J. Jeong, S.G. Ahn, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR
- 18:00 - 18:00 **10P - Prognosis and effect of adjuvant treatment in small, node(-), HER2(+) breast cancer**
S. Lim¹, J. Sohn², G. Kim², Y. Moon³, J.H. Kim⁴, ¹Wonju Severance Christianity Hospital, Gangwon-do, KR, ²Yonsei Cancer Center, Seoul, KR, ³Bundang Cha Hospital, Bundang, KR, ⁴Gangnam Severance Hospital, Seoul, KR
- 18:00 - 18:00 **11P - The prognosis of rare histopathologic subtype of breast cancer**
S.Y. Bae¹, J.Y. Kim², ¹Korea University Anam Hospital, Seoul, KR, ²Jeju National University Hospital, Jeju, KR
- 18:00 - 18:00 **12P - Daily collection of physical activity via smartphone application and smart band for development of distress screening tools in breast cancer survivors: A feasibility study**
Y. Shin¹, I.Y. Chung², ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Asan Medical Center - Asan Institute for Life Science, Seoul, KR
- 18:00 - 18:00 **13P - Breast cancer distribution in East Azerbaijan, Iran: Results of population-based cancer registry**
S. Pashaei¹, R. Dolatkhah², M.H. Somi³, R. Asghari⁴, ¹Ghazi Hospital-Tabriz University, Tabriz, IR, ²Epidemiologic Profile of Gastric Cancer in East Azerbaijan, Iran: 2 years Population Based Cancer Registry Results, Tabriz, IR, ³Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Tabriz, IR, ⁴Urmia university of medical sciences, Tabriz, IR
- 18:00 - 18:00 **14P - Validation of the optimum timing of assessment of tumour infiltrating lymphocytes during preoperative chemotherapy for breast cancer**
S. Kashiwagi¹, Y. Asano¹, R. Kouhashi², S. Ishihara², Y. Tauchi², T. Morisaki², S. Noda², T. Takashima², N. Onoda², K. Hirakawa², M. Ohira², ¹Osaka City University Medical School, Osaka, JP, ²Osaka City University Graduate School of Medicine, Osaka, JP
- 18:00 - 18:00 **15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons**
N. Takeda, Yokkaichi Municipal Hospital, Yokkaichi, JP
- 18:00 - 18:00 **16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy**
K. Taroeno Hariadi¹, R. Pudiyasari², L. Choridah³, T. Aryandono¹, ¹Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID, ²Div.Hematology-Oncology, Yogyakarta, ID, ³Breast Imaging, Yogyakarta, ID

- 18:00 - 18:00 **17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia**
A. Khan¹, H. Martin², L. Spalding³, A. Redfern³, ¹Sir Charles Gairdner Hospital, Nedlands, AU, ²Fiona Stanley Hospital, Perth, AU, ³University of Western Australia, Perth, AU
- 18:00 - 18:00 **18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center**
Y. Raof Al-Bairmany, Baghdad Medical City (Teaching Hospital), Baghdad, IQ
- 18:00 - 18:00 **19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts**
M. Paulpandi, K. Murugan, Bharathiar University, Coimbatore, IN
- 18:00 - 18:00 **20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis**
A. Shamshirian¹, K. Heydari², A.R. Aref³, R. Alizadeh-Navaei⁴, D. Shamshirian⁵, Z. Hamzehgardeshi⁶, M. Moosazadeh⁶, ¹School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, IR, ²School of Medicine, Mazandaran University of Medical Sciences, Ramsar, IR, ³Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, ⁴Mazandaran University of Medical Sciences, Imam Khomeini Hospital, Sari, IR, ⁵Shahid Beheshti University of Medical Sciences, Tehran, IR, ⁶Mazandaran University of Medical Sciences, Sari, IR
- 18:00 - 18:00 **21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients**
T.T. Aye¹, S. Mon¹, M. Khine², N. Sein², N. Thant², A. Win², E. Aung², P. Hnin², ¹Bahosi Medical Centre Bahosi Housing Complex, Yangon, MM, ²Thurein Mon Clinic, Yangon, MM
- 18:00 - 18:00 **22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients**
H.Y. Lee¹, D.Y. Yu², Y.W. Chang³, G.S. Son³, ¹Korea University College of Medicine, Seoul, KR, ²Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, KR, ³Korea University Ansan Hospital, Ansan, KR
- 18:00 - 18:00 **23P - The correlations between knowledge and attitudes of productive age women toward 'SADARI' (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali**
I.B.Y. Brahmantya¹, A.B.S. Satyarsa¹, S.A. Arta Suryantari², K. Puspitasari³, A.T. Adiputra¹, ¹Medical Faculty Of Udayana University, Denpasar, ID, ²Medical Faculty of Udayana University, Denpasar, ID, ³Faculty of Medicine Udayana University, Denpasar, ID
- 18:00 - 18:00 **24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2+ breast cancer**
F. Cardoso¹, A. Bardia², F. André³, D. Cescon⁴, H. Mcarthur⁵, M. Telli⁶, S. Loi⁷, J.

Cortes⁸, P. Schmid⁹, N. Harbeck¹⁰, C. Denkert¹¹, C. Jackisch¹², L. Jia¹³, K. Hirshfield¹⁴, V. Karantza¹⁵, ¹Champalimaud Foundation Cancer Center, Lisbon, PT, ²Massachusetts Gen Hosp, Harvard Med School, Boston, US, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴Princess Margaret Cancer Centre, Toronto, CA, ⁵Cedars-Sinai Medical Center, Los Angeles, US, ⁶Stanford University School of Medicine, Stanford, US, ⁷Peter MacCallum Cancer Center, Melbourne, AU, ⁸Ramon y Cajal University Hospital, Madrid, ES, ⁹Barts Cancer Institute-Queen Mary University of London, London, GB, ¹⁰Ludwig Maximilians University - Grosshadern, Munich, DE, ¹¹Uniklinikum Giessen und Marburg, Marburg, DE, ¹²Klinikum Offenbach GmbH, Offenbach am Main, DE, ¹³Merck & Co., Inc., Kenilworth, US, ¹⁴Merck & Co, Rahway, US, ¹⁵MSD-Merck Sharp & Dohme, Kenilworth, US

18:00 - 18:00 **Breast cancer, locally advanced**

18:00 - 18:00 **27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy**

S.J. Bae, S. Park, C. Cha, J. Lee, D. Kim, S.G. Ahn, J. Jeong, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR

18:00 - 18:00 **28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study**

N. Hariharan¹, T.S. Rao¹, S. Rajappa², C.C.K. Naidu¹, K.V.V.N. Raju¹, V. Koppula¹, R. Sudhir¹, S. Murthy¹, S. Kodandapani¹, D. Fonseca¹, ¹Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN, ²Basavatkaram Indo American Cancer Hospital, Hyderabad, IN

18:00 - 18:00 **29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood**

B. Tribukait, Karolinska Institutet, Stockholm, SE

18:00 - 18:00 **30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer**

H.-H. Ryu¹, S.H. Ahn¹, B.H. Son¹, J.W. Lee¹, B.S. Ko¹, J. Kim¹, I.Y. Chung², H. Kim¹, ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Asan Medical Center - Asan Institute for Life Science, Seoul, KR

18:00 - 18:00 **31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer**

S.L. Anwar, T. Aryandono, S. Haryana, Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID

18:00 - 18:00 **32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019**

C. Aryanti, I.G.B. Setiawan, I.W. Sudarsa, Medical Faculty Of Udayana University,

Denpasar, ID

- 18:00 - 18:00 **33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers**
B.H. Choi, Gyeongsang National University Changwon Hospital, Changwon, KR
- 18:00 - 18:00 **34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer**
Y. Asano¹, S. Kashiwagi¹, R. Kouhashi², S. Ishihara², Y. Tauchi², T. Morisaki², S. Noda², T. Takashima², N. Onoda², K. Hirakawa², M. Ohira², ¹Osaka City University Medical School, Osaka, JP, ²Osaka City University Graduate School of Medicine, Osaka, JP
- 18:00 - 18:00 **35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR⁺, HER2⁻; inoperable locally advanced breast cancer (ABC): RIGHT choice study**
Y.-S. Lu¹, S. Malwinder², H. Azim³, Y. Eralp⁴, S.-A. Im⁵, Y.S. Yap⁶, T. Delgar Alfaro⁷, M. Gao⁷, N. El Saghir⁸, ¹National Taiwan University Hospital, Taipei City, TW, ²University Malaya Medical Center, Kuala Lumpur, MY, ³Cairo University Hospital, Giza Governorate, EG, ⁴Istanbul Florence Hospital, Istanbul, TR, ⁵Seoul National University Hospital, Seoul, KR, ⁶NCCS - National Cancer Centre Singapore, Singapore, SG, ⁷Novartis, Basel, CH, ⁸American University of Beirut Medical Center, Beirut, LB
- 18:00 - 18:00 **36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India**
S. Goyal¹, A. Rudresha¹, D. Lokanatha¹, L. Jacob¹, S. Babu Mc¹, K. Lokesh¹, L. Rajeev¹, S. Smitha¹, A. Thottian², ¹Kidwai Cancer Institute, Bangalore, IN, ²AIIMS - All India Institute of Medical Sciences, New Delhi, IN
- 18:00 - 18:00 **Breast cancer, metastatic**
- 18:00 - 18:00 **41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients**
W. Goto¹, Y. Kamei², C. Watanabe², S. Kashiwagi¹, K. Ikeda², Y. Ogawa², ¹Osaka City University Medical School, Osaka, JP, ²Osaka City General Hospital, Osaka, JP
- 18:00 - 18:00 **42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis**
S. Imani¹, Z. Linglin², M. Maghsoudloo³, Q. Wen², ¹Southwest Medical University, Luzhou, CN, ²The Affiliated Hospital of Southwest Medical University, Luzhou, CN, ³Kish International Campus, University of Tehran, kish, IR
- 18:00 - 18:00 **43P - A hotspot variants p.H1047R and p.H1047L in p110^β;Np63^β; complex affects structure, function**

and contributes to susceptibility metastatic breast cancer

Z. Linglin¹, S. Imani², M. Dehghan Shasaltaneh³, Q. Wen¹, ¹The Affiliated Hospital of Southwest Medical University, Luzhou, CN, ²Southwest Medical University, Luzhou, CN, ³Faculty of Science, University of Zanjan,, Zanjan, IR

- 18:00 - 18:00 **44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer**
V.P.B. Koyyala¹, S. Saini², D.C. Doval¹, A. Mehta², M. Suryavanshi², P. Goyal¹, U. Maheshwari¹, A. Jajodia¹, M. Sharma¹, S. Goyal¹, ¹Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, ²Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN
- 18:00 - 18:00 **45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location**
H. Beaumont¹, N. Faye², A. Iannessi³, C. Klifa¹, C.-Y. Hsieh⁴, ¹MEDIAN Technologies, Valbonne, FR, ²MEDIAN Technologies, valbonne, FR, ³Centre Anticancer Antoine Lacassagne, Nice, FR, ⁴ASLAN Pharmaceuticals, Singapore, SG
- 18:00 - 18:00 **46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics**
A. Romadhoni¹, A. Rachman², C. Irawan², S. Koesnoe², ¹RSUPN - Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo, Central Jakarta/ Jakarta Pusat, ID, ²Cipto Mangunkusumo General Hospital (RSCM) University of Indonesia, Jakarta, ID
- 18:00 - 18:00 **47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer**
M. Miki¹, S. Takao², M. Konishi³, Y. Shigeoka⁴, M. Miyashita⁵, H. Suwa⁶, M. Imamura⁷, T. Okuno⁸, K. Hirokaga², Y. Miyoshi⁷, K. Murase⁷, A. Yanai⁷, K. Yamagami⁹, K. Akazawa¹⁰, ¹Kobe University Hospital, Kobe, JP, ²Hyogo Cancer Center, Akashi, JP, ³Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, JP, ⁴Yodogawa Christian Hospital, Osaka, JP, ⁵Konan Hospital, kobe, JP, ⁶hyogo Prefectural Amagasaki General Medical Center, Amagasaki, JP, ⁷Hyogo Colledge of Medicine, Nishinomiya, JP, ⁸Nishikobe Medical Center, Kobe, JP, ⁹Shinko Hospital, Kobe, JP, ¹⁰Niigata University, Niigata, JP
- 18:00 - 18:00 **48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis**
A.H. Murtadha¹, N.F. Mokhtar², ¹INFORMM - Institute for Research in Molecular Medicine - Universiti Sains Malaysia, Kubang Kerian, MY, ²Universiti Sains Malaysia, Kubang Kerian, MY
- 18:00 - 18:00 **49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer**
A. Alhanafy¹, S. Tayel², S. Ahmed³, A. Altorgoman³, I. Elsayed³, ¹Faculty of Medicine - Menoufia University, Shebin El Kom, EG, ²Faculty of Medicine - Menoufia University, sheben elkom, EG, ³Faculty of Science - Menoufia University, sheben elkom, EG
- 18:00 - 18:00 **50P - Prognostic factors of recurrence or distant metastasis in elderly breast**

cancer patients

S. Lee, Pusan National University Yangsan Hospital, Yangsan, KR

- 18:00 - 18:00 **51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator**
H. Xiong, W. Zheng, X.-F. Yu, The Second Affiliated Hospital - Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN
- 18:00 - 18:00 **52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma**
B.W. Choi, Y.J. Jeong, S.H. Park, H.K. Oh, S. Kang, Daegu Catholic University Hospital, Daegu, KR
- 18:00 - 18:00 **CNS tumours**
- 18:00 - 18:00 **53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report**
A. Altwairgi¹, F. Alnajjar², H. Alhussain², E. Alsaeed², A. Balbaid², S. Aldandan², Y. Orz², A. Lary², W. Alghareeb², A. Alsharm², ¹King Fahad Medical City-(KFMC), Riyadh, SA, ²King Fahad Medical City, riyadh, SA
- 18:00 - 18:00 **54P - Association between Parkinson's disease and brain tumours: A nationwide population-based cohort study**
J.-H. Park, Korea University Medical Center, Seoul, KR
- 18:00 - 18:00 **55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma**
K.S.-P. Yuan, C.-L. Chang, S.-Y. Wu, Taipei Medical University - Municipal Wan Fang Hospital, Taipei, TW
- 18:00 - 18:00 **56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment**
V. Pareek¹, R. Bhalavat², M. Chandra², ¹Jupiter Hospital, Mumbai, IN, ²Jupiter Hospital, Thane, IN
- 18:00 - 18:00 **57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?**
A. Rajpurohit¹, V. Patil², V. Noronha³, A. Joshi³, N. Menon⁴, A. Puranik³, N. Purandare³, A. Mahajan³, N. Mummudi³, R. Krishnatry³, R. Kumar³, S. Yadav³, K. Prabhash³, ¹Tata Memorial Hospital - Parel, Mumbai, IN, ²Tata Memorial Hospital Centre, Mumbai, IN, ³Tata Memorial Hospital, Mumbai, IN, ⁴Prince Aly Khan Hospital, Mumbai, IN
- 18:00 - 18:00 **58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy**
J. Ayala Alvarez¹, R. Trejo Rosales², R. Riera Salas¹, M. Chilaca Rosas¹, S. Rivera

Rivera¹, J. Silva Godinez¹, B. Salvador Bonilla¹, ¹Instituto Mexicano del Seguro Social, Ciudad de México, MX, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, MX

- 18:00 - 18:00 **59P - Pattern of care in high-grade gliomas after recurrence**
N. Menon¹, V. Simha², A. Abhyankar³, D. Kalra², R. Krishnatry², T. Gupta², R. Jalali², V. Patil⁴, ¹Prince Aly Khan Hospital, Mumbai, IN, ²Tata Memorial Hospital, Mumbai, IN, ³J J Hospital, Mumbai, IN, ⁴Tata Memorial Hospital Centre, Mumbai, IN
- 18:00 - 18:00 **60P - Five fractions plus γ SRS; boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)**
A. Rashid, M.A. Memon, A.S. Hashim, Neurospinal & Cancer Care Institute (NCCI), Karachi, PK
- 18:00 - 18:00 **Developmental therapeutics**
- 18:00 - 18:00 **64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001**
F. De Braud¹, S. Siena², F. Barlesi³, A. Drilon⁴, B. Simmons⁵, X. Huang⁵, S. Osborne⁵, R. Doebele⁶, ¹Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, IT, ²Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, IT, ³Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵Genentech, South San Francisco, US, ⁶University of Colorado, Aurora, US
- 18:00 - 18:00 **65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001**
C. Rolfo¹, R. Dziadziuszko², R. Doebele³, G. Demetri⁴, B. Simmons⁵, A. Aziez⁶, X. Huang⁵, S. Osborne⁷, L. Paz-Ares⁸, ¹Maryland University, Baltimore, US, ²Medical University of Gdansk, Gdansk, PL, ³University of Colorado, Aurora, US, ⁴Dana-Farber Cancer Institute, Boston, US, ⁵Genentech, South San Francisco, US, ⁶F. Hoffmann-La Roche, Basel, CH, ⁷F. Hoffmann-La Roche, Basel, US, ⁸University Hospital 12 De Octubre, Madrid, ES
- 18:00 - 18:00 **66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers**
M. Krebs¹, L. Perez², A. Surinach³, R. Doebele⁴, R. Martina⁵, M. Martinec², T. Riehl⁶, N. Meropol⁷, W. Wong⁶, G. Crane⁸, ¹Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester and The Christie NHS Foundation Trust, Manchester, GB, ²F. Hoffmann-La Roche Ltd, Basel, CH, ³Genesis Research, Hoboken, US, ⁴University of Colorado, Aurora, US, ⁵University of Liverpool, Liverpool, GB, ⁶Genentech, South San Francisco, US, ⁷Flatiron Health, New York, US, ⁸F. Hoffmann-La Roche Ltd, Welwyn Garden City, GB

- 18:00 - 18:00 **67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours**
K. Yamazaki¹, B.-Y. Ryoo², T. Doi³, P. Paik⁴, R. Veillon⁵, T. Decaens⁶, S. Faivre⁷, G. Falchook⁸, D. Hong⁹, J. Scheele¹⁰, R. Bruns¹⁰, K. Berghoff¹⁰, S. Qin¹¹, ¹Shizuoka Cancer Center, Shizuoka, JP, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ³National Cancer Center Hospital East, Chiba, JP, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵Hopital Universitaire de Bordeaux, Pessac, FR, ⁶Centre Hospitalier Universitaire de Grenoble - Hôpital Nord, Grenoble, FR, ⁷Beaujon University Hospital, Assistance Publique—Hôpitaux de Paris, Clichy, FR, ⁸Sarah Cannon Research Institute at HealthONE, Denver, US, ⁹MD Anderson Cancer Center, Houston, US, ¹⁰Merck KGaA, Darmstadt, DE, ¹¹Nanjing Bayi Hospital, Nanjing, CN
- 18:00 - 18:00 **68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck**
M.M. Hou¹, C.L. Ho², H.Y. Lin³, W. Jiang⁴, S. Liu⁴, Y. Hong⁴, A. Luk⁵, S.F. Lin⁶, T.C. Hsieh⁶, E. Liu⁴, ¹Linkou Chang Gung Memorial Hospital, Taipei, TW, ²Tri-Service General Hospital, National Defense Medical Center, Taipei, TW, ³Changhua Christian Hospital, Changhua, TW, ⁴Shanghai Henlius Biotech, Inc., Shanghai, CN, ⁵Shanghai Henlius Biopharm, Shanghai, CN, ⁶Taiwan Henlix Biotech., Co., LTD., Taipei, TW
- 18:00 - 18:00 **69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer**
H. Ishikawa¹, D. Tsuji², T. Miyagi², Y. Kawasaki³, K. Yamamoto⁴, M. Nakao⁵, S. Nakagaki⁶, T. Hayashi⁷, H. Ayuhara⁸, T. Harada⁹, S. Tamaki¹⁰, A. Maeda¹¹, Y. Ohashi¹², Y. Arakawa¹³, Y. Fujita¹⁴, Y. Miyamoto¹⁵, T. Yano¹⁶, R. Tanaka¹⁷, K. Itou², ¹Shizuoka Cancer Center, Shizuoka, JP, ²Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Shizuoka, JP, ³Clinical Research Center, Chiba University Hospital, Chiba, JP, ⁴Seirei Hamamatsu General Hospital, Hamamatsu, JP, ⁵Osaka City General Hospital, Osaka, JP, ⁶Shizuoka General Hospital, Shizuoka, JP, ⁷Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, JP, ⁸Tokyo Medical University Hospital, Tokyo, JP, ⁹Kanagawa Cancer Center, Kanagawa, JP, ¹⁰National Hospital Organization Hokkaido Cancer Center, Hokkaido, JP, ¹¹Aichi Cancer Center Hospital, Aichi, JP, ¹²National hospital Organization Tokyo medical center, Tokyo, JP, ¹³Tochigi Cancer Center, Tochigi, JP, ¹⁴Gunma prefectural cancer center, Gunma, JP, ¹⁵Hamamatsu Medical Center, Hamamatsu, JP, ¹⁶Sumitomo Besshi Hospital, Ehime, JP, ¹⁷Tokyo university of Science, Chiba, JP
- 18:00 - 18:00 **70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis**
J. Cao¹, M. Chen², B. Zhang³, X. Cai², ¹Sir Run Run Shaw Hospital - Zhejiang University School of Medicine - Xiasha Campus, Hangzhou, CN, ²Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, CN, ³Sir Run Run Shaw Hospital Zhejiang University, School of Medicine, Hangzhou, CN
- 18:00 - 18:00 **71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis**

C. He, Sun Yat-sen University Cancer Center, Guangzhou, CN

- 18:00 - 18:00 **72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study**
W. Peng¹, X. Fu², ¹Affiliated Hospital of North Sichuan Medical College, Nanchong, CN, ²Affiliated hospital of North Sichuan Medical College, Nanchong, CN
- 18:00 - 18:00 **73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models**
F. Benzaghoul¹, S. Rolland², S. Klinz³, F. Meyer-Losic², J. Nakhle², R. Delille², M. Hillairet De Boisferonc⁴, ¹IPSEN Bioscience, Inc., Cambridge, US, ²Ipsen Innovation, Les Ulis, FR, ³Ipsen Bioscience, Cambridge, US, ⁴Oncodesign, Dijon, FR
- 18:00 - 18:00 **74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours**
K. Yamazaki¹, T. Koyama², T. Shimizu², T. Takahashi¹, J. Watanabe¹, Y. Tanaka³, H. Myobudani³, N. Yamamoto², ¹Shizuoka Cancer Center, Shizuoka, JP, ²National Cancer Center Hospital, Tokyo, JP, ³Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JP
- 18:00 - 18:00 **General interest**
- 18:00 - 18:00 **75P - A parallel deep learning network framework for whole-body bone scan image analysis**
X. Pu¹, G. Tang², K. Cai³, Y. Huang², M. Ping³, Z. Peng³, H. Qiu¹, ¹University of Electronic Science and Technology of China, Chengdu, CN, ²Sichuan University, Chengdu, CN, ³Electronic Science and Technology of China, Chengdu, CN
- 18:00 - 18:00 **76P - Perception and satisfaction of cancer patients in clinical trials**
J. Jeon¹, J.H. Kim¹, K.P. Kim², ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Asan Medical Center, Seoul, KR
- 18:00 - 18:00 **77P - A prognostic nomogram for the prediction of neuroblastoma**
J.-G. Zhou¹, H. Ma², ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²Zunyi Medical College Affiliated Hospital, Zunyi City, CN
- 18:00 - 18:00 **GI, crc**
- 18:00 - 18:00 **80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study**
S. Fujino¹, N. Miyoshi², M. Ohue³, M. Yasui³, M. Sakon³, N. Matsuura³, ¹Graduate School of Medicine / Faculty of Medicine, Osaka University, Osaka, JP, ²Osaka

International Cancer Institution, Osaka, JP, ³Osaka International Cancer Institute, Osaka, JP

- 18:00 - 18:00 **81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study**
J. Zhang, Y. Deng, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN
- 18:00 - 18:00 **82P - Body mass index, tumour location, and colorectal cancer survival**
D. Chu, J. Zhang, X. Bu, C. Dang, W. Wang, Z. Zhang, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, CN
- 18:00 - 18:00 **83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4⁺CD45RB⁺ T cells**
X. Fu¹, W. Peng², ¹Affiliated hospital of North Sichuan Medical College, Nanchong, CN, ²Affiliated Hospital of North Sichuan Medical College, Nanchong, CN
- 18:00 - 18:00 **84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation**
J. Xu¹, Y. Chen¹, W. Chang², Y. Wei², ¹Zhongshan Hospital, Fudan University, Shanghai, CN, ²Zhongshan Hospital, Fudan University, shanghai, CN
- 18:00 - 18:00 **85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center**
J. Wang¹, J. Zhu², ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²fudan university shanghai cancer center, Shanghai, CN
- 18:00 - 18:00 **87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer**
P. Jonnada¹, R. C², R. C², A. Syed², S. C², ¹Kidwai Cancer Institute, Bangalore, IN, ²Kidwai Cancer Institute, bengaluru, IN
- 18:00 - 18:00 **88P - The Sidra LUMC advanced colon cancer NGS cohort**
W. Hendrickx¹, J. Roelands², P. Kuppen³, F. Marincola⁴, D. Bedognetti⁵, ¹Sidra Medical and Research Center, Al-Rayyan, QA, ²Sidra Medicine, Doha, QA, ³Leiden University Medical Center, Leiden, NL, ⁴Refuge Biotechnologies, Redwood City, US, ⁵Sidra Medicine, Doah, QA
- 18:00 - 18:00 **89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection**
M. Noguchi¹, K. Shitara², A. Kawazoe³, D. Yamamoto⁴, Y. Takii⁵, Y. Saito⁶, T. Sato⁷, T. Horimatsu⁸, H. Ishikawa⁹, Y. Ito¹⁰, M. Ito¹¹, H. Ikematsu², ¹Jikei University School of Medicine, Tokyo, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴Ishikawa Prefectural Central Hospital, Ishikawa, JP, ⁵Niigata Cancer Centre, Niigata-shi, JP, ⁶National Cancer Center Hospital East, Chuo-ku,

JP, ⁷Yamagata Prefectural Central Hospital, Yamagata, JP, ⁸Kyoto University-Graduate school of medicine, Kyoto, JP, ⁹Kyoto Prefectural University of Medicine, Kyoto, JP, ¹⁰Showa University School of Medicine, Shinagawa-ku, JP, ¹¹National Cancer Center Hospital East, Chiba, JP

- 18:00 - 18:00 **90P - High MICB expression confers prognostic benefit in colorectal cancer**
S. Yu, Zhongshan Hospital - Fudan University, Shanghai, CN
- 18:00 - 18:00 **91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study**
C.-H. Chen, S.-Y. Wu, Taipei Medical University - Municipal Wan Fang Hospital, Taipei, TW
- 18:00 - 18:00 **92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma**
V. Goel, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN
- 18:00 - 18:00 **93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis**
Y. Chen¹, W. Chang², Y. Wei², J. Xu¹, ¹Zhongshan Hospital, Fudan University, Shanghai, CN, ²Zhongshan Hospital, Fudan University, Shanghai, CN
- 18:00 - 18:00 **94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis**
M. Nakamura¹, S. Yuki², N. Takahashi², T. Shichinohe², H. Nakatsumi², Y. Kawamoto², T. Kusumi³, A. Ishiguro⁴, K. Harada⁵, I. Iwanaga⁶, K. Hatanaka⁷, K. Oomori⁸, N. Senmaru⁹, K. Iwai¹⁰, M. Koike¹¹, N. Sakamoto², A. Taketomi², S. Hirano², N. Nishimoto², Y. Komatsu², ¹Sapporo City General Hospital, Sapporo, JP, ²Hokkaido University Hospital, Sapporo, JP, ³Keiyukai Sapporo Hospital, Sapporo, JP, ⁴Teine Keijinkai Hospital, Sapporo, JP, ⁵Kushiro Rosai Hospital, Kushiro, JP, ⁶Kitami Red Cross Hospital, Kitami, JP, ⁷Hakodate Municipal Hospital, Hakodate, JP, ⁸Keiwakai Ebetsu Hospital, Ebetsu, JP, ⁹Steel Memorial Muroran Hospital, Muroran, JP, ¹⁰Oji General Hospital, Tomakomai, JP, ¹¹KKR Sapporo Medical Center, Sapporo, JP
- 18:00 - 18:00 **95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases**
Y. Wei¹, Y. Chen², W. Chang¹, J. Xu², ¹Zhongshan Hospital, Fudan University, Shanghai, CN, ²Zhongshan Hospital, Fudan University, Shanghai, CN
- 18:00 - 18:00 **96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases**
N. Taylor¹, K.Y.M. Wong¹, J. Jayamohan¹, J. Shannon², D. Karikios², A. Nagrial¹, ¹Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, AU, ²Nepean Cancer Centre, Penrith, AU

- 18:00 - 18:00 **97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer**
J.H. Lee, St Vincent Hospital The Catholic University of Korea, Suwon, KR
- 18:00 - 18:00 **98P - Influence of DPYD#x0002A;9, DPYD#x0002A;6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients**
A. Varma, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IN
- 18:00 - 18:00 **99P - Patient-derived tumour model by new culture method leading to the precision medicine**
N. Miyoshi¹, S. Fujino², K. Saso², M. Sasaki², T. Ogino², H. Takahashi³, M. Uemura², M. Chu³, T. Mizushima³, M. Mori⁴, Y. Doki³, ¹Osaka International Cancer Institution, Osaka, JP, ²Osaka University, Suita, JP, ³Osaka University, 吹田市, JP, ⁴Kyusyu University, Fukuoka, JP
- 18:00 - 18:00 **100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer**
K.-Y. Lin¹, C.-L. Fang², Y.-H. Uen³, D.-P. Sun⁴, ¹Chi-Mei Medical Center, Tainan City, TW, ²Taipei Medical University, Taipei, TW, ³Asia University Hospital, Taichung, TW, ⁴Chi Mei Medical Center, Tainan, TW
- 18:00 - 18:00 **101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer**
C. Wang, L. Xie, Y. Wang, T. Liang, H. Wu, H. He, The First Hospital of Jilin University, Changchun, CN
- 18:00 - 18:00 **102P - Clinical features of anorectal cancer in patients with Crohn#x02019;s disease: Japanese single center study**
K. Watanabe¹, A. Kohyama², H. Suzuki², T. Kajiwara², H. Karasawa³, S. Ohnuma³, H. Musha², T. Kamei⁴, T. Naitoh⁴, M. Unno⁴, ¹Graduate School of Dentistry, Tohoku University, Sendai, JP, ²Graduate School of Medicine, Tohoku University, Sendai, JP, ³Tohoku University Hospital, Sendai, JP, ⁴Tohoku University Graduate School of Medicine, Sendai, JP
- 18:00 - 18:00 **103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy**
Y. Yang¹, J. Yang², ¹West China Medical Center of Sichuan University, Chengdu, CN, ²West China Hospital of Sichuan University, Chengdu, CN
- 18:00 - 18:00 **104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer**
S. Hosseini, OMID Hospital Mashhad University of Medical Sciences, Mashhad, IR
- 18:00 - 18:00 **105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer**

S. Dong, Qilu Hospital of Shandong University, Jinan, CN

- 18:00 - 18:00 **106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum**
Y. Ten¹, M. Tillyashakhov², H. Islamov¹, Y. Ziyaev¹, ¹National Cancer Research Center of Uzbekistan, Tashkent, UZ, ²NCC of Uzbekistan, Tashkent, UZ
- 18:00 - 18:00 **107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases**
M. Shibutani¹, H. Nagahara¹, T. Fukuoka¹, Y. Iseki¹, K. Hirakawa², M. Ohira², ¹A2 Healthcare Corporation, Osaka, JP, ²Osaka City University Graduate School of Medicine, Osaka, JP
- 18:00 - 18:00 **108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer**
T. Sone, T. Murai, K. Itaya, Y. Koike, Y. Ono, M. Nakamura, Sapporo City General Hospital, Sapporo, JP
- 18:00 - 18:00 **109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer**
J. Yang¹, Y. Cheng², X. Ma³, ¹West China Hospital of Sichuan University, Chengdu, CN, ²West China Hospital, Sichuan University, Chengdu, CN, ³State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China., Chengdu, CN
- 18:00 - 18:00 **110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer**
W.B. Ji, Y.W. Chang, Korea University Ansan Hospital, Ansan, KR
- 18:00 - 18:00 **111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study**
J. Madyarov, A. Rasulov, Z. Mamedli, D. Kuzmichev, N. N. Blokhin National Medical Research Center of Oncology, Moscow, RU
- 18:00 - 18:00 **112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer**
R. Kozuki, E. Shinozaki, H. Osumi, T. Wakatuki, M. Suenaga, M. Ogura, T. Suzuki, I. Nakayama, D. Takahari, K. Chin, T. Nagasaki, T. Konishi, S. Nagayama, Y. Fukunaga, M. Ueno, K. Yamaguchi, Cancer Institute Hospital of JFCR, Tokyo, JP
- 18:00 - 18:00 **113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs**
L.-Y. Hung, National Cheng Kung University, Tainan, TW
- 18:00 - 18:00 **114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic**

colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial

J. Zhu¹, S. Li¹, C. Zhu², ¹Jiangsu Province Cancer Hospital, Nanjing, CN, ²The First Affiliated Hospital of Soochow University, Suzhou, CN

- 18:00 - 18:00 **115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer**
K. Zhabagin, Semey Nuclear medicine and oncology center, Semey, KZ
- 18:00 - 18:00 **116P - Clinical significance and conversion rate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study**
M. Ji, W. Tang, Zhongshan Hospital, Fudan University, Shanghai, CN
- 18:00 - 18:00 **117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study**
W. Huang¹, Y. Chen¹, W. Chang², Y. Wei², J. Xu¹, ¹Zhongshan Hospital, Fudan University, Shanghai, CN, ²Zhongshan Hospital, Fudan University, Shanghai, CN
- 18:00 - 18:00 **119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)**
F. Jin¹, J. Zhou², H. Luo³, S. Li³, X. Tan³, Y. Wu³, Y. Wang³, ¹Chongqing Cancer Hospital, Chongqing, CN, ²Southwest University of Political Science and Law, Chongqing, CN, ³Chongqing University Cancer Hospital, Chongqing, CN
- 18:00 - 18:00 **120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer**
A. Bilici¹, B. Cakan¹, T. Demir², B.B. Oven³, O. Acikgoz⁴, J. Hamdard⁴, O.F. Olmez⁴, O. Olmuscelik⁴, M. Seker², O. Yildiz⁴, ¹Medipol Mega Hospitals Complex (University Hospital), Istanbul, TR, ²Bezmialem Vakif University, Istanbul, TR, ³Bahçeşehir University, Medical Faculty, Istanbul, TR, ⁴Medipol University, Medical Faculty, Istanbul, TR
- 18:00 - 18:00 **121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer**
L. Li¹, Y. Guo², X. Yang³, W. Zhang³, F. Lili³, ¹The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ²Lanzhou university second hospital, Lanzhou, CN, ³Gansu Provincial Hospital, Lanzhou, CN
- 18:00 - 18:00 **GI, non- crc**
- 18:00 - 18:00 **127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)**
S. Chan¹, R. Miksad², I. Cicin³, Y. Chen⁴, H.J. Klumpen⁵, S. Kim⁶, Z.Z. Lin⁷, J. Youkstetter⁸, S. Sen⁸, A.-L. Cheng⁹, A. El-Khoueiry¹⁰, T. Meyer¹¹, R.K. Kelley¹², G. Abou-

Alfa¹³, ¹The Chinese University of Hong Kong, Department of Clinical Oncology, Hong Kong, HK, ²Flatiron Health, New York, US, ³Trakya University Rektörlüğü, Edirne, TR, ⁴The Chinese University of Hong Kong, Hong Kong, HK, ⁵Academic Medical Center (AMC), Amsterdam, NL, ⁶CHU Besançon, Hôpital Jean Minjot, Besançon, FR, ⁷National Taiwan University Hospital, Taipei City, TW, ⁸Exelixis Inc., Alameda, US, ⁹National Taiwan University, Taipei, TW, ¹⁰University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ¹¹UCL Cancer Institute/Paul O'Gorman Building, London, GB, ¹²University of California San Francisco Parnassus Campus, San Francisco, US, ¹³Memorial Sloan-Kettering Cancer Center, New York, US

- 18:00 - 18:00 **128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)**
Y. Bai¹, N. Xu², X. Yuan³, B. Wang⁴, E. Li⁵, X. Li⁶, Y. Li⁶, X. Wang⁶, S. Yang⁷, J. Xu⁸,
¹Harbin Medical University Cancer Hospital, Harbin, CN, ²The First Affiliated Hospital of Zhejiang University, Hangzhou, CN, ³Tongji Hospital, Wuhan, CN, ⁴Northern Jiangsu People's Hospital, Yangzhou, CN, ⁵First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, CN, ⁶BeiGene (Beijing) Co., Ltd., Beijing, China, Beijing, CN, ⁷BeiGene (Beijing) Co., Ltd., Beijing, CN, ⁸307 Hospital of the Chinese People's Liberation Army, Beijing, CN
- 18:00 - 18:00 **129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)**
T. Fu, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN
- 18:00 - 18:00 **130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening**
X. Feng¹, N. Li¹, G. Wang², S. Chen³, Z. Lyu⁴, L. Wei¹, X. Li¹, Y. Wen⁵, E. Giovannucci⁶, S. Wu³, M. Dai¹, J. He⁷, ¹CAMS and PUMC - National Cancer Center, Cancer Hospital, Beijing, CN, ²Kailuan General Hospital, Tangshan, CN, ³Kailuan Group, Tangshan, CN, ⁴Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁵Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, CN, ⁶Harvard T. H. Chan School of Public Health, Boston, US, ⁷National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 18:00 - 18:00 **131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis**
C.-H. Hsu¹, L. Nguyen², A.-L. Cheng³, T.X.Q. Nguyen⁴, K. Brendel⁴, V. Aslanis⁴, F. Benzaghoul⁴, ¹National Taiwan University Hospital, Taipei City, TW, ²Exelixis Inc., Alameda, US, ³National Taiwan University, Taipei, TW, ⁴Ipsen Innovation, Les Ulis, FR
- 18:00 - 18:00 **132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)**
T. Ioka¹, S. Nakamori², K. Sugimori³, M. Kanai⁴, M. Ikeda⁵, M. Ozaka⁶, M. Furukawa⁷, T. Okusaka⁸, K. Kawabe⁹, J. Furuse¹⁰, Y. Komatsu¹¹, A. Sato¹², S. Shimizu¹³, P. Chugh¹⁴, R. Tang¹⁵, M. Ueno¹⁶, ¹Osaka International Cancer Institute, Osaka, JP, ²NHO Osaka

National Hospital, Osaka, JP, ³Gastroenterological Center, Yokohama, JP, ⁴Graduate School of Medicine, Kyoto University, Kyoto, JP, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Cancer Institute Hospital of JFCR, Tokyo, JP, ⁷NHO Kyushu Cancer Center, Fukuoka, JP, ⁸National Cancer Center Hospital, Tokyo, JP, ⁹Kyushu University, Fukuoka, JP, ¹⁰Kyorin University Faculty of Medicine, Mitaka, Tokyo, JP, ¹¹Hokkaido University Hospital, Sapporo, JP, ¹²Hirosaki University Graduate School of Medicine, Hirosaki, JP, ¹³Saitama Cancer Center, Saitama, JP, ¹⁴Shire Pharmaceuticals, Boston, US, ¹⁵Servier Pharmaceuticals, Boston, US, ¹⁶Kanagawa Cancer Center, Yokohama, JP

- 18:00 - 18:00 **133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)**
T. Yau¹, T. Meyer², R.K. Kelley³, M. Mangeshkar⁴, A.-L. Cheng⁵, A. El-Khoueiry⁶, G. Abou-Alfa⁷, ¹Queen Mary Hospital, Hong Kong, HK, ²UCL Cancer Institute/Paul O'Gorman Building, London, GB, ³University of California San Francisco Parnassus Campus, San Francisco, US, ⁴Exelixis, Alameda, US, ⁵National Taiwan University, Taipei, TW, ⁶University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ⁷Memorial Sloan-Kettering Cancer Center, New York, US
- 18:00 - 18:00 **134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer**
D. Izumi¹, F. Gao², Y. Chen³, T. Ishimoto⁴, K. Horino¹, S. Shimada¹, Y. Kodaera⁵, H. Baba⁴, J. Chen³, X. Wang⁶, A. Goel⁷, ¹JCHO Kumamoto General Hospital, Yatsushiro, JP, ²City University of Hong Kong, Hong Kong, HK, ³Nanjing Medical University, Nanjin, CN, ⁴Kumamoto University, Kumamoto, JP, ⁵Nagoya University, Graduate School of Medicine, Nagoya, JP, ⁶City University of Hong Kong, Hong Kong, CN, ⁷Baylor University Medical Center, Dallas, US
- 18:00 - 18:00 **135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma**
J. Fang, L. Pan, X. Cai, Y. Wang, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, CN
- 18:00 - 18:00 **136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features**
Y. Cheng, X. Ma, J. Yang, West China Hospital of Sichuan University, Chengdu, CN
- 18:00 - 18:00 **137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer**
Z. Chen, Y. Xu, J. Gong, M. Zhang, T. Tian, X. Zhang, C. Zhang, J. Gao, L. Shen, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN
- 18:00 - 18:00 **138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre**
A. Palod¹, A. Jain², M. Sadhwani², S. J Pandya¹, ¹Gujarat Cancer Research Institute, Ahmedabad, IN, ²GUJARAT CANCER RESEARCH INSTITUTE, AHMEDABAD, IN
- 18:00 - 18:00 **139P - Prognostic usefulness of advanced lung cancer inflammation index in**

locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy

A. Besen¹, E. Topkan², ¹Adana Numune Research and Training Hospital, Adana, TR, ²Baskent University, Adana, TR

- 18:00 - 18:00 **140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma**
M. Abdelkader, Suez Canal University - Faculty of Medicine, Ismailia, EG
- 18:00 - 18:00 **141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients**
J. Chang, M. Xu, W. Li, H. Sun, X. Zhu, Fudan University Shanghai Cancer Center, Shanghai, CN
- 18:00 - 18:00 **142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients**
S. Gohar¹, B. Montaser², N. Elabd², M. Elhamoly², A. Saleh², E. Salem², G. Abo-Zeid², M. Rizk², ¹Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG, ²Faculty of Medicine - Menoufia University, Shebin El Kom, EG
- 18:00 - 18:00 **143P - NOTCH3 expression predicts poor survival in advanced esophageal squamous cell cancers**
R. Pramanik¹, P. Das², A. Sharma², S. Kumar², S. Bhorawal², S. Pathy², A. Saraya², ¹Institute Rotary Cancer Hospital, New Delhi, IN, ²All India Institute of Medical Sciences, New Delhi, IN
- 18:00 - 18:00 **144P - Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial**
R. Obermannova¹, D. Valik¹, D. Hasenclever², L. Zdrzilova-Dubska³, U. Hacker⁴, R. Demlova¹, I. Selingerova¹, F. Lordick⁵, ¹Masaryk Memorial Cancer Institute, Brno, CZ, ²Medical Faculty of University Leipzig, Germany, Leipzig, DE, ³Masaryk University Faculty of Medicine, Brno, CZ, ⁴University of Leipzig, Leipzig, DE, ⁵Uniklinikum Leipzig - Gefaessmedizinisches Zentrum, Leipzig, DE
- 18:00 - 18:00 **145P - Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status**
T. Moriwaki¹, N. Hasegawa¹, Y. Yamamoto¹, T. Yamada¹, M. Kanai², S. Kobayashi³, H. Eguchi⁴, S. Seo⁵, A. Taketomi⁶, K. Yoshimura⁷, E. Hatano⁸, H. Nagano⁹, T. Ioka³, ¹University of Tsukuba, Tsukuba, JP, ²Graduate School of Medicine, Kyoto University, Kyoto, JP, ³Osaka International Cancer Institute, Osaka, JP, ⁴Osaka University, Suita, JP, ⁵Kyoto University, Kyoto, JP, ⁶Hokkaido University Hospital, Sapporo, JP, ⁷Kanazawa University, Kanazawa, JP, ⁸Hyogo College of Medicine, Nishinomiya, JP, ⁹Yamaguchi University Graduate School of Medicine, Ube, JP
- 18:00 - 18:00 **146P - Anatomic versus non-anatomic resection for hepatocellular carcinoma: A meta-analysis of high-quality studies**

B. Zhang¹, M. Chen², J. Cao¹, L. Pan², Y. Liang², X. Cai², ¹Sir Run Run Shaw Hospital Zhejiang University, School of Medicine, Hangzhou, CN, ²Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, CN

- 18:00 - 18:00 **147P - Clinical outcomes of proximal gastrectomy versus total gastrectomy for locally advanced proximal gastric cancer: a propensity score matching analysis**
Y. Chen¹, L. Zhao², S. Hu¹, D. Zhao¹, ¹Cancer Hospital - Chinese Academy of Medical Sciences, Beijing, CN, ²Chinese Academy of Medical Sciences, - National Cancer Center, Cancer Hospital, Beijing, CN
- 18:00 - 18:00 **148P - Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage**
S. Lee¹, I.-H. Kim², K. Shin¹, ¹Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR, ²The Catholic University of Korea, College of Medicine, Seoul, KR
- 18:00 - 18:00 **150P - A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction**
Y. Chao¹, M. Maglakelidze², L. Bulat³, T. Yau⁴, S. Tanasanvimon⁵, C. Charoentum⁶, W. Arpornwirat⁷, J. Maneechavakajorn⁸, A. Dechaphunkul⁹, T. Ungtrakul¹⁰, C.-J. Yen¹¹, L.-Y. Bai¹², W.-C. Chou¹³, U. Weidemann¹⁴, E. Garner-Spitzer¹⁵, N. Ede¹⁶, L. Chong¹⁶, A. Good¹⁶, ¹Taipei Veterans General Hospital, Taipei, TW, ²ARENSIA, Tbilisi, GE, ³Institute of Oncology-Chisinau, Chisinau, MD, ⁴Queen Mary Hospital, Hong Kong, HK, ⁵Chulalongkorn University Faculty of Medicine, Pathumwan, TH, ⁶Maharaj Nakorn Chiang Mai Hospital, TH, ⁷National Cancer Institute, Bangkok, TH, ⁸Rajavithi Hospital, Pathumwan, TH, ⁹Songklanagarind Hospital, Hat Yai, TH, ¹⁰Chulabhorn Hospital, Bangkok, TH, ¹¹National Cheng Kung University Hospital, Tainan, TW, ¹²China Medical University Hospital, Taichung, TW, ¹³Linkou Chang Gung Memorial Hospital, Taoyuan, TW, ¹⁴Medical University Vienna, Vienna, AT, ¹⁵MedUni Wien - Institute of Specific Prophylaxis and Tropical Medicine, Wien, AT, ¹⁶Imugene, Sydney, AU
- 18:00 - 18:00 **151P - Gene expression profiling for a better understanding of gastric cancer: From the perspective of metabolic rearrangement**
M. Xu, J. Chang, X. Wang, M. Ye, W. Weng, C. Tan, S.-J. Ni, D. Huang, L. Wang, W. Sheng, Fudan University Shanghai Cancer Center, Shanghai, CN
- 18:00 - 18:00 **152P - Long-term outcomes of three-dimensional conformal radiotherapy-based and intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma**
C.-L. Chang, S.-Y. Wu, Taipei Medical University - Municipal Wan Fang Hospital, Taipei, TW
- 18:00 - 18:00 **153P - Exosomal LINC00174 facilitates epithelial-mesenchymal transition in residual hepatocellular carcinoma after insufficient radiofrequency ablation by regulating c-JUN/MYCBP/c-Myc axis**
D. Ma, Zhejiang Cancer Hospital, Hangzhou, CN

18:00 - 18:00

154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study

K. Murali¹, A. Collins², L. Salmon³, M. Nikfarjam³, T. John³, ¹Austin Hospital, Heidelberg, AU, ²Austin Health, Heidelberg, AU, ³Austin Health, Melbourne, AU

18:00 - 18:00 155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?

G. M. S¹, R. Arjunan², C. Ramachandra², S. Altaf², ¹Kidwai Memorial Institute of Oncology, Bangalore, IN, ²Kidwai Cancer Institute, Bangalore, IN

18:00 - 18:00 156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis

Z. Xiang, Shanghai Jiao Tong University School of Medicine, Shanghai, CN

18:00 - 18:00 157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy

J. Yadav¹, J. Purkayastha², A. Talukdar¹, ¹Dr B Borooah Cancer Institute, Guwahati, IN, ²Dr. B. Borooah Cancer Institute, Guwahati, IN

18:00 - 18:00 158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer

K. Jinkook, SNUBH - Seoul National University Bundang Hospital, Seongnam, KR

18:00 - 18:00 159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016

H.M. Kim¹, J.S. Choi², ¹Yonsei University Wonju College of Medicine, Wonju, KR, ²Catholic Kwandong University, Incheon, KR

18:00 - 18:00 160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma

J. Ha¹, K. Bang², C. Yoo¹, J. Jeong¹, H.-M. Chang¹, D. Oh¹, T.J. Song¹, D.H. Park¹, S.S. Lee¹, S.K. Lee¹, M.-H. Kim¹, J.-H. Park¹, K.-P. Kim¹, B.-Y. Ryoo¹, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²Asan Medical Center, Seoul, KR

18:00 - 18:00 161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma

A. Alhanafy¹, S. El-Hefnawy², A. Saleh², O. Elbahr³, ¹Faculty of Medicine - Menoufia University, Shebin El Kom, EG, ²Faculty of Medicine - Menoufia University, sheben elkom, EG, ³National Liver Institute - Menoufia University, sheben elkom, EG

18:00 - 18:00 162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival

I.Y. Jo¹, M.-S. Kim², J.S. Seong³, J.W. Kim³, H.C. Park⁴, T.H. Kim⁵, J.H. Lee⁶, W.S. Yoon⁷, Y.H. Lee⁸, C.-S. Kay², ¹Soon Chun Hyang University Hospital, Cheonan, Cheonan, KR, ²St.mary hospital, incheon, Incheon, KR, ³Yonsei University College of Medicine, Seoul,

KR, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Research Institute and Hospital, National Cancer Center, Goyang, KR, ⁶St Vincent Hospital The Catholic University of Korea, Suwon, KR, ⁷Korea University College of Medicine, Ansan, KR, ⁸Gyeongsang National University Hospital, Jinju, KR

- 18:00 - 18:00 **163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma**
T. Sanlung, Srinagarind Hospital, Khon Kaen, TH
- 18:00 - 18:00 **164P - Multi-centered phase II trial of weekly 5-FU plus I-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)**
Y. Sasaki¹, T. Muranaka², Y. Kawamoto³, K. Sawada⁴, H. Nakatsumi³, K. Harada⁵, T. Miyagishima⁵, K. Hatanaka⁶, M. Dazai⁷, A. Ueda⁸, T. Sasaki³, K. Shinada⁹, Y. Tsuji¹⁰, S. Yuki³, N. Sakamoto³, N. Nishimoto³, Y. Sakata¹¹, Y. Komatsu³, ¹Hakodate Central General Hospital, Hakodate, JP, ²Municipal Wakkanai Hospital, Wakkanai, JP, ³Hokkaido University Hospital, Sapporo, JP, ⁴National Cancer Center Hospital East Japan, Chiba, JP, ⁵Kushiro Rosai Hospital, Kushiro, JP, ⁶Hakodate Municipal Hospital, Hakodate, JP, ⁷Sapporo Medical Center NTT EC, Sapporo, JP, ⁸Toyama Red Cross Hospital, Toyama, JP, ⁹Keiwakai Ebetsu Hospital, Ebetsu, JP, ¹⁰KKR Tonan Hospital, Sapporo, JP, ¹¹Misawa City Hospital, Misawa, JP
- 18:00 - 18:00 **165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety**
T. Oikawa, K. Yusa, T. Okamoto, M. Yonezawa, T. Satou, T. Abe, K. Endo, K. Sawara, H. Kuroda, Y. Takikawa, Iwate Medical University School of Medicine, Morioka, JP
- 18:00 - 18:00 **166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study**
T. Sasaki¹, S. Nakano¹, S. Yuki¹, K. Sawada², T. Muranaka³, Y. Kawamoto¹, H. Nakatsumi¹, T. Ando⁴, H. Yoshita⁴, K. Harada⁵, Y. Kobayashi⁵, T. Miyagishima⁵, K. Hatanaka⁶, A. Tanimoto⁷, A. Ishiguro⁷, T. Honda⁸, M. Dazai⁹, Y. Komatsu¹, ¹Hokkaido University Hospital, Sapporo, JP, ²National Cancer Center Hospital East Japan, Chiba, JP, ³Municipal Wakkanai Hospital, Wakkanai, JP, ⁴Toyama University Hospital, Toyama, JP, ⁵Kushiro Rosai Hospital, Kushiro, JP, ⁶Hakodate Municipal Hospital, Hakodate, JP, ⁷Teine Keijinkai Hospital, Sapporo, JP, ⁸Nagasaki University Hospital, Nagasaki, JP, ⁹Sapporo Medical Center NTT EC, Sapporo, JP
- 18:00 - 18:00 **167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)**
A. Makiyama¹, J. Nakazawa², T. Otsuka³, M. Shimokawa⁴, F. Koga³, Y. Ueda⁵, A. Komori⁶, S. Arima⁷, M. Fukahori⁸, T. Honda⁹, T. Shibuki¹⁰, T. Shirakawa¹¹, K. Nio¹², Y. Ide¹³, N. Ureshino³, K. Mitsugi¹⁴, ¹JCHO Kyusyu Hospital, Kitakyushu, JP, ²Kagoshima City Hospital, Kagoshima, JP, ³Saga-ken Medical Centre Koseikan, Saga, JP, ⁴National Hospital Organization Kyusyu Cancer Center, Hakata, JP, ⁵Japanese Red Cross Kumamoto Hospital, Kumamoto, JP, ⁶Oita University Faculty of Medicine, Oita, JP, ⁷Kagoshima

University Graduate School of Medical and Dental Sciences, Kagoshima, JP, ⁸Kurume University Hospital, Fukuoka, JP, ⁹Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JP, ¹⁰Imari Arita Kyoritsu Hospital, Saga, JP, ¹¹Fukuoka Wajiro Hospital, Fukuoka, JP, ¹²Sasebo Kyosai Hospital, Nagasaki, JP, ¹³Japanese Red Cross Karatsu Hospital, Saga, JP, ¹⁴Hamanomachi Hospital, Fukuoka, JP

- 18:00 - 18:00 **168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)**
T. Honda¹, S. Nakano², S. Yuki², K. Sawada³, T. Muranaka⁴, Y. Kawamoto², H. Nakatsumi², H. Yoshita⁵, T. Ando⁵, K. Harada⁶, Y. Kobayashi⁶, T. Miyagishima⁶, K. Hatanaka⁷, A. Tanimoto⁸, A. Ishiguro⁸, M. Dazai⁹, T. Sasaki², Y. Komatsu², ¹Nagasaki University Hospital, Nagasaki, JP, ²Hokkaido University Hospital, Sapporo, JP, ³National Cancer Center Hospital East Japan, Chiba, JP, ⁴Municipal Wakkanai Hospital, Wakkanai, JP, ⁵Toyama University Hospital, Toyama, JP, ⁶Kushiro Rosai Hospital, Kushiro, JP, ⁷Hakodate Municipal Hospital, Hakodate, JP, ⁸Teine Keijinkai Hospital, Sapporo, JP, ⁹Sapporo Medical Center NTT EC, Sapporo, JP
- 18:00 - 18:00 **169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways**
Y. Wang¹, C. Wang¹, H. Xiao², H. Wu¹, H. He¹, J. Cui¹, W. Li¹, ¹The First Hospital of Jilin University, Changchun, CN, ²ChinaJapan Union Hospital of Jilin University, Changchun, CN
- 18:00 - 18:00 **170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma**
Y. Ashraf¹, M. Mostafa², ¹Suez Canal University - Faculty of Medicine, Ismailia, EG, ²faculty of medicine suez canal university, Ismailia, EG
- 18:00 - 18:00 **171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy**
Y. Wang, 4th Hospital Hebei Medical University, Shijiazhuang, CN
- 18:00 - 18:00 **172P - Preoperative neutrophil-to-lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)**
T. Miura¹, T. Aoki², H. Ohtsuka², S. Aoki², T. Hata², M. Iseki², T. Takadate², K. Ariake², K. Kawaguchi², K. Masuda², M. Ishida², M. Mizuma², H. Hayashi², K. Nakagawa², T. Morikawa², F. Motoi², H. Sasano², T. Naitoh², T. Kamei², M. Unno², ¹Tohoku University Hospital, Sendai, JP, ²Tohoku University Graduate School of Medicine, Sendai, JP
- 18:00 - 18:00 **173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells**
R. Tsunedomi¹, K. Yoshimura², Y. Kimura¹, M. Nishiyama¹, S. Matsukuma¹, Y. Tokumitsu¹, S. Tomochika¹, M. Iida¹, N. Suzuki¹, S. Takeda¹, S. Yoshino³, S. Hazama⁴, H. Nagano¹, ¹Yamaguchi University Graduate School of Medicine, Ube, JP, ²Showa University, Shinagawa, JP, ³Yamaguchi University Hospital, Ube, JP, ⁴Yamaguchi University, Ube, JP

- 18:00 - 18:00 **174P - Progression of computer aided diagnosis on gastric cancer**
Y. Yu, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN
- 18:00 - 18:00 **175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer**
Y.-T. Lee¹, P.-Y. Hsu², Y.-M. Chuang², H. Jin³, A.S.L. Cheng⁴, E.K.W. Ng⁴, C.-J. Liu⁵, Y.-C. Chen⁶, F. Cheng⁶, M.W.Y. Chan⁶, ¹Chia Yi Christian Hospital, Chiayi City, TW, ²National Chung Cheng University, Min Hsiung, TW, ³Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, CN, ⁴Chinese University of Hong Kong, Hong Kong, HK, ⁵Taipei Veterans General Hospital, Taipei, TW, ⁶National Chung Cheng University, Min Hsiung, Chiayi, TW
- 18:00 - 18:00 **176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma**
J. Yao¹, X. Fan¹, Y. Ge¹, J. Liu¹, N. Weygant², G. An¹, ¹Beijing Chaoyang Hospital - Capital Medical University, Beijing, CN, ²The University of Oklahoma Health Sciences Center, Oklahoma City, US
- 18:00 - 18:00 **177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer**
Y. Horita, Y. Mihara, T. Hamaguchi, Saitama Medical University International Medical Center, Hidaka, JP
- 18:00 - 18:00 **178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer**
A. Yamamura¹, J. Matsuo², M. Lim Yi Hui², D. Liana Heng², K. Kofu², Z.H. Md², D. Douchi², K.G. Yeoh³, T. Kamei⁴, T. Naitoh⁴, M. Osato², M. Unno⁴, Y. Ito², ¹Tohoku University, Sendai, JP, ²National University of Singapore, Singapore, SG, ³National University Health System, Singapore, SG, ⁴Tohoku University Graduate School of Medicine, Sendai, JP
- 18:00 - 18:00 **179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study**
M. Chen¹, J. Cao¹, L. Pan², B. Zhang¹, X. Cai², ¹Sir Run Run Shaw Hospital Zhejiang University, School of Medicine, Hangzhou, CN, ²Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, CN
- 18:00 - 18:00 **180P - LHPP inhibit the cell proliferation and EMT via the TGF β 2/SMAD3 signaling pathway in ICCA**
D. Wang, Fudan University Shanghai Cancer Center, Shanghai, CN
- 18:00 - 18:00 **181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma**
A. Dean¹, A. Das², M. McNulty³, N. Travers³, ¹Saint John of God Hospital Subiaco,

Subiaco, AU, ²St. John of God, SUBIACO, AU, ³St. John of God Subiaco, SUBIACO, AU

- 18:00 - 18:00 **182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less**
A. Das¹, A. Dean², N. Travers³, M. Johansson³, I. Yusoff³, ¹St. John of God, SUBIACO, AU, ²Saint John of God Hospital Subiaco, Subiaco, AU, ³St. John of God Subiaco, SUBIACO, AU
- 18:00 - 18:00 **183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results**
P. Jabbaripour¹, Z. Sanaat², R. Dolatkah³, M.H. Somi⁴, ¹Ghazi Hospital-Tabriz University, Tabriz, IR, ²Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Tabriz, IR, ³Epidemiologic Profile of Gastric Cancer in East Azerbaijan, Iran: 2 years Population Based Cancer Registry Results, Tabriz, IR, ⁴Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Tabriz, IR
- 18:00 - 18:00 **184P - Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8 cell density and CCL12 expression**
J. Ji, Shanghai Ruijin Hospital, Shanghai Jiao Tong University, College of Medicine, Shanghai, CN
- 18:00 - 18:00 **185P - Evaluation of the effect of choleosorption on the concentration of TNF- α in the serum of the blood in tumours of the biliopancreatoduodenal zone**
M. Salokhiddinov¹, S. Matmuratov¹, E. Stamou², ¹Tashkent Medical Academy, Tashkent, UZ, ²University of Aberdeen, QP, GB
- 18:00 - 18:00 **186P - Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis**
Y. Yuan¹, Y. Yun², L. Lei³, N. Junsheng³, Z. Weiping⁴, ¹110th People's Hospital of Shanghai, Tongji University, Shanghai, CN, ²Ministry of Education, Shanghai, CN, ³Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai, CN, ⁴Second Military Medical University, Shanghai, CN
- 18:00 - 18:00 **187P - Correlation between splenic dose and grade of hematological toxicity in chemoradiation of stomach**
U. Velu, A. Singh, D. Fernandes, Kasturba Medical College - Manipal, Manipal, IN
- 18:00 - 18:00 **188P - Survival and prognostic factors in cholangiocarcinoma: A single-center experience**
S. Payapwattanawong¹, K. Maneenil², S. Limtapatip², S. Laohavinij², ¹Rajavithi Hospital, Pathumwan, TH, ²Rajavithi Hospital, Bangkok, TH
- 18:00 - 18:00 **189P - Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastasis to liver: A single Institution experience**
S. Paul, V.A.R. Palkonda, L. Kashyap, K. Bhattacharya, P. Upadhyay, Apollo Cancer Institute, Hyderabad, IN

- 18:00 - 18:00 **190P - Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer**
Y. Nagata¹, C. Kinoshita¹, U. Ishimoto², T. Kano³, M. Ishikawa⁴, H. Mikuni⁵, K. Nakatsuka⁶, K. Harada¹, T. Nishimura¹, M. Noguchi¹, R. Sawada¹, K. Amano¹, M. Saruta¹, ¹Jikei University School of Medicine, Tokyo, JP, ²Jikei University Paison Hospital, Tokyo, JP, ³Machida Municipal Hospital, -- Asahi-cho, Machida-shi, Tokyo, JP, ⁴The Jikei University Kashiwa Hospital, Chiba, JP, ⁵Fuji City General Hospital, Shizuoka, JP, ⁶The Jikei University Katsushika Medical Center, Tokyo, JP
- 18:00 - 18:00 **191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients**
N. El Baghdady¹, L. El Wakeel², M. Ellithy³, N. Eltohamy⁴, S. Shaheen⁵, A.E.R. El Naggar⁶, ¹Modern University for Technology and Information, Cairo, EG, ²Ain Shams University, Cairo, EG, ³Ain Shams university Faculty of medicine, Cairo, EG, ⁴Electricity Hospital, Cairo, EG, ⁵Ain Shams University - Faculty of Pharmacy, Cairo, EG, ⁶Cairo University- Faculty of Medicine, Giza, EG
- 18:00 - 18:00 **192P - Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone**
M. Salokhiddinov¹, S. Matmuratov¹, E. Stamou², ¹Tashkent Medical Academy, Tashkent, UZ, ²University of Aberdeen, QP, GB
- 18:00 - 18:00 **193P - Metastatic carcinoma gall bladder: A clinicoepidemiological profile of Indian patients**
A. Rathore, Army Hospital Research & Referral, New Delhi, IN
- 18:00 - 18:00 **195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)**
A. Tanimoto¹, M. Yagisawa², S. Nakano², Y. Kawamoto², S. Yuki², A. Ishiguro¹, T. Takahata³, A. Sato³, I. Iwanaga⁴, N. Ehira⁴, M. Uebayashi⁴, O. Muto⁵, T. Sasaki², K. Hatanaka⁶, M. Tateyama⁷, T. Wakabayashi⁸, M. Dazai⁹, S. Minami¹⁰, Y. Sakata¹¹, Y. Komatsu², ¹Teine Keijinkai Hospital, Sapporo, JP, ²Hokkaido University Hospital, Sapporo, JP, ³Hirosaki University Graduate School of Medicine, Hirosaki, JP, ⁴Kitami Red Cross Hospital, Kitami, JP, ⁵Japanese Red Cross Akita Hospital, Akita, JP, ⁶Hakodate Municipal Hospital, Hakodate, JP, ⁷Tomakomai Nisshou Hospital, Tomakomai, JP, ⁸Akita City Hospital, Akita, JP, ⁹Sapporo Medical Center NTT EC, Sapporo, JP, ¹⁰Oji General Hospital, Tomakomai, JP, ¹¹Misawa City Hospital, Misawa, JP
- 18:00 - 18:00 **196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma**
N. Travers¹, A. Dean², K. Armstrong¹, L. Peeperkorn¹, M. Tan¹, A. Das³, ¹St. John of God Subiaco, SUBIACO, AU, ²Saint John of God Hospital Subiaco, Subiaco, AU, ³St. John of God, SUBIACO, AU
- 18:00 - 18:00 **197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo**

CAPOX as first-line treatment for patients with Claudin18.2/HER2; Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study

R.-H. Xu¹, Z. Dongsheng², J. Ajani³, S.-E. Al-Batran⁴, Y.-J. Bang⁵, D. Catenacci⁶, P. Enzinger⁷, D. Ilson⁸, S. Kim⁹, F. Lordick¹⁰, K. Shitara¹¹, E. Van Cutsem¹², A. Arozullah¹³, J. Wook Park¹³, M. Shah¹⁴, ¹SunYat-Sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³The University of Texas, MD Anderson Cancer Center, Houston, US, ⁴Institut für Klinisch-Onkologische Forschung, Frankfurt, DE, ⁵Seoul National University Hospital, Seoul, KR, ⁶University of Chicago, Chicago, US, ⁷Center for Esophageal and Gastric Cancer, Dana-Farber Cancer Institute, Boston, US, ⁸Memorial Sloan Kettering Cancer Center, New York City, US, ⁹Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, US, ¹⁰Uniklinikum Leipzig - Gefaessmedizinisches Zentrum, Leipzig, DE, ¹¹National Cancer Center Hospital East, Kashiwa, JP, ¹²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹³Astellas Pharma Global Development, Inc., Northbrook, US, ¹⁴Weill Cornell Medical College, New York City, US

18:00 - 18:00 **198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2/HER2; locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study**

K. Yamaguchi¹, K. Shitara², S.-E. Al-Batran³, Y.-J. Bang⁴, D. Catenacci⁵, P. Enzinger⁶, D. Ilson⁷, S. Kim⁸, F. Lordick⁹, M. Shah¹⁰, E. Van Cutsem¹¹, R.-H. Xu¹², A. Arozullah¹³, J. Wook Park¹³, J. Ajani¹⁴, ¹Cancer Institute Hospital of JFCR, Tokyo, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³Institut für Klinisch-Onkologische Forschung, Frankfurt, DE, ⁴Seoul National University Hospital, Seoul, KR, ⁵University of Chicago, Chicago, US, ⁶Center for Esophageal and Gastric Cancer, Dana-Farber Cancer Institute, Boston, US, ⁷Memorial Sloan Kettering Cancer Center, New York City, US, ⁸Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, US, ⁹Uniklinikum Leipzig - Gefaessmedizinisches Zentrum, Leipzig, DE, ¹⁰Weill Cornell Medical College, New York City, US, ¹¹University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹²SunYat-Sen University Cancer Center, Guangzhou, CN, ¹³Astellas Pharma Global Development, Inc., Northbrook, US, ¹⁴The University of Texas, MD Anderson Cancer Center, Houston, US

18:00 - 18:00 **199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy**

T. Yau¹, L. Rimassa², A.-L. Cheng³, J.-W. Park⁴, F. Braiteh⁵, A. Chaudhry⁶, F. Benzaghoul⁷, P. Thuluvath⁸, S. Hazra⁹, S. Milwee⁹, B. Tan¹⁰, R. Sinha¹¹, Z. Kayali¹², A. Zhu¹³, R.K. Kelley¹⁴, ¹Queen Mary Hospital, Hong Kong, HK, ²Istituto Clinico Humanitas, Rozzano, IT, ³National Taiwan University, Taipei, TW, ⁴National Cancer Center, Goyang, KR, ⁵Comprehensive Cancer Centers of Nevada, Las Vegas, US, ⁶Summit Cancer Centers, Spokane, US, ⁷Ipsen Innovation, Les Ulis, FR, ⁸Mercy Medical Center, Baltimore, US, ⁹Exelixis, Alameda, US, ¹⁰Siteman Cancer Center, St. Louis, US, ¹¹Piedmont Cancer Institute, Atlanta, US, ¹²Riverside Community Hospital, Rialto, US, ¹³Massachusetts General Hospital, Boston, US, ¹⁴University of California San Francisco Parnassus Campus, San Francisco, US

- 18:00 - 18:00 **GU, pca**
- 18:00 - 18:00 **200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study**
B.H. Chung¹, K. Mcquarrie², A. Bjartell³, S. Chowdhury⁴, A. Pereira De Santana Gomes⁵, M. Özgüroğlu⁶, Á. Juárez Soto⁷, A. Merseburger⁸, H. Uemura⁹, D. Ye¹⁰, R. Given¹¹, B. Miladinovic¹², N. Li¹³, S. Hudgens¹³, L. Floden¹³, A. Lopez-Gitlitz¹⁴, K. Chi¹⁵, N. Agarwal¹⁶, ¹Yonsei University College of Medicine and Gangnam Severance Hospital, Seoul, KR, ²Janssen Research & Development, Spring House, US, ³Skåne University Hospital, Lund University, Malmö, SE, ⁴Guy's, King's, and St Thomas' Hospitals, and Sarah Cannon Research Institute, London, GB, ⁵Liga Norte Riograndense Contra O Cancer, Natal, BR, ⁶Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Fatih/Istanbul, TR, ⁷Hospital Universitario de Jerez de la Frontera, Cadiz, ES, ⁸University Hospital Schleswig-Holstein, Lübeck, DE, ⁹Kindai University Faculty of Medicine, Osaka, JP, ¹⁰Fudan University Shanghai Cancer Center, Shanghai, CN, ¹¹Urology of Virginia, Eastern Virginia Medical School, Norfolk, US, ¹²Janssen Research & Development, San Diego, US, ¹³Clinical Outcomes Solutions, Tucson, US, ¹⁴Janssen Research & Development, Los Angeles, US, ¹⁵BC Cancer, Vancouver, CA, ¹⁶Huntsman Cancer Institute, Salt Lake City, US
- 18:00 - 18:00 **201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial**
J.S.-T. Pang¹, N. Shore², M. Smith³, T. Tammela⁴, A. Ulys⁵, E. Vjaters⁶, S. Polyakov⁷, M. Jievaltas⁸, M. Luz⁹, B. Alekseev¹⁰, I. Kuss¹¹, M.-A. Le Berre¹², A. Snapir¹³, T. Sarapohja¹³, K. Fizazi¹⁴, ¹Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, ²Atlantic Urology Clinics, Myrtle Beach, US, ³Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, US, ⁴Tampere University Hospital, Tampere, FI, ⁵Institute of Oncology, Vilnius, LT, ⁶Pauls Stradins Clinical University Hospital, Riga, LV, ⁷N.N. Alexandrov National Cancer Centre, Minsk, BY, ⁸Lithuanian University of Health Sciences, Medical Academy, Kaunas, LT, ⁹Hospital Erasto Gaertner, Curitiba, BR, ¹⁰Hertzen Moscow Oncology Research Institute, Moscow, RU, ¹¹Bayer AG, Berlin, DE, ¹²Bayer Healthcare, Loos, FR, ¹³Orion Corporation Orion Pharma, Espoo, FI, ¹⁴Institut Gustave Roussy, Villejuif, FR
- 18:00 - 18:00 **202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis**
T.H. So¹, C.L. Chiang², T.-C. Lam², F.T. Chan³, H. Choi⁴, ¹Queen Mary Hospital, Hong Kong, HK, ²Tuen Mun Hospital, Tuen Mun, HK, ³Private Oncologist, Hong Kong, HK, ⁴University of Hong Kong, Hong Kong, HK
- 18:00 - 18:00 **203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer**
S. Singla¹, S. Maheboob Hussain¹, G. Shrivastav², N. Sonthwal³, H. Chaturvedi², A. Gupta⁴, ¹Max Institute of Cancer Care, New Delhi, IN, ²Max Super Specialty Hospital, Delhi, IN, ³All India Institute of Medical Sciences, Delhi, IN, ⁴Institute Rotary Cancer

Hospital, New Delhi, IN

- 18:00 - 18:00 **204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)**
A. Liman¹, A. Liman², R. Shah², V. Passero², J. Tan², H. Rai², L. Harrold², A. Liman², J. Tokarsky², ¹University of Pittsburgh Cancer Institute, Pittsburgh, US, ²VA Pittsburgh Healthcare System-University of Pittsburgh Cancer Institute, Pittsburgh, US
- 18:00 - 18:00 **205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong**
D. Poon¹, K.C.W. Wong², K. Law³, T.-W. Chan⁴, S. Siu⁵, H. Sze⁶, ¹The Chinese University of Hong Kong, Hong Kong, HK, ²State Key Laboratory of Translational Oncology, Sir YK Pao Cancer Center, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, HK, ³Princess Margaret Hospital, Hong Kong, HK, ⁴Queen Elizabeth Hospital, Hong Kong, HK, ⁵Queen Mary Hospital/ The University of Hong Kong, Hong Kong, HK, ⁶Pamela Youde Nethersole Eastern Hospital, Hong Kong, HK
- 18:00 - 18:00 **206P - Population-based validation of the risk stratification among prostate cancer patients**
M. Xie, Peking University First Hospital, Beijing, CN
- 18:00 - 18:00 **GU, non pca**
- 18:00 - 18:00 **211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis**
C.F. Ng¹, T.G. Kwon², M. Eto³, H. Miyake⁴, S.I. Seo⁵, S.-S. Byun⁶, J.L. Lee⁷, B. Rosbrook⁸, E. Grande⁹, M. Gross-Goupil¹⁰, D. Quinn¹¹, ¹The Chinese University of Hong Kong, Hong Kong, HK, ²School of Medicine, Kyungpook National University, Daegu, KR, ³Kyushu University, Fukuoka, JP, ⁴Hamamatsu University School of Medicine, Hamamatsu, JP, ⁵Sungkyunkwan University, Seoul, KR, ⁶Seoul National University Bundang Hospital, Seongnam, KR, ⁷Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁸Pfizer Oncology, San Diego, US, ⁹MD Anderson Cancer Center Madrid, Madrid, ES, ¹⁰CHU Bordeaux Hopital St. André, Bordeaux, FR, ¹¹University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US
- 18:00 - 18:00 **212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice**
A. Rauthan, P. Patil, S. Sampige Prasannakumar, S. Zaveri, Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN
- 18:00 - 18:00 **213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre**
R. Kanesvaran¹, J. Chan², H.-S. Tan², J. Hong², C.K. Toh², Q.S. Ng², T. Rajasekaran², L. Sivabalan², C. Ng Yl², ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²National Cancer Center Singapore, Singapore, SG

- 18:00 - 18:00 **214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib**
R. Sharma, E. Kadife, G. Kannourakis, N. Ahmed, P. Prithviraj, Fiona Elsey Cancer Research Institute, Ballarat, AU
- 18:00 - 18:00 **215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications**
S. Singh, MAX SUPERICIALITY HOSPITAL SHALIMAR BAGH, Delhi, IN
- 18:00 - 18:00 **216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour**
M. Mostafa¹, Y. Ashraf², ¹faculty of medecine suez canal university, Ismailia, EG, ²Suez Canal University - Faculty of Medicine, Ismailia, EG
- 18:00 - 18:00 **217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab**
K. Ogiwara¹, E. Kikuchi¹, T. Okabe², S. Hattori³, R. Yamashita⁴, S. Yoshimine⁵, S. Shirotake², K. Matsumoto¹, R. Mizuno¹, S. Hara³, M. Oyama², M. Niwakawa⁴, M. Oya¹, ¹Keio University School of Medicine, Tokyo, JP, ²Saitama Medical University International Medical Center, Saitama, JP, ³Kawasaki Municipal Hospital, Kanagawa, JP, ⁴Shizuoka Cancer Center, Shizuoka, JP, ⁵Saitama City Hospital, Saitama, JP
- 18:00 - 18:00 **219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients**
A.D. Satiti¹, H. Mistry², Y.P. Song³, A. Choudhury³, ¹Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID, ²University of Manchester, Manchester, GB, ³The Christie Hospital NHS Foundation Trust, Manchester, GB
- 18:00 - 18:00 **220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma**
A. Tamhankar, P. Ahluwalia, G. Gagan, S. Singh, Max institute of cancer care, Delhi, IN
- 18:00 - 18:00 **221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence**
H. Lai¹, Y.-L. Su², S.-Y. Huang¹, C.-C. Wu¹, ¹Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TW, ²Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, TW
- 18:00 - 18:00 **222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis**
R. Kanodia¹, A. Jalan², R. Malhotra¹, S. Gurung², ¹All India Institute of Medical Sciences, Delhi, IN, ²BP Koirala Memorial Cancer Hospital, Chitwan, NP
- 18:00 - 18:00 **223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial**

carcinoma

D. Petrylak¹, J. Rosenberg², J. Lee³, J. Yonese⁴, I. Duran⁵, Y. Loriot⁶, G. Sonpavde⁷, C. Wu⁸, E. Gartner⁹, A. Melhem-Bertrandt⁸, T. Powles¹⁰, ¹Yale University School of Medicine, New Haven, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁴Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, ⁵Hospital Universitario "Marqués de Valdecilla", Santander, ES, ⁶Institut Gustave Roussy, Paris, FR, ⁷Dana Farber Cancer Institute,, Boston, US, ⁸Astellas Pharma US, Inc., Northbrook, US, ⁹Seattle Genetics, Inc., Bothell, US, ¹⁰Barts Cancer Institute, Queen Mary University of London, London, GB

18:00 - 18:00 **Gynaecological cancers**

18:00 - 18:00 **230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort**

L. Wu¹, J. Zhu², R. Yin³, X. Wu⁴, G. Lou⁵, J. Wang⁶, Y. Gao⁷, B. Kong⁸, X. Lu⁹, Q. Zhou¹⁰, Y. Wang¹¹, Y. Chen¹², W. Lu¹³, W. Li¹⁴, Y. Cheng¹⁵, J. Liu¹⁶, X. Ma¹⁷, J. Zhang¹⁷, ¹Cancer Hospital - Chinese Academy of Medical Sciences, Beijing, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³West China Second University Hospital, Sichuan University, Chengdu, CN, ⁴Obstetrics and Gynecology Hospital of Fudan University, Shanghai, CN, ⁵Harbin Medical University Cancer Hospital, Harbin, CN, ⁶Hunan Cancer Hospital, Changsha, CN, ⁷Beijing Cancer Hospital, Beijing, CN, ⁸Qilu Hospital of Shandong University, Jinan, CN, ⁹Obstetrics and Gynecology Hospital, Fudan University, Shanghai, CN, ¹⁰Chongqing Cancer Hospital, Chongqing, CN, ¹¹Xi'an Jiatong University, Xi'an, CN, ¹²The First Affiliated Hospital of Soochow University, Suzhou, CN, ¹³Women's Hospital, Zhejiang University, Hangzhou, CN, ¹⁴The First Hospital of Jilin University, Changchun, CN, ¹⁵Jilin Cancer Hospital, Changchun, CN, ¹⁶Sun Yat-sen University Cancer Center, Guangzhou, CN, ¹⁷AstraZeneca, Shanghai, CN

18:00 - 18:00 **231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore**

D.S. Tan¹, J.J. Chan², J.K. Loke³, R. Hettle⁴, W. Ghosh⁵, A. Viswambaram⁵, C.C. Yu³, ¹NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ²National Cancer Centre, Singapore, SG, ³AstraZeneca, Singapore, SG, ⁴PAREXEL Access, London, GB, ⁵Costello Medical Singapore Pte Ltd, Singapore, SG

18:00 - 18:00 **232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors**

D. Richardson¹, G. Shapiro², K. Do³, C. Leath, Iii⁴, J. Sachdev⁵, J. Melear⁶, E. Hamilton⁷, G. Fleming⁸, C. Mathews⁹, J. Hou¹⁰, C. Anderson¹¹, K. Papadopoulos¹², J. Chan¹³, D. Miller¹⁴, S. Richey¹⁵, S. Mathews¹⁶, D. Ngo¹⁶, G. Hodgson¹⁶, D. Roth¹⁶, D. Juric¹⁷, ¹Stephenson Cancer Centre, Oklahoma City, US, ²Dana-Farber Cancer Institute, Boston, US, ³Dan-Farber Cancer Institute, Boston, US, ⁴University of Alabama, Tuscaloosa, US, ⁵Virginia G. Piper Cancer Center Clinical Trials, Scottsdale, US, ⁶Texas Oncology, Austin, US, ⁷Sarah Cannon Research Institute and Tennessee Oncology, Nashville Tennessee, US,

⁸University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ⁹Women and Infants of Rhode Island, Providence, US, ¹⁰Columbia University Medical Center, New York, US, ¹¹Willamette Valley Cancer Institute and Research Center, Eugene, US, ¹²South Texas Accelerated Research Therapeutics (START), San Antonio, US, ¹³Sutter Health, Sacramento, US, ¹⁴UT Southwestern Medical, Dallas, US, ¹⁵Texas Oncology, Fort Worth, US, ¹⁶Syros Pharmaceuticals, Cambridge, US, ¹⁷Massachusetts General Hospital, Boston, US

- 18:00 - 18:00 **233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility**
N. Hitchen, A. Mweempwa, M. Wilson, Auckland City Hospital, Auckland, NZ
- 18:00 - 18:00 **234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre**
E. Wong, K. Chrystal, M. Wilson, L. Wilson, C. Forgeng, K. Gamet, R. Stephens, Auckland City Hospital, Auckland, NZ
- 18:00 - 18:00 **235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study**
J.-G. Zhou¹, S.-H. Jin², H. Ma³, ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²Zunyi Medical College Affiliated Stematological Hospital, Zunyi City, CN, ³Zunyi Medical College Affiliated Hospital, Zunyi City, CN
- 18:00 - 18:00 **236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What's next PARP inhibitors?**
H. Gong, West China Second Hospital,, Chengdu, CN
- 18:00 - 18:00 **237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience**
S. Baghmar¹, A. Agarwal², C. Gauda³, S. Qureshi³, P. Malik⁴, V. Vaibhav³, ¹Institute of Liver and Biliary Sciences, New Delhi, IN, ²BLK Superspeciality Hospital, New Delhi, IN, ³BLK Superspeciality Hospital, new delhi, IN, ⁴B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), New Delhi, IN
- 18:00 - 18:00 **238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center**
V. Gupta, K. Raju, T.S. Rao, R. Iyer, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN
- 18:00 - 18:00 **239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer**
V. Pareek¹, R. Bhalavat², M. Chandra², ¹Jupiter Hospital, Mumbai, IN, ²Jupiter Hospital, Thane, IN
- 18:00 - 18:00 **240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan**
A. Zhabagina, Semey State Medical University, Semey, KZ

- 18:00 - 18:00 **241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer**
I. Kuno¹, D. Takayanagi², H. Yoshida³, S. Hirose², N. Murakami³, M. Uno³, M. Ishikawa³, M. Matsuda², Y. Asami², Y. Shimada², K. Okuma³, T. Kohno², J. Itami³, K. Shiraishi², T. Kato³, ¹Osaka International Cancer Institute, Osaka, JP, ²National Cancer Center Research Institute, Tokyo, JP, ³National Cancer Center Hospital, Tokyo, JP
- 18:00 - 18:00 **242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment**
V. Pareek¹, R. Bhalavat², M. Chandra², ¹Jupiter Hospital, Mumbai, IN, ²Jupiter Hospital, Thane, IN
- 18:00 - 18:00 **243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening**
P. Wibisono¹, V. Damay¹, K. Waren¹, I.K. Effendi², ¹University of Pelita Harapan, Tangerang, ID, ²Siloam Hospital Lippo Village, Tangerang, ID
- 18:00 - 18:00 **245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia**
H. Puspitaningtyas¹, D. Napitupulu², K. Mualim³, A. Kusumanto², L. Lazuardi⁴, S. Hutajulu¹, ¹Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID, ²Universitas Gadjah Mada, Sleman, ID, ³Temanggung Distric Health Office, Temanggung, ID, ⁴Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sleman, ID
- 18:00 - 18:00 **246P - The main of reasons of advanced stage cervical cancer in Uzbekistan**
Z. Nargiza¹, O. Akhmedov², V. Saidakhmedova², E. Osmanova³, N. Umarova⁴, G. Nekova², M. Otajonov², ¹National Oncology Center, Fergana-Uzbekistan, Fergana, UZ, ²National Cancer Center, Tashkent, UZ, ³Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Tashkent, UZ, ⁴National Cancer Research Center of Uzbekistan, Tashkent, UZ
- 18:00 - 18:00 **247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease**
V.P.B. Koyyala, A. Jajodia, A. Chaturvedi, V. Mahawar, M. Sharma, P. Goyal, V. Talwar, S. Goyal, D.C. Doval, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN
- 18:00 - 18:00 **248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India**
A. Halder, D. Lokanatha, L. Jacob, M. Sureshababu, K. Lokesh, A. Rudresha, L. Rajeev, S. Smitha, Kidwai Cancer Institute, Bangalore, IN
- 18:00 - 18:00 **249P - Accuracy of endometrial biopsy by Pipelle: A systematic review and meta-analysis**
J. Gou¹, Z.Y. Li², ¹West China Second Hospital,, Chengdu, CN, ²West China Second Hospital, Sichuan University, Chengdu, CN

- 18:00 - 18:00 **250P - Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities**
G. Nogueira Da Costa¹, I. Eiriz², I. Fernandes³, M. Batista², R. Vicente², A. Mendes², T. Tomás², C. Santos², S. Braga², ¹Hospital Nossa Senhora do Rosário (Centro Hospitalar Barreiro Montijo, EPE), Barreiro, PT, ²Hospital Prof. Dr Fernando Fonseca E.P.E (Amadora/Sintra), Amadora, PT, ³Centro Hospitalar Barreiro Montijo, Barreiro, PT
- 18:00 - 18:00 **251P - A prognostic index model for predicting long-term recurrence of uterine leiomyoma after initial myomectomy in women aged 18-44 years**
X. Ming¹, N. Li², D. Nie³, J.H. Gou⁴, L.Q. Xue⁴, Z.Y. Li⁴, ¹West China Second Hospital,, Chengdu, CN, ²the First People's Hospital of Zun Yi, Chengdu, CN, ³the Affiliated Hospital of Southwest Medical University, Chengdu, CN, ⁴West China Second Hospital, Sichuan University, Chengdu, CN
- 18:00 - 18:00 **252P - Uterine sarcomas in Qatar: Clinico-pathological characteristics and treatment outcome**
A. Fadlelseid, H. Mr Ghazouani, W. Al Saadi, N. Omar, H. Al Malik, Hamad Medical Corporation (HMC)-National Center for Cancer Care and Research (Al Amal Hospital), Doha, QA
- 18:00 - 18:00 **253P - Anti-PD-1-induced reinvigoration of tumour-infiltrating CD8⁺ T cells in epithelial ovarian cancer patients is correlated with T cell factor-1**
J. Park¹, G. Leem², E.-C. Shin³, Y.J. Lee¹, J.-Y. Lee¹, S.-H. Park³, S. Kim¹, ¹Yonsei University College of Medicine, Seoul, KR, ² Korea Advanced Institute of Science and Technology, Daejeon, KR, ³Korea Advanced Institute of Science and Technology, Daejeon, KR
- 18:00 - 18:00 **254P - Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)**
D. Aziz¹, C. Lee², V. Chin², K. Fernandez², D. Etemadmoghadam³, D. Bowtell⁴, P. Waring¹, C.E. Caldon², ¹The University of Melbourne, Melbourne, AU, ²The Kinghorn Cancer Centre, Sydney, AU, ³Victorian Comprehensive Cancer Center, Parkville, AU, ⁴Peter MacCallum Cancer Center, Melbourne, AU
- 18:00 - 18:00 **255P - MEX3A is a prognostic biomarker and correlates with RNA splicing and cell proliferation in endometrial cancer by analysis of RNA-seq data**
H. Jing, West China Medical Center of Sichuan University, Chengdu, CN
- 18:00 - 18:00 **256P - Lnc-AL445665.1-4 may be involved in the development of multiple uterine leiomyoma through interacting with miR-146b-5p**
E. Yang, West China Second Hospital,, Chengdu, CN
- 18:00 - 18:00 **257P - Treatment results of low risk gestational trophoblastic neoplasia (GTN) from a tertiary hospital, Chennai, India**
R. M. P., Madras Medical College, Chennai, IN
- 18:00 - 18:00 **258P - Assessment of sexual health in patients treated for ovarian cancer**

R. Madan, C. Dracham, A. Elangovan, B. Rai, S. Ghoshal, PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IN

- 18:00 - 18:00 **259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis**
L. Na¹, T.W.Y. Hu², X. Ming², Z.Y. Li³, ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²West China Second Hospital, Chengdu, CN, ³West China Second Hospital, Sichuan University, Chengdu, CN
- 18:00 - 18:00 **260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts**
D. Chekini¹, A. Tryakin², M. Fedyanin², A. Bulanov³, I. Pokataev¹, K. Zhordania⁴, E. Ignatova¹, S. Tjuliandin⁵, ¹FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ²N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ³No place of work provided Iran, Teheran, IR, ⁴Russian Cancer Research Center. NN Blokhin, Moscow, RU, ⁵FSBI "Center for strategic planning" of the Ministry of Health of the Russian Federation, Moscow, RU
- 18:00 - 18:00 **261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India**
V. Sreedath, K. K, S.K. S, Madras Medical College, Chennai, IN
- 18:00 - 18:00 **262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases**
K. Oualla¹, L. Nouiak¹, K. Messoudi¹, Z. Benbrahim¹, S. Arifi¹, N. Mellas², ¹CHU - University Hospital of Hassan II, Fez, MA, ²University Hospital of Hassan II, Fez, MA
- 18:00 - 18:00 **263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib; the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer**
K. Fujiwara¹, H.-H. Chou², J.-W. Kim³, D.S. Tan⁴, K. Tamura⁵, N. Katsumata⁶, K. Harano⁶, K. Hasegawa⁷, S. Hume⁸, E. Jones⁸, S. Goble⁸, L. Sullivan⁸, D. Shih⁸, R. Coleman⁹, I. Mcneish¹⁰, B. Monk¹¹, R. Kristeleit¹², ¹Saitama Medical University Internatl Medical Centre, Saitama, JP, ²Chang Gung Memorial Hospital, Taoyuan City, TW, ³Seoul National University College of Medicine, Seoul, KR, ⁴NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ⁵National Cancer Center Hospital (NCCH), Tokyo, JP, ⁶Nippon Medical School Musashi Kosugi Hospital, Kawasaki, JP, ⁷Saitama Medical University International Medical Center, Saitama, JP, ⁸Clovis Oncology, Inc., Boulder, US, ⁹The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁰Imperial College London - Hammersmith Hospital, London, GB, ¹¹Arizona Oncology (US Oncology Network), Phoenix, US, ¹²UCL Cancer Institute/Paul O'Gorman Building, London, GB
- 18:00 - 18:00 **264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer**
K. Fujiwara¹, I. Vergote², J. Sehouli³, V. Salutaris⁴, P. Zola⁵, R. Madry⁶, R. Wenham⁷, J.

Korach⁸, P. Pautier⁹, D. Cibula¹⁰, S. Lheureux¹¹, K. Hasegawa¹², B.-G. Kim¹³, C.-H. Lai¹⁴, A. Gonzalez-Martinez¹⁵, Q. Liu¹⁶, S. Keefe¹⁷, M. Puglisi¹⁸, S. Topuz¹⁹, ¹Saitama Medical University Internatl Medical Centre, Saitama, JP, ²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ³Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ⁴Policlinico Universitario A. Gemelli, Rome, IT, ⁵University of Turin, Turin, IT, ⁶Clinical Hospital of the Transfiguration-University of Medical Sciences, Poznan, PL, ⁷Moffitt Cancer Center, Tampa, US, ⁸Chaim Sheba Medical Center, Ramat Gan, IL, ⁹Gustave Roussy, Villejuif, FR, ¹⁰Charles University First Faculty of Medicine Department of Oncology, Prague, CZ, ¹¹Princess Margaret Cancer Center, Toronto, CA, ¹²Saitama Medical University International Medical Center, Saitama, JP, ¹³Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁴Linkou Chang Gung Memorial Hospital, Taipei, TW, ¹⁵Clinica Universidad de Navarra, Pamplona (Navarra), ES, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹⁸Merck Sharp & Dohme Limited (MSD), Hoddesdon, GB, ¹⁹Istanbul Medical Faculty Hospital, Istanbul, TR

18:00 - 18:00 **265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer**

K. Fujiwara¹, R. Shapira-Frommer², J. Alexandre³, B. Monk⁴, T. Fehm⁵, N. Colombo⁶, M.V. Caceres⁷, K. Hasegawa⁸, C. Dubot⁹, J. Li¹⁰, K. Stein¹¹, S. Keefe¹¹, K. Tewari¹², ¹Saitama Medical University Internatl Medical Centre, Saitama, JP, ²Chaim Sheba Medical Center, Ramat Gan, IL, ³Hôpital Cochin, Paris, FR, ⁴Arizona Oncology (US Oncology Network), Phoenix, US, ⁵Univesitätsklinikum Düsseldorf, Düsseldorf, DE, ⁶Istituto Europeo di Oncologia, Milan, IT, ⁷Roche S.A. Q. e I. - Argentina, Ricardo Rojas, AR, ⁸Saitama Medical University International Medical Center, Saitama, JP, ⁹Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ¹⁰Merck & Co., Inc., Kenilworth, US, ¹¹Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹²University of California, Irvine Medical Center, Orange, US

18:00 - 18:00 **Haematological malignancies**

18:00 - 18:00 **271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India**

L. Moharana, D. Lokanatha, L. Jacob, M. Sureshababu, K. Lokesh, A. Rudresha, L. Rajeev, S. Smitha, Kidwai Cancer Institute, Bangalore, IN

18:00 - 18:00 **272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF- κ B pathway**

X. Sun, 2nd Affiliated Hospital of Dalian Medical University, Dalian, CN

18:00 - 18:00 **273P - MALT1- A20 and NF- κ B expression pattern in patients with non-Hodgkin lymphomas**

A. Alhanafy¹, M. Elshafie², E.S. Abou Elnour², S. Genena², ¹Faculty of Medicine - Menoufia University, Shebin El Kom, EG, ²Faculty of Medicine - Menoufia University, sheben elkom, EG

- 18:00 - 18:00 **274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene**
R. Karakulov¹, Z. Amankulov², ¹Kazakh Institute of Oncology & Radiology, ALMATY, KZ, ²Kazakh Reserch Institute of Oncology & Radiology, Almaty, KZ
- 18:00 - 18:00 **275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam**
G. Nguyen Hoang¹, P. Nguyen², H. Nguyen², K. Do², ¹Hanoi Oncology Hospital, Hanoi, VN, ²K Hospital, Hanoi, VN
- 18:00 - 18:00 **276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis**
G. Veni Prasanna¹, R.R. Boya², C. Bendi¹, P. Voonna², V. Murali Krishna¹, ¹Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam, IN, ²Mahatma Gandhi Cancer Hospital & Research Institute, VISAKHAPATNAM, IN
- 18:00 - 18:00 **277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia**
Z. Ahmed, A. Nasir, M. Sheikh, A. Rizvi, T. Moatter, The Aga Khan University Hospital, Karachi, PK
- 18:00 - 18:00 **278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma**
G. Mangat¹, N. Pilkhwal¹, N. Kayam², S. Attri¹, ¹PAREXEL International, Mohali, IN, ²PAREXEL International, Bangalore, IN
- 18:00 - 18:00 **280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL**
K. Mishra¹, U. Yanamandra², A. Shukla², S. Pramanik², R. Kapoor², S. Das², ¹PGIMER, Chandigarh, Chandigarh, IN, ²Army Hospital (R&R), New Delhi, IN
- 18:00 - 18:00 **281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine**
J. Sun, Z. Zhang, D. Huang, X. Hu, X. Yu, The Second Affiliated Hospital - Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN
- 18:00 - 18:00 **282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling**
N. Gupta¹, R. Kumar², A. Sharma², ¹AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ²All India Institute of Medical Sciences, Delhi, IN
- 18:00 - 18:00 **283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis**
J. Cho, J. Kim, J. Park, J.H. Lim, M.H. Lee, Inha University Hospital, Incheon, KR

- 18:00 - 18:00 **284P - Differences in disease characteristics and survival outcomes of follicular lymphoma in young adults and older population: An institutional analysis**
S. Goyal¹, A. Rudresha¹, D. Lokanatha¹, L. Jacob¹, S. Babu Mc¹, K. Lokesh¹, L. Rajeev¹, S. Smitha¹, B. Sansar², ¹Kidwai Cancer Institute, Bangalore, IN, ²Kidwai Memorial Institute of Oncology, Bangalore, IN
- 18:00 - 18:00 **285TiP - Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667**
C. Mauz-Koerholz¹, K. Kelly², F. Keller³, R. Ramchandren⁴, A. Nahar⁵, L. Giulino-Roth⁶, ¹Universitätsklinik Giessen, Giessen, DE, ²Roswell Park Comprehensive Cancer Center and University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, US, ³Children's Healthcare of Atlanta and Emory University, Atlanta, US, ⁴Karamos Cancer Institute, Detroit, US, ⁵Merck & Co., Inc., Kenilworth, US, ⁶Weill Cornell Medical College, New York City, US
- 18:00 - 18:00 **Head and neck cancer, excluding thyroid**
- 18:00 - 18:00 **294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up**
L.-R. Wu¹, X. He², ¹Jiangsu Province Cancer Hospital, Nanjing, CN, ²Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, CN
- 18:00 - 18:00 **295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma**
S.K. Chan¹, C.W. Choi², T.C. Chau², S.C. Chau², K.O. Lam², S.Y. Chan², C.C. Tong², W.L. Chan², D.L.W. Kwong², T.W. Leung², M.Y. Luk², A.W.M. Lee², V.H.F. Lee², ¹The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, HK, ²LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, HK
- 18:00 - 18:00 **296P - Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution**
W.P. Ch' Ng¹, K.B. Law², J. Khoo¹, ¹National Cancer Institute (Institut Kanser Negara) Malaysia, Putrajaya, MY, ²National Institutes for Health, Shah Alam, MY
- 18:00 - 18:00 **297P - Global longitudinal assessment of treatment outcomes in nasopharyngeal carcinoma (GLANCE-NPC) study**
M.-J. Ahn¹, D. Chirovsky², H. Kuyas³, V. Auclair³, S. Abounit³, S. Joo², R. Shah², M.-H. Yang⁴, ¹Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ²MSD-Merck Sharp & Dohme, Kenilworth, US, ³Kantar, Paris, FR, ⁴Taipei Veterans General Hospital, Taipei, TW
- 18:00 - 18:00 **298P - Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer**
S.-H. Cho, I.J. Chung, W.K. Bae, J. Hwang, Chonnam National University Medical School

& Chonnam National University Hwasun Hospital, Hwasun, KR

- 18:00 - 18:00 **299P - Weekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer**
S. Sudibio¹, H. Handoko², M. Auzan², G. Prajogi², ¹RSUPN - Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo, Central Jakarta/ Jakarta Pusat, ID, ²Cipto Mangunkusumo National General Hospital, Jakarta, ID
- 18:00 - 18:00 **300P - Endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma**
M.-Y. Chen¹, L. You-Ping², X. Zou¹, X. Lv¹, Y.-J. Hua¹, M.-H. Hong¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN
- 18:00 - 18:00 **301P - Oncological outcome following 3 Drug NACT for Bucco-Alveolar carcinoma with Supra-notch ITF extension**
K. Gupta¹, D. Mandlik², K. Patel², ¹Medanta-The Medicity, Gurgaon, IN, ²HCG Cancer Center, Ahmedabad, IN
- 18:00 - 18:00 **303P - Segmental mandibulectomy without reconstruction**
Y. Morishita¹, R. Hayashi², K. Matsuura², T. Shinozaki², W. Okano², T. Tomioka², ¹National Cancer Center Hospital, Tokyo, JP, ²National Cancer Center Hospital East, Chiba, JP
- 18:00 - 18:00 **304P - Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study**
F. Pontes¹, I. Rego², I. Domingues³, L. Pinto⁴, R. Garcia², M. Teixeira³, T. Serra², L. Khoury², M. Mariano¹, G. Sousa³, ¹Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, ²Portuguese Oncology Institute of Coimbra, Coimbra, PT, ³Instituto Português Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, ⁴Centro Hospitalar e Universitário de Coimbra, Coimbra, PT
- 18:00 - 18:00 **305P - A retrospective study to evaluate patient characteristics for recurrent head and neck cancer after definitive treatment**
T. Wakasugi¹, H. Suzuki², ¹University of Occupational and Environmental, Japan , Kitakyushu, JP, ²University of Occupational and Environmental Health, Japan, Kitakyushu, JP
- 18:00 - 18:00 **306P - Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck**
L. Gui¹, X. He², ¹CAMS and PUMC - National Cancer Center, Cancer Hospital, Beijing, CN, ²CAMS & PUMC ,Cancer Hospital, Beijing, CN
- 18:00 - 18:00 **307P - Lacrimal gland tumours: Clinical and epidemiological patterns in the United States**

M. Khalafallah¹, M. Gouda², A. Alfaar³, ¹Faculty of Medicine - Menoufia University, Shebeen El-Kom, EG, ²Faculty of Medicine - Menoufia University, Shebin ElKom, EG, ³Charité - Universitätsmedizin Berlin, Berlin, DE

18:00 - 18:00 **308P - Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study**

Y.-F. Huang¹, C.-T. Chang², ¹Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, ²Far Eastern Memorial Hospital, Taipei, TW

18:00 - 18:00 **309P - Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients**

A. Horinouchi¹, S. Suzuki², H. Kamata², A. Kaneko², T. Fujisawa², Y. Ueda², T. Enokida², K. Ito², S. Okano², H. Makabe³, T. Kawasaki⁴, M. Tahara², ¹Saitama Medical University International Medical Center, Hidaka, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³Saitama medical university International medical Center, Hidaka, JP, ⁴National Hospital Organization Tokyo Medical Center, Meguro, JP

18:00 - 18:00 **310P - Laser and PDT for the oral leukoplakia**

S. Rasul, Tashkent Medical Academy, Tashkent, UZ

18:00 - 18:00 **311P - Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital**

P. Caguioa¹, K.G. Bebero², M. Bendebel³, J. Saldana⁴, ¹University of Santo Tomas Hospital, Manila, PH, ²USTH - University of Santo Tomas Hospital, Manila, PH, ³USTH - University of Santo Tomas Hospital - Benavides Cancer Institute,, Manila, PH, ⁴USTH - University of Santo Tomas Hospital - Benavides Cancer Institute, Manila, PH

18:00 - 18:00 **312P - Oral health disparities among privileged and underprivileged tribes of south India - A study on precancerous oral lesions prevalence**

S. Palliyal, DM Wayanad Institute of Medical Sciences, Kalpetta, IN

18:00 - 18:00 **313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019**

J.P. Chen, National Taiwan University Hospital - Yunlin Branch, Douliu City, TW

18:00 - 18:00 **314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo**

H. Kitano, A. Mamiya, Y. Masaoka, C. Hidai, Nihon University School of Medicine, Tokyo, JP

18:00 - 18:00 **315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab**

J. Bonner¹, H. Trummell², E. Yang¹, ¹University of Alabama at Birmingham Hospital, Birmingham, US, ²University of Alabama at Birmingham, Birmingham, US

18:00 - 18:00 **316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of**

care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study

E. Cohen¹, R. Uppaluri², N. Lee³, W. Westra⁴, R. Haddad⁵, S. Temam⁶, C. Le Tourneau⁷, R. Chernock⁸, S. Safina⁹, Y. Tao¹⁰, A. Klochikhin¹¹, A. Meirovitz¹², I. Brana¹³, J.Y. Ge¹⁴, R. Swaby¹⁵, B. Bidad¹⁶, D. Adkins⁸, ¹Moore's Cancer Center at UC San Diego Health, La Jolla, US, ²Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, US, ³Memorial Sloan-Kettering Cancer Center, New York, US, ⁴Icahn School of Medicine at Mount Sinai, New York, US, ⁵Dana-Farber Cancer Institute, Boston, US, ⁶Gustave Roussy, Villejuif, FR, ⁷Institut Curie, Paris, FR, ⁸Washington University School of Medicine, St. Louis, US, ⁹Republican Dispensary of Tatarstan MoH, Kazan, RU, ¹⁰Institut Gustave Roussy, Villejuif, FR, ¹¹Yaroslavl State Medical Academy, Yaroslavl, RU, ¹²Hadassah Ein Kerem, Jerusalem, IL, ¹³Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹⁴Merck & Co., Inc., Kenilworth, US, ¹⁵Merck & Co Inc, North Wales, US, ¹⁶Merck, Sharpe & Dohme NA, New York, US

18:00 - 18:00 **Immunotherapy of cancer**

18:00 - 18:00 **322P - Three-year overall survival update from the PACIFIC trial**

Y.-L. Wu¹, J. Gray², A. Villegas³, D. Daniel⁴, D. Vicente⁵, S. Murakami⁶, R. Hui⁷, T. Kurata⁸, A. Chiappori², K.H. Lee⁹, B.C. Cho¹⁰, D. Planchard¹¹, L. Paz-Ares¹², C. Faivre-Finn¹³, J. Vansteenkiste¹⁴, D. Spigel¹⁵, M. Taboada¹⁶, P. Dennis¹⁷, M. Özgüroğlu¹⁸, S. Antonia¹⁹, ¹Guangdong General Hospital, Guangzhou, CN, ²H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ³Cancer Specialists of North Florida, Tampa, US, ⁴Tennessee Oncology, Chattanooga, US, ⁵Hospital Universitario Virgen Macarena, Sevilla, ES, ⁶Kanagawa Cancer Center, Yokohama, JP, ⁷The Crown Princess Mary Cancer Centre, Westmead, AU, ⁸Kansai Medical University, Hirakata, JP, ⁹Chungbuk National University Hospital, Cheongju, KR, ¹⁰Yonsei University, Seoul, KR, ¹¹Institut Gustave Roussy, Villejuif, FR, ¹²University Hospital 12 De Octubre, Madrid, ES, ¹³The Christie NHS Foundation Trust, Manchester, GB, ¹⁴University Hospitals Leuven, Leuven, BE, ¹⁵Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ¹⁶AstraZeneca, Royston, GB, ¹⁷AstraZeneca USA, Gaithersburg, US, ¹⁸Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Fatih/İstanbul, TR, ¹⁹Duke University Medical Center - Trent Center, Durham, US

18:00 - 18:00 **323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort**

Y. Li¹, Z. Chen², L. Wu³, W. Tao³, ¹Hubei General Hospital (Wuhan University Renmin Hospital), Wuhan, CN, ²Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ³Renmin Hospital of Wuhan University, Wuhan, CN

18:00 - 18:00 **324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy**

T.Y. Chao¹, C.L. Ho², W.H. Cheng³, C.L. Chang⁴, Y.Y. Hsieh¹, W. Jiang⁵, S. Liu⁵, A. Luk⁶, S.F. Lin⁷, T.C. Hsieh⁷, E. Liu⁵, ¹Shuang-Ho hospital, Taipei Medical University, New Taipei City, TW, ²Tri-Service General Hospital, National Defense Medical Center, Taipei, TW, ³School of Medicine, College of Medicine, Taipei Medical University, Taipei, TW,

⁴Wan Fang Hospital, Taipei Medical University, Taipei, TW, ⁵Shanghai Henlius Biotech, Inc., Shanghai, CN, ⁶Shanghai Henlius Biopharm, Shanghai, CN, ⁷Taiwan Henlix Biotech., Co., LTD., Taipei, TW

- 18:00 - 18:00 **325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma**
L. Wong¹, A. Ang¹, K. Ng², S.H. Tan², S.P. Choo², D. Tai³, J. Lee², ¹NUS-National University of Singapore-Yong Loo Lin School of Medicine (YLLSoM), Singapore, SG, ²NCCS - National Cancer Centre Singapore, Singapore, SG, ³National Cancer Centre Singapore (NCCS), Singapore, SG
- 18:00 - 18:00 **326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies**
E. Rozali, C. Chiang, P. Wang, H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG
- 18:00 - 18:00 **327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution**
X. Liu, Z. Li, Z. Cai, G. Chen, J. Liu, Fujian Medical University, Fuzhou, CN
- 18:00 - 18:00 **328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors**
F. Hayashi¹, H. Taniguchi¹, S. Takayuki¹, Y. Umeyama¹, Y. Dotsu¹, H. Gyotoku¹, H. Senju¹, S. Takemoto¹, H. Yamaguchi¹, S. Ono², H. Tomono², M. Shimada², H. Soda², M. Fukuda³, M. Hiroshi¹, ¹Nagasaki University Hospital, Nagasaki, JP, ²Sasebo City General Hospital, Sasebo, JP, ³Nagasaki University Hospital, nagasaki, JP
- 18:00 - 18:00 **329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pneumonectomy**
X. Liu, Jinzhou Medical University, Jinzhou, CN
- 18:00 - 18:00 **331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder**
S. Ono¹, H. Senju¹, H. Taniguchi¹, H. Tomono², M. Shimada², F. Hayashi¹, T. Suyama¹, N. Honda¹, Y. Umeyama¹, Y. Dotsu¹, H. Gyotoku¹, S. Takemoto¹, H. Yamaguchi¹, M. Fukuda¹, H. Soda², H. Mukae¹, ¹Nagasaki University Hospital, Nagasaki, JP, ²Sasebo City General Hospital, Sasebo, JP
- 18:00 - 18:00 **332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)**
C.-Y. Cheng¹, P.-J. Su², K.-C. Chang³, T.-C. Tsai³, H.-Y. Chen³, S.-T. Deng³, W.-C. Chang³, ¹Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, ²Chang Gung Memorial Hospital, Linkou, Taoyuan, TW, ³Chang Gung Memorial Hospital, Linkou, Taoyuan City, TW

- 18:00 - 18:00 **333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT**
K. Kibata¹, H. Izuno¹, K. Nakahama¹, Y. Yamanaka¹, T. Kaneda¹, H. Yoshioka², T. Kurata¹, S. Nomura¹, ¹Kansai Medical University, Hirakata, JP, ²Kurashiki Central Hospital, Kurashiki, JP
- 18:00 - 18:00 **334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy**
D. Etoh¹, T. Harada², A. Shimauchi², R. Ibusuki², T. Kayukawa², Y. Okamatsu², K. Inoue², K. Tsubouchi², ¹Japan Community Healthcare Organization, Kyushu Hospital, Kitakyushu, JP, ²JCHO Kyusyu Hospital, Kitakyushu, JP
- 18:00 - 18:00 **335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia**
H. Handoko¹, S. Gondhowiardjo¹, M. Adham¹, L. Lisnawati¹, D. Tobing², H. Kodrat¹, I.M. Haryoga¹, A. Dwiyono¹, Y. Kristian¹, T. Mayang Permata¹, ¹Faculty of Medicine University of Indonesia, Central Jakarta, ID, ²Dharmais Cancer Hospital, Central Jakarta, ID
- 18:00 - 18:00 **336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world**
J. Sugisaka, S. Sugawara, Y. Toi, T. Ogasawara, M. Aso, K. Tsurumi, K. Ono, H. Shimizu, Y. Domeki, T. Aiba, S. Kawana, R. Saito, K. Terayama, Y. Kawashima, A. Nakamura, S. Yamanda, Y. Kimura, Y. Honda, Sendai Kousei Hospital, Sendai, JP
- 18:00 - 18:00 **337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor**
R. Takahashi, E. Shibata, T. Higashiyama, T. Kamei, A. Tada, H. Ishigaki, Y. Nakajima, Y. Negi, M. Niki, K. Mikami, T. Minami, T. Yokoi, K. Kuribayashi, T. Kijima, Hyogo College of Medicine, Nishinomiya, JP
- 18:00 - 18:00 **338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells**
A. Dutta, D. Sengupta, S. Paul, S. Chakraborty, S. Mukherjee, T. Das, Bose Institute, Kolkata, IN
- 18:00 - 18:00 **339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC**
Y.-L. Wu¹, L. Wang², M.A.N. Sendur³, Y.-C. Kim⁴, Z. Zhu⁵, Y. Cheng⁶, P. Li⁷, Y. Qin⁷, E. Macpherson⁸, P. Dennis⁹, S. Lu¹⁰, ¹Guangdong General Hospital and Guangdong Academy of Medical Sciences, Gaungzhou, CN, ² Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ³Ankara Ataturk Research and Teaching Hospital, Ankara, TR, ⁴Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, KR, ⁵Fudan University Shanghai Cancer Center, CN, ⁶Jilin Provincial Cancer Hospital, Changchun, CN, ⁷AstraZeneca, Shanghai, CN, ⁸AstraZeneca, Macclesfield, GB, ⁹AstraZeneca USA, Gaithersburg, US, ¹⁰Shanghai Jiao Tong University, Shanghai, CN

18:00 - 18:00

340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection

S. Yan¹, Y. Zhang², X. Bi³, J. Zhao⁴, S. Du⁵, Z. Huang⁴, Y. Zhang³, D. Liu⁶, Z. Li³, J. Zhou³, J. Cai³, H. Zhao⁷, ¹Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN, ²Affiliate Tumor Hospital of Harbin Medical University, Harbin, CN, ³Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN, ⁴Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁵Peking Union Medical College Hospital, Beijing, CN, ⁶Xuanwu Hospital Capital Medical University, Beijing, CN, ⁷Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, CN

18:00 - 18:00 **Melanoma and other skin tumours**

18:00 - 18:00 **347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma**

Y. Teramoto¹, N. Baba¹, S. Saito¹, K. Sasaki¹, Y. Asami¹, T. Matsuya¹, A. Yamamoto¹, Y. Nakamura², ¹Saitama Medical University Internatl Medical Centre, Saitama, JP, ²Saitama Medical University International Medical Center, Saitama, JP

18:00 - 18:00 **348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients**

S. Shishak¹, S. Rastogi², R. Pandey¹, A. Barwad¹, E. Dhamija¹, A. Aggarwal³, K. Kalra⁴, S.A. Shamim¹, M. Parisa¹, ¹AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ²All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, IN, ³National Cancer Institute-AIIMS, Jhajjar, Haryana, IN, ⁴Vardhman Mahavir Medical College & Safdarjung Hospital(VMMC-SJH), New Delhi, IN

18:00 - 18:00 **349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential**

S. Mishra, Barkatullah University, Bhopal, IN

18:00 - 18:00 **350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases**

A. Hiura¹, K. Yoshino², T. Maeda¹, S. Oaku¹, K. Nagai¹, M. Kato¹, C. Yamashita¹, J. Uehara¹, Y. Fujisawa³, ¹Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, ²Komagome Hospital, Tokyo, JP, ³University of Tsukuba, Tsukuba, JP

18:00 - 18:00 **Palliative care**

18:00 - 18:00 **353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer**

Y. Kim, K.A. Kwon, Dongnam Institute of Radological and Medical Sciences-DIRAMS, Busan, KR

- 18:00 - 18:00 **354P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer**
V. Pareek, Jupiter Hospital, Mumbai, IN
- 18:00 - 18:00 **355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis**
V. Selvaraj, D.K. Gudipudi, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN
- 18:00 - 18:00 **356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective**
V. Dusi¹, S. Attili², M. Singaraju¹, ¹Omega Hospitals, HYDERABAD, IN, ²Omega Hospitals, Hyderabad, IN
- 18:00 - 18:00 **357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain**
S. Joga¹, M.S. Sahi¹, V.P.B. Koyyala¹, P. Medisetty², A. Jajodia¹, K. Chaudhari¹, S. Goyal¹, S. Bommera¹, M. Gairola¹, ¹Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, ²Baba Saheb Ambedkar Hospital, New Delhi, IN
- 18:00 - 18:00 **358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies**
S. Revannasiddaiah¹, K. Pandey¹, I. Madabhavi², N. Pant¹, S. Singh¹, S. Susheela³, M. Rastogi⁴, ¹Swami Rama Cancer Hospital & Research Institute, Uttarakhand, IN, ²Gujarat Cancer and Research Institute, Ahmedabad, IN, ³HCG-Bangalore Institute of Oncology, Bengaluru, IN, ⁴Dr RML Institute of Medical Sciences, Lucknow, IN
- 18:00 - 18:00 **359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community**
M. Yuki¹, K. Kosugi¹, Y. Nishiguchi², T. Miura¹, D. Fujisawa³, Y. Uehara¹, T. Kawaguchi⁴, K. Izumi⁵, J. Takehana⁵, Y. Matsumoto¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²General Incorporated Association Cancer Parents, Tokyo, JP, ³Keio University School of Medicine, Tokyo, JP, ⁴Tokyo University of Pharmacy and Life Sciences, Hachioji, JP, ⁵Medilead Inc, Tokyo, JP
- 18:00 - 18:00 **360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic**
B. De Guzman¹, N. Cabaya², F.I. Ting¹, J. Tan³, ¹University of the Philippines - Philippine General Hospital, Manila, PH, ²Corazon Locsin Montelibano Memorial Regional Hospital, Bacolod City, PH, ³Division of Medical Oncology, Manila, PH
- 18:00 - 18:00 **361P - The role of volunteers in quality palliative care delivery**
N. Mandal, Narikeldaha Prayas, East Medinipur, IN

- 18:00 - 18:00 **362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison**
R. D. Arora, All India Institute of Medical Sciences, Delhi, IN
- 18:00 - 18:00 **Precision medicine**
- 18:00 - 18:00 **366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours**
D. Ziegler¹, F. Doz², B. Georger³, S. Dubois⁴, J. Grilley-Olson⁵, C. Van Tilburg⁶, A. Italiano⁷, A. Lissat⁸, J.-H. Kang⁹, M. Tahara¹⁰, V. Boni¹¹, S. Perreault¹², M. Capra¹³, S. Nanda¹⁴, N. Brega¹⁴, A. Holynskij¹⁴, D. Hong¹⁵, D. Hyman¹⁶, A. Drilon¹⁷, ¹Sydney Children's Hospital, Randwick, AU, ²Paris Descartes University, Paris, FR, ³Université Paris-Sud, Université Paris-Saclay, Villejuif, FR, ⁴Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, US, ⁵University of North Carolina Hospitals, Chapel Hill, US, ⁶Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, DE, ⁷Institute Bergonie, Bordeaux, FR, ⁸Universitätsmedizin Berlin Charite Campus, Berlin, DE, ⁹Seoul St Marys Hospital, Seoul, KR, ¹⁰National Cancer Center Hospital East, Kashiwa, JP, ¹¹START Madrid CIOCC, Madrid, ES, ¹²CHU Sainte Justine, Montreal, CA, ¹³Our Lady Children's Hospital, Dublin, IE, ¹⁴Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, ¹⁵MD Anderson Cancer Center, Houston, US, ¹⁶Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, ¹⁷Memorial Sloan Kettering Cancer Center, New York, US
- 18:00 - 18:00 **367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer**
J. Li, Y. Wang, J. Xu, S. Cao, H. Zhong, Shanghai Chest Hospital, Shanghai, CN
- 18:00 - 18:00 **368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers**
S.-H. Teo¹, M. Zabidi¹, J.W. Pan¹, P.S. Ng¹, M.Y. Meng¹, N. Hasan¹, B. Sandey², C.H. Yip³, P. Rajadurai³, O. Rueda², C. Caldas⁴, S.F. Chin², ¹Cancer Research Malaysia, Subang Jaya, MY, ²CRUK Cambridge Cancer Institute, Cambridge, GB, ³Sime Darby Medical Centre Subang Jaya, Subang Jaya, MY, ⁴Cancer Research UK & University of Cambridge UK, Cambridge, GB
- 18:00 - 18:00 **369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases**
H. Loong¹, C. Chow², K. Ho², J. Fung², J. Koh², T.-C. Chan², L. Leung², W. Yeo¹, B. Ma¹, S. Chan², E. Hui¹, K. Lee², A. Wong², D.C.M. Lam³, K.C.W. Wong³, S.-T. Mok², K.-F. To², ¹The Chinese University of Hong Kong, Shatin, HK, ²The Chinese University of Hong Kong, Hong Kong, HK, ³State Key Laboratory of Translational Oncology, Sir YK Pao Cancer Center, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, HK
- 18:00 - 18:00 **370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals**

cancer type-specific mechanisms for high mutation burden

Y.-S. Zang¹, X.-D. Jiao¹, X.-C. Zhang², B. Qin¹, D. Liu², L. Liu³, J. Ni³, Z. Ning³, L. Chen⁴, L. Zhu⁴, S. Qin⁵, J. Zhou⁶, S. Ying⁷, X. Chen⁸, A. Li⁹, T. Hou¹⁰, A. Lizaso¹⁰, H.-H. Zhang¹⁰, K. Liu¹, Z. Wang¹, ¹Shanghai Changzheng Hospital, Shanghai, CN, ²The Affiliated Hospital of Qingdao University, Qingdao, CN, ³Fudan University Shanghai Cancer Center, Shanghai, CN, ⁴The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, CN, ⁵The First Affiliated Hospital of Suzhou University, Suzhou, CN, ⁶First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, ⁷Taizhou Central Hospital, Taizhou, CN, ⁸Hangzhou Cancer Hospital, Hangzhou, CN, ⁹Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, CN, ¹⁰Burning Rock Biotech, Shanghai, CN

18:00 - 18:00 **371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers**

R. Nagarkar¹, D. Patil², V. Palwe¹, V. Datta², A. Ghaisas², N. Srivastava², A. Srinivasan², D. Akolkar², R. Datar², ¹HCG Manavata Cancer Centre, Nasik, IN, ²Datar Cancer Genetics, Nashik, IN

18:00 - 18:00 **372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequencing: A multicenter study**

Y. Shen¹, S. Fang², X. Cai³, Y. Fang⁴, R. Lin⁵, Y. Zhang⁶, J. Li⁷, X. Liang⁸, L. Wang⁹, L. Lin¹⁰, L. Zhang¹¹, H. Feng¹², S. Lan¹³, X. Cai¹⁴, C. Xu⁵, W. Wang¹⁵, M. Fang¹⁵, J. Zhang¹⁶, ¹The Second Affiliated Hospital of Jiaying Medical College, Jiaying, CN, ²Daping Hospital and Research Institute of Surgery, Army Medical University, Chongqing, CN, ³Sun Yat-sen University Cancer Hospital, Guangzhou, CN, ⁴Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, CN, ⁵Fujian Cancer Hospital, Fuzhou, CN, ⁶The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, CN, ⁷Xiamen Cancer Hospital, Xiamen, CN, ⁸The Third People's Hospital of Zhengzhou, Zhengzhou, CN, ⁹Baotou Cancer Hospital, Baotou, CN, ¹⁰Peking University International Hospital, Beijing, CN, ¹¹Daxing Teaching Hospital of Capital Medical University, Beijing, CN, ¹²Shanxi Dayi Hospital, Shanxi Academy of Medical Science, Taiyuan, CN, ¹³The First Hospital of Jilin University, Changchun, CN, ¹⁴the First Affiliated Hospital of Dalian Medical University, Dalian, CN, ¹⁵Zhejiang Cancer Hospital, Hangzhou, CN, ¹⁶The Seven Medical Centre of Chinese PLA General Hospital, Beijing, CN

18:00 - 18:00 **373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)**

A. Tan¹, H. Loong², G.F. Ho³, A. Seet⁴, B. Chiam⁵, D. Cheah⁵, G.S. Tan⁶, K.H. Lim⁶, J.C.-H. Yang⁷, T.S.K. Mok⁸, D.-W. Kim⁹, D.S.W. Tan¹⁰, ¹RNSH - Royal North Shore Hospital, St Leonards, AU, ²The Chinese University of Hong Kong, Shatin, HK, ³University Malaya Medical Center, Kuala Lumpur, MY, ⁴NCCS - National Cancer Centre Singapore, Singapore, SG, ⁵National Cancer Centre Singapore, Singapore, SG, ⁶Singapore General Hospital, Singapore, SG, ⁷National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, ⁸Prince of Wales Hospital, Hong Kong, CN, ⁹Seoul National University Hospital, Seoul, KR, ¹⁰National Cancer Center Singapore, Singapore, SG

18:00 - 18:00 **374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of**

unknown primary (CUP)

N. Peled¹, H. Okuma², O. Rotem³, E. Dudnik³, S. Ikeda⁴, S. Stemmer³, S. Olsen⁵, ¹Ben-Gurion University, Beer Sheva, IL, ²National Cancer Center Hospital, Tokyo, JP, ³Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, ⁴Tokyo Medical and Dental University, Tokyo, JP, ⁵Guardant Health Pte. Ltd., Singapore, SG

- 18:00 - 18:00 **375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer**
H. Lin¹, W. Ran², X. Chen¹, B. Wang¹, P. Yang³, Y. Li², Y. Xiao², X. Wang², G. Li², L. Wang², Y. Han¹, Y. Peng¹, J. Lang¹, Y. Liang¹, G. Tian¹, D. Yuan¹, J. Yang¹, C. Deng¹, X. Xing², ¹Geneis Co. LTD, Beijing, CN, ²The Affiliated Hospital of Qingdao University, Qingdao, CN, ³Yantai Yuhuangding Hospital, Yantai, CN
- 18:00 - 18:00 **376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country**
P. Dash¹, V.P.B. Koyyala¹, M. Suryavanshi², A. Jajodia¹, S. Pasricha¹, V. Goel¹, S. Bothra³, S. Goyal¹, U. Batra¹, D.C. Doval¹, ¹Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, ²Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN, ³Rajiv Gandhi Cancer Institute & Research Centre, Delhi, IN
- 18:00 - 18:00 **377P - NGS in advanced NSCLC in a developing country: Ready for prime time?**
A. B P¹, M. Sharma¹, P. Jain¹, S. Joga¹, V.P.B. Koyyala¹, A. Mehta², U. Batra¹, ¹Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, ²Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN
- 18:00 - 18:00 **378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore**
C.W. Lim¹, J. Samol¹, M. Flook¹, L.L. Goh¹, M.-H. Tan², ¹NHG-National Healthcare Group-Tan Tock Seng Hospital, Singapore, SG, ²Lucence Diagnostics Pte Ltd, Singapore, SG
- 18:00 - 18:00 **379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India**
P. Kulkarni¹, S. Gandhi², A. Dastane³, C. Deshmukh², S. Hingmire², G. Karve³, A. Prayag⁴, D. Kelkar², ¹Noble Hospital, Pune, IN, ²Deenanath Mangeshkar Hospital & Research Centre, Pune, IN, ³Deenanath Mangeshkar Hospital, Pune, IN, ⁴Deenanath Mangeshkar Hospital and Research Centre, Pune, IN
- 18:00 - 18:00 **380P - Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma**
V. Pareek¹, R. Bhalavat², M. Chandra², ¹Jupiter Hospital, Mumbai, IN, ²Jupiter Hospital, Thane, IN
- 18:00 - 18:00 **381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients**
K. Havrysh¹, M. Bogdanov², A. Nurgalieva³, R. Kiyamova³, ¹Taras Shevchenko National University of Kyiv, Educational and scientific centre "Institute of biology", Kiev, UA,

²University of Texas Health Science Center, McGovern Medical School, Houston, US,

³Institute of Fundamental Medicine and Biology of Kazan Federal University, Kazan, RU

- 18:00 - 18:00 **382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma**
S. Bhatia¹, V. Chauhan², M. Vermani², ¹Amity University, Noida, IN, ²Amity Institute of Biotechnology, Noida, IN
- 18:00 - 18:00 **383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer**
Y. Peng¹, H. Lin², Y. Zhang², ¹Geneis (Beijing) Co. Ltd., Beijing, CN, ²the Geneis Co. Ltd., Beijing, CN
- 18:00 - 18:00 **384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients**
M.K. Kim, Samsung Changwon Hospital Sung Kyun Kwan University, Changwon, KR
- 18:00 - 18:00 **385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population**
A. Pasdar¹, F. Afzaljavan², F. Homaei Shandiz², M.M. Kooshyar³, ¹Mashhad University of Medical Science, Mashhad, IR, ²Mashhad University of Medical Sciences, Mashhad, IR, ³Mshhad univaersity of Medical sciences, Mashhad, IR
- 18:00 - 18:00 **386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation**
L. Minigulova¹, V. Skripova¹, A. Nurgalieva², N. Ionova², D. Reshetnikova¹, M. Bogdanov³, R. Kiyamova², ¹Kazan Federal University, Kazan, RU, ²Institute of Fundamental Medicine and Biology of Kazan Federal University, Kazan, RU, ³University of Texas Health Science Center, McGovern Medical School, Houston, US
- 18:00 - 18:00 **387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea**
J.H. Ahn, J.H. Yu, S.J. Nam, J.E. Lee, S.W. Kim, S.K. Lee, B.J. Chae, J.M. Ryu, Samsung Medical Center (SMC), Seoul, KR
- 18:00 - 18:00 **388P - To identify circulating tumour cells by machine learning approach**
Y. Liang, H. Lin, G. Tian, J. Yang, Geneis Co. LTD, Beijing, CN
- 18:00 - 18:00 **389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer**
J.-H. Chen¹, X.-P. Chu¹, J.-T. Zhang¹, Q. Nie¹, J. Su¹, H.-H. Yan¹, H.-P. Zheng², X. Chen², M.-M. Song³, L.-P. Chang³, P.-S. Li³, Y.-F. Guan³, Y.-L. Wu⁴, W.-Z. Zhong¹, ¹Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, ²Accurate International Biotechnology Co., Guangzhou, CN, ³Geneplus Beijing, Beijing, CN, ⁴Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

- 18:00 - 18:00 **Public policy**
- 18:00 - 18:00 **395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019**
L.I. Catedral¹, C.M. Berba², J. Tan², I.T. Tan³, ¹University of the Philippines - Philippine General Hospital, Manila, PH, ²Division of Medical Oncology, Manila, PH, ³Medical Informatics Unit, Manila, PH
- 18:00 - 18:00 **396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute**
C. Mpamani, Uganda Cancer Institute, Kampala, UG
- 18:00 - 18:00 **397P - Development of prediction model for hepatocellular carcinoma in chronic hepatitis B patients**
T. Ungtrakul¹, K. Soonklang², J. Dechma², P. Kusuman², W. Pongpun², ¹Chulabhorn Hospital, Bangkok, TH, ²Chulabhorn Royal Academy, Bangkok, TH
- 18:00 - 18:00 **398P - Planning for future cancer control programs in Uganda: Projections of top five cancers in 2019; incidence in the next decade**
J. Asasira¹, T. Mai², S. Lee², H. Wabinga³, Y. Chang², S.-Y. Jung², H. Cho², ¹NCC-National Cancer Center, Goyang, KR, ²NCC-National Cancer Center, Goyang-si, KR, ³Kampala cancer registry, Kampala, UG
- 18:00 - 18:00 **399P - Prevalence of colorectal cancer risk factors in apparently healthy adults in Suluhan Village, Bali**
C. Trisina¹, C. Driansha¹, C. Driansha¹, R. Martianus¹, L. Soesilopranoto¹, I.W. Sudarsa², ¹Medical Faculty Of Udayana University, Denpasar, ID, ²RSUP Sanglah Denpasar, Denpasar, ID
- 18:00 - 18:00 **400P - Female lung cancer: Emerging issue in Bangladesh**
M.R. Islam, M. Rahman, A.A.M. Khan, M. Alam, S. Siddiqua, National Institute of Cancer Research & Hospital, Dhaka, BD
- 18:00 - 18:00 **401P - Women in oncology: Alarming figures from India**
S. Mailankody¹, J. Bajpai², ¹Cancer Institute Adyar Chennai, Chennai, IN, ²Tata Memorial Centre, Mumbai, IN
- 18:00 - 18:00 **402P - Work-related outcomes among cancer survivors in Singapore**
C.J. Tan¹, L.C. Tan¹, K. Loh², P.S.H. Neo³, E. Finkelstein⁴, A. Chan¹, ¹National University of Singapore, Singapore, SG, ²Singapore Society of Oncology, Singapore, SG, ³National Cancer Centre Singapore, Singapore, SG, ⁴Duke-NUS Medical School, Singapore, SG
- 18:00 - 18:00 **Sarcoma**

- 18:00 - 18:00 **407P - Focal treatments for metastatic soft tissue sarcoma (mSTS) is associated with improved overall survival**
C.T. Chen¹, T.W.-W. Chen², H.-W. Chen¹, C.-Y. Hsu¹, W.-H. Lin¹, P.-M. Huang¹, J.-C. Lee¹, K.-H. Huang¹, R.-S. Yang¹, R.-L. Hong¹, H.-M. Chen³, C.Y. Yang¹, C.-C. Chang¹, ¹National Taiwan University Hospital, Taipei City, TW, ²National Taiwan University Hospital, Taipei, TW, ³National Taiwan University, Taipei City, TW
- 18:00 - 18:00 **408P - The Asian sarcoma consortium sarcoma preceptorship program: A program evaluation study utilizing the Kirkpatrick model (Level 1 and 2)**
F. Gracieux Jr., Philippine General Hospital, Manila, PH
- 18:00 - 18:00 **409P - Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients**
Y. Zhou¹, W. Lu², Y. Zhang², H. Tong², W. Liu³, R. Zhuang², H. Guo⁴, ¹Zhongshan Hospital - Fudan University, Shanghai, CN, ²Zhongshan Hospital, Fudan University, Shanghai, CN, ³Zhongshan Hospital (South Branch), Fudan University, Shanghai, CN, ⁴GenomiCare Biotechnology, Shanghai, CN
- 18:00 - 18:00 **410P - Treatment patterns and outcomes of elderly patients with metastatic soft tissue sarcomas (mSTS)**
Y.-J. Kuo¹, T.W.-W. Chen², H.-W. Chen¹, C.-Y. Hsu¹, W.-H. Lin¹, P.-M. Huang¹, J.-C. Lee¹, H.-M. Chen³, K.-H. Huang¹, C.Y. Yang¹, C.-C. Chang¹, R.-S. Yang¹, R.-L. Hong¹, ¹National Taiwan University Hospital, Taipei City, TW, ²NTU - National Taiwan University - College of Medicine, Taipei City, TW, ³National Taiwan University, Taipei City, TW
- 18:00 - 18:00 **411P - Comparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour**
Y. Suehara, K. Sasa, T. Okubo, T. Hayashi, K. Sano, T. Kurihara, K. Akaike, M. Ishii, Y. Kim, K. Kaneko, T. Saito, Juntendo University International Center (JUIC), Tokyo, JP
- 18:00 - 18:00 **412P - The evaluation of chromosomal changes in patients with osteosarcoma**
N. Karimova, National Cancer Research Center of Uzbekistan, Tashkent, UZ
- 18:00 - 18:00 **413P - The state of molecular biological markers in osteosarcoma**
D. Polatova, Republican Oncology Research Center of Uzbekistan, Tashkent, UZ
- 18:00 - 18:00 **414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital**
K. Mu, M. Maw, M. Aung, A. Win, K. Kyaw, T. Tun, Yangon General Hospital, Yangon, MM
- 18:00 - 18:00 **415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy**
F. Chamberlain¹, E. Cojocaru¹, M. Scaranti¹, J. Noujaim², K. Thway¹, C. Fisher³, C. Messiou¹, D. Strauss¹, A. Miah¹, S. Zaidi¹, C. Benson¹, S. Gennatas¹, R. Jones¹, ¹The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ²Maisonneuve-Rosemont

Hospital, Montreal, CA, ³University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB

- 18:00 - 18:00 **417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India**
D. Bharathi, G. Karunanidhi, P. Sethi, M. Muthukarthikeyan, M. Manivannan, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IN
- 18:00 - 18:00 **418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India**
S. Pawar¹, S. Rastogi¹, E. Dhamija¹, A. Barwad¹, V. Kumar¹, R. Pandey¹, S. Shishak¹, K. Kalra², A. Aggarwal³, A. Garg¹, A. Mridha¹, J. Chaubey¹, S.A. Khan¹, ¹AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ²Vardhman Mahavir Medical College & Safdarjung Hospital(VMMC-SJH), New Delhi, IN, ³National Cancer Institute, AIIMS Jhajjar, Badsa, IN
- 18:00 - 18:00 **Supportive care**
- 18:00 - 18:00 **423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis**
T. Hayashi¹, M. Shimokawa², K. Matsuo³, H. Iihara⁴, J. Nishimura⁵, T. Nakano¹, T. Egawa¹, ¹Fukuoka University, Fukuoka, JP, ²National Hospital Organization Kyusyu Cancer Center, Hakata, JP, ³Fukuoka University Chikushi Hospital, Chikushino, JP, ⁴Gifu University Hospital, Gifu, JP, ⁵Osaka International Cancer Institute, Osaka, JP
- 18:00 - 18:00 **424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients**
J.S. Park¹, Y.J. Lee¹, S.-T. Lee¹, J.W. Han¹, T.I. Kim¹, E.J. Nam¹, H.S. Park², ¹Yonsei University, Seoul, KR, ²Severance Hospital, Yonsei University College of Medicine, Seoul, KR
- 18:00 - 18:00 **425P - Economic and safety evaluation of 5-HT3 receptor antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study**
K. Yamakita¹, Y. Kitano², Y. Suzuki³, H. Iwamoto³, K. Takahashi³, T. Ota³, ¹Asahikawa Medical University Hospital, Asahikawa, JP, ²Asahikawa Medical University Hospital, Asahikawa Hokkaido, JP, ³Asahikawa Medical University, Asahikawa, JP
- 18:00 - 18:00 **426P - Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy**
N. Takeuchi, S. Kurosawa, K. Koike, S. Yoshida, Ina Central Hospital, Ina, JP
- 18:00 - 18:00 **427P - Sahai: A restorative support to address unmet needs of women with cancer – impact on quality of life**

P. Maurya¹, A. Sadanandan¹, M. Aal², S. Ravi³, P.P. Bapsy⁴, ¹Apollo Hospitals, Bangalore, IN, ²Health Care Global (HCG), Bangalore, IN, ³Prameya Health Care Pvt. Ltd., Bangalore, IN, ⁴Apollo Hospitals - Bangalore, Bangalore, IN

- 18:00 - 18:00 **428P - A pilot study on comparative efficacy of tramadol or eutectic mixture of local anaesthetics (prilocaine plus lignocaine) in preventing bone marrow aspiration associated pain**
- B. Sansar¹, A. Rudresha², D. Lokanatha², L. Jacob², M. Sureshbabu², K. Lokesh², L. Rajeev², S. Smitha², S. Goyal², S. Hassan², ¹Kidwai Memorial Institute of Oncology, Bangalore, IN, ²Kidwai Cancer Institute, Bangalore, IN
- 18:00 - 18:00 **429P - Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events**
- S.Y. Oh¹, J.H. Ji², Y. Kim³, S. Lee¹, S.J. Huh¹, J.H. Lee¹, K.-H. Song¹, C.H. Son¹, J.H. Kang⁴, M.S. Roh¹, J.M. Kim⁵, J.E. Choo⁵, ¹Dong-A University College of Medicine, Busan, KR, ²Samsung Changwon Hospital, Changwon, KR, ³Gachon University Gil Medical Center, Incheon, KR, ⁴Gyeongsang National University Hospital, Jinju, KR, ⁵Daewoong Pharmacy, Yongin, KR
- 18:00 - 18:00 **430P - Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis**
- K. Matsuo¹, M. Shimokawa², T. Hayashi³, H. Iihara⁴, T. Nakano⁵, O. Imakyure⁶, T. Egawa³, ¹Fukuoka University Chikushi Hospital, Chikushino, JP, ²National Hospital Organization Kyusyu Cancer Center, Hakata, JP, ³Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, JP, ⁴Gifu University Hospital, Gifu, JP, ⁵Fukuoka University, Fukuoka, JP, ⁶Fukuoka University Chikushi Hospital, Fukuoka, JP
- 18:00 - 18:00 **431P - An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue**
- N.Y. Yap¹, H.K. Ho¹, H.F. Zheng², C.J. Tan¹, Y.L. Toh¹, C.C. Ng¹, A. Chan¹, ¹National University of Singapore, Singapore, SG, ²Singapore Thong Chai Medical Institute, Singapore, SG
- 18:00 - 18:00 **432P - Chemotherapy induced extravasation: Incidence and possible predictors**
- S. Somayaji¹, S. Reddy¹, M. Krishna Murthy¹, V. Maka², ¹M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ²M. S. Ramaiah Medical College and Hospitals, Bangalore, IN
- 18:00 - 18:00 **433P - Prospective outcomes of adolescent and young adult (AYA) patients received treatment from a tertiary cancer hospital in Bangladesh**
- A.A.M. Khan¹, M. Islam¹, M. Sumon², M. Alam¹, A.T.M. Hasan¹, ¹National Institute of Cancer Research & Hospital, Dhaka, BD, ²Kurmitola General Hospital, Dhaka, BD
- 18:00 - 18:00 **434P - Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases**

S. Kaku¹, H. Horinouchi², H. Watanabe¹, K. Tamura³, T. Okusaka², N. Boku², N. Yamazaki², Y. Ohe², M. Kusumoto², ¹National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP, ²National Cancer Center Hospital, Tokyo, JP, ³National Cancer Center Hospital (NCCH), Tokyo, JP

- 18:00 - 18:00 **435P - Telephonic communication in palliative care for better management of terminal cancer patients in rural India: An NGO based approach**
N. Mandal, Narikeldaha Prayas, East Medinipur, IN
- 18:00 - 18:00 **436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists**
F.I. Ting, J.M. Callueng, J. Vallente, R.A. Hurtado, A. Ramirez, L.I. Catedral, R.E. King, K.A. Mondragon, R. Velasco, Jr., J. Ignacio, C. Ngelangel, University of the Philippines - Philippine General Hospital, Manila, PH
- 18:00 - 18:00 **437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients**
A. Kurniawan¹, R. Hatma², A. Adisasmita², N. Soetandyo³, F. Witjaksono³, S. Panigoro³, D. Rivami⁴, R. Sumantri⁵, T. Tamin³, F. Wijovi⁶, H. Putri⁶, W. Raffaello⁶, O. Saroso⁶, J. Rahman⁶, D. Halim⁶, ¹Siloam Hospital/Medical faculty of Pelita Harapan University, Tangerang, ID, ²Faculty of Public Health, Universitas Indonesia, Depok, ID, ³Faculty of Medicine, Universitas Indonesia, Jakarta, ID, ⁴Faculty of Medicine, Pelita Harapan University, Jakarta, ID, ⁵Faculty of Medicine, Padjadjaran University, Bandung, ID, ⁶Faculty of Medicine, Pelita Harapan University, Tangerang, ID
- 18:00 - 18:00 **438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients**
Y.L. Toh¹, S. Maung², A. Chan², ¹NUS- National University of Singapore-Department Of Pharmacy, Singapore, SG, ²National University of Singapore, Singapore, SG
- 18:00 - 18:00 **440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients**
J. Harika¹, V. Maka², A. D³, M. Krishna Murthy³, A. Mandepudi³, P. Paibhavi³, S.P. Kanneganti³, S. Vungarala⁴, ¹MS Ramaiah Memorial Hospital, Bangalore, IN, ²M. S. Ramaiah Medical College and Hospitals, Bangalore, IN, ³M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ⁴M. S. Ramaiah University of Applied Sciences, bangalore, IN
- 18:00 - 18:00 **441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine**
T.H. So¹, Z. Chow², K.S. Chan², K.O. Lam³, V.H.F. Lee³, H. Choi², ¹Queen Mary Hospital, Hong Kong, HK, ²University of Hong Kong, Hong Kong, HK, ³LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, HK
- 18:00 - 18:00 **442P - Relationship between QOL and support elderly patients with permanent colostomies**
Y. Orii, Kanagawa University of Health Services, Tokyo, JP

- 18:00 - 18:00 **443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study**
S. Koshimoto¹, M. Arimoto², K. Saitou², A. Hashizume², J. Kako³, K. Mcmanus¹, K. Amano⁴, Y. Nakajima², H. Uetake², E. Matsushima⁵, ¹Tokiwa University, Mito, JP, ²Tokyo Medical and Dental University Hospital, Tokyo, JP, ³Hiroshima University, Hiroshima, JP, ⁴Osaka City General Hospital, Osaka, JP, ⁵Tokyo Medical and Dental University, Tokyo, JP
- 18:00 - 18:00 **444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine**
T. Tsuchiya¹, T. Kume¹, K. Akiyama¹, K. Yoshitsugu², M. Fukaya², T. Enami², R. Tatara², M. Shino¹, T. Ikeda², ¹Shizuoka Cancer Center Hospital, Nagaizumi, JP, ²Shizuoka Cancer Center, Shizuoka, JP
- 18:00 - 18:00 **445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments**
S.B. Oh, J.-J. Kim, S.-Y. Oh, K. Park, Pusan National University Yangsan Hospital, Yangsan, KR
- 18:00 - 18:00 **446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy**
J. Harika¹, V. Maka², A. D³, M. Krishna Murthy³, A. Mandepudi³, P. Paibhavi³, S.P. Kanneganti³, S. Vungarala⁴, ¹MS Ramaiah Memorial Hospital, Bangalore, IN, ²M. S. Ramaiah Medical College and Hospitals, Bangalore, IN, ³M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ⁴M. S. Ramaiah University of Applied Sciences, bangalore, IN
- 18:00 - 18:00 **447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation**
S. Ahmed¹, A.K. Sengupta¹, M.R.U. Nabi¹, M. Sumon², ¹United Hospital Ltd, Dhaka, BD, ²Kurmitola General Hospital, Dhaka, BD
- 18:00 - 18:00 **448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy**
A. Mandepudi¹, P. Paibhavi¹, M. M¹, V. Maka², J. Harika³, ¹M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ²M. S. Ramaiah Medical College and Hospitals, Bangalore, IN, ³MS Ramaiah Memorial Hospital, Bangalore, IN
- 18:00 - 18:00 **449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients**
P. Paibhavi¹, M.K. Muddiguba¹, V. Maka², A. Mandepudi¹, S.P. Kanneganti¹, ¹M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ²M. S. Ramaiah Medical College and Hospitals, Bangalore, IN

- 18:00 - 18:00 **450P - Supportive care to control nausea and dizziness in malignant tumours: A systematic review**
R. Spiegel¹, S. Rothschild², R. Kalla³, ¹Berufsgenossenschaftliche Unfallklinik Tübingen, Tuebingen, DE, ²Universitätsspital Basel, Basel, CH, ³Bern University Hospital, Bern, CH
- 18:00 - 18:00 **451P - The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study**
N. Hattori¹, T. Yamaguchi², H. Kodama³, T. Miyamoto⁴, T. Terazawa¹, T. Kii⁵, E. Gotoh¹, M. Gotoh¹, ¹Osaka Medical College, Takatsuki, JP, ²National Cancer Center Hospital, Tokyo, JP, ³Rakuwakai Otowa Hospital, Kyoto-fu, JP, ⁴National Cancer Center Research Institute, Chuo-ku, JP, ⁵Osaka Medical College Hospital, Osaka, JP
- 18:00 - 18:00 **452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count**
I. Wahid, Faculty of Medicine, Andalas University, Padang, ID
- 18:00 - 18:00 **453P - Body mass index did not correlate with short term overall survival in breast cancers**
J. Lee, Inje University Haeundae Paik Hospital, Busan, KR
- 18:00 - 18:00 **454P - Predictors of severity and comparison of CTCAE V3.0 vs V4.3 in assessing chemotherapy induced extravasation injuries**
S. Reddy¹, S. Somayaji¹, M. Krishna Murthy¹, V. Maka², ¹M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ²M. S. Ramaiah Medical College and Hospitals, Bangalore, IN
- 18:00 - 18:00 **455P - Assessment of nutritional status and quality of life among cancer patients undergoing chemotherapy**
S. Prathima¹, M. Murthy², V. Maka³, P. Paibhavi¹, J. Harika⁴, S. Vungarala², ¹M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ²M. S. Ramaiah University of Applied Sciences, bangalore, IN, ³M. S. Ramaiah Medical College and Hospitals, Bangalore, IN, ⁴MS Ramaiah Memorial Hospital, Bangalore, IN
- 18:00 - 18:00 **456P - Use of gamma irradiated bone allografts in treatment of various bone tumours**
A. Mishra¹, S. Kapoor², S. Mishra³, Y. Mishra⁴, ¹Gandhi Medical College, Bhopal, IN, ²ISIC, new delhi, IN, ³Barkatullah University, Bhopal, IN, ⁴peoples college of medical sciences, bhopal, IN
- 18:00 - 18:00 **457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival**
C. Ngokngarm¹, C. Bandidwattanawong², ¹Queen Savang Vadhana Memorial Hospital, Amphoe Si Racha, TH, ²Bangkok Metropolitan Administration Medical School and Vajira Hospital, Pathumwan, TH
- 18:00 - 18:00 **Thoracic tumours, early stage**

- 18:00 - 18:00 **458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC**
M. Filipits¹, M.J. Hochmair², A. Buder¹, S. Watzka³, ¹Institute of Cancer Research - Medical University of Vienna, Vienna, AT, ²Otto Wagner Hospital, Sanatoriumstrasse 2, 1140, Vienna, AT, ³Otto Wagner Spital, Vienna, AT
- 18:00 - 18:00 **460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk**
J. Shen¹, H. Zhou², W. Fang², J. Liu¹, Y. Zhang², Y. Huang², L. Zhang², ¹Zhongshan School of Medicine, Sun Yat-sen University North campus, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN
- 18:00 - 18:00 **461P - Blood trace minerals and lung cancer: A Mendelian randomization study**
W. Xian¹, H. Zhou², Y. Zhang², J. Shen¹, J. Liu², L. Zhang², ¹Zhongshan School of Medicine, Sun Yat-sen University North campus, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN
- 18:00 - 18:00 **463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging**
Y. Saeki, S. Kitazawa, N. Kobayashi, S. Kikuchi, Y. Goto, Y. Sato, University of Tsukuba, Tsukuba, JP
- 18:00 - 18:00 **459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women**
C. Cao, Y. Li, Q. Jiang, Ningbo No.1 Hospital, Ningbo, CN
- 18:00 - 18:00 **462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography**
S. Takeo¹, F. Shoji², G. Toyokawa², K. Yamazaki², Y. Kozuma², ¹Kyushu University, Fukuoka, JP, ²National Hospital Organization Kyushu Medical Center, Fukuoka, JP
- 18:00 - 18:00 **Thoracic tumours, locally advanced**
- 18:00 - 18:00 **468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer**
M. Tsuboi¹, Y. Zenke¹, Y. Chiba², M. Satouchi³, S. Mitsuoka⁴, J. Shimizu⁵, H. Daga⁶, D. Fujimoto⁷, M. Mori⁸, T. Aoki⁹, T. Sawa¹⁰, S. Omori¹¹, H. Saka¹², Y. Iwamoto¹³, M. Okuno¹⁴, T. Hirashima¹⁵, K. Kashiwabara¹⁶, M. Tachihara¹⁷, N. Yamamoto¹⁸, K. Nakagawa², ¹National Cancer Center Hospital East, Kashiwa, JP, ²Kindai University Hospital, Osaka, JP, ³Hyogo Cancer Center, Akashi, JP, ⁴Osaka City University Medical School, Osaka, JP, ⁵Aichi Cancer Center Hospital, Nagoya, JP, ⁶Osaka City General Hospital, Osaka, JP, ⁷Kobe City Medical Center General Hospital, Kobe, JP, ⁸National

Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, JP, ⁹Tokai University School of Medicine, Kanagawa, JP, ¹⁰Gifu Municipal Hospital, Gifu, JP, ¹¹Shizuoka Cancer Center, Shizuoka, JP, ¹²National Hospital Organization Nagoya Medical Center, Aichi, JP, ¹³Hiroshima City Hospital, Hiroshima, JP, ¹⁴Okazaki City Aichi Hospital, Aichi, JP, ¹⁵Osaka Habikino Medical Center, Habikino Osaka, JP, ¹⁶Kumamoto Regional Medical Center, Kumamoto, JP, ¹⁷Kobe University Graduate School of Medicine, Kobe, JP, ¹⁸Wakayama Medical University, Wakayama, JP

- 18:00 - 18:00 **469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial**
A. Ata¹, A. Küçük², Ş. Eskici², T. Şanlı², E. Nayır³, ¹Mersin State Hospital, Mersin, TR, ²Mersin State Hospital, MERSİN, TR, ³Medical Park Mersin Hospital, MERSİN, TR
- 18:00 - 18:00 **472P - Integration of expression rate and absolute cell counts of PD-1+stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma**
Q. Song, F. Shi, Q. Zhou, H. Chang, Beijing Shijitan hospital, Beijing, CN
- 18:00 - 18:00 **467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC**
O. Bulgakova, A. Kussainova, A. Kausbekova, R. Bersimbaev, L.N.Gumilyov Eurasian National University, Astana, KZ
- 18:00 - 18:00 **465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis**
J. Wang¹, J. Zhao², H. Bai¹, X. Wang¹, Y. Wang², J. Duan¹, H. Chen³, S. Meng⁴, Y. Tian³, D.C.-L. Huang⁵, Y.-L. Wu⁶, ¹National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN, ³Beijing Cancer Hospital, Beijing, CN, ⁴Ltd, Shanghai, CN, ⁵Boehringer Ingelheim Taiwan, Taipei, TW, ⁶Guangdong General Hospital and Guangdong Academy of Medical Sciences, Gaungzhou, CN
- 18:00 - 18:00 **470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review**
R. Velasco¹, C.E. Barbon², D.B. Sacdalan¹, ¹Philippine General Hospital, Manila, PH, ²University of the Philippines - Philippine General Hospital, Manila, PH
- 18:00 - 18:00 **471P - Chemotherapy in advanced thymic malignancies**
A. Varshney¹, I. Vanidassane², D. Ramavth², P. Malik³, S. Khurana⁴, V. Garg¹, S. Vadlamani², K. Kalra⁵, S. Gunasekar⁶, S. Kumar⁷, S. Sethi², M. Yadav², S. Pathy⁷, D. Jain², ¹AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ²AIIMS - All India Institute of Medical Sciences, NEW DELHI, IN, ³B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), New Delhi, IN, ⁴AIIMS - All India Institute of Medical Sciences, Delhi, IN, ⁵Vardhman Mahavir Medical College & Safdarjung Hospital(VMMC-SJH), New Delhi, IN, ⁶Institute Rotary Cancer Hospital, New Delhi, IN, ⁷All India Institute of Medical

Sciences, New Delhi, IN

- 18:00 - 18:00 **466P - Cancer immunotherapy efficacy and patients' age: A systematic review and meta-analysis**
Y. Jiang, Z. Su, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 18:00 - 18:00 **Thoracic tumours, metastatic**
- 18:00 - 18:00 **506P - Efficacy and safety of pegvorhialuronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)**
J. Ward¹, M. Shum², E. Bertino³, V. Lin⁴, V. Kuruvadi⁴, T. Heineman⁴, ¹Washington University School of Medicine, St. Louis, US, ²The Oncology Institute of Hope and Innovation, Whittier, US, ³Ohio State University, Columbus, US, ⁴Halozyne Inc., San Diego, US
- 18:00 - 18:00 **480P - Safety and efficacy of dacomitinib for EGFR^{WT}; NSCLC in the subgroup of Asian patients from ARCHER 1050**
T.S.K. Mok¹, Y. Cheng², X. Zhou³, K.H. Lee⁴, K. Nakagawa⁵, S. Niho⁶, R. Rosell⁷, R. Linke⁸, C.H. Wong⁹, Y. Tang¹⁰, M. Singh¹¹, K. Wilner¹⁰, Y.-L. Wu¹², ¹Prince of Wales Hospital, Hong Kong, CN, ²Jilin Provincial Cancer Hospital, Changchun, CN, ³First Affiliated Hospital of Third Military Medical University, Chongqing, CN, ⁴Chungbuk National University Hospital, Cheongju, KR, ⁵Kindai University Hospital, Osaka, JP, ⁶National Cancer Center Hospital East, Kashiwa, JP, ⁷Catalan Institute of Oncology, Barcelona, ES, ⁸SFJ Pharmaceuticals®, Pleasanton, US, ⁹Pfizer Inc., MapleTree Business City, SG, ¹⁰Pfizer Oncology, La Jolla, US, ¹¹Pfizer Biopharmaceuticals Group, Hong Kong, HK, ¹²Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN
- 18:00 - 18:00 **503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials**
A. Passaro¹, F. De Marinis¹, H. Tu², K.K. Laktionov³, J. Feng⁴, A. Poltoratskiy⁵, J. Zhao⁶, E.-H. Tan⁷, M. Gottfried⁸, V. Lee⁹, D. Kowalski¹⁰, C.-T. Yang¹¹, B. Srinivasa¹², L. Clementi¹³, W. Tang¹⁴, D.C.-L. Huang¹⁵, A. Cseh¹⁶, K. Park¹⁷, C. Zhou¹⁸, Y.-L. Wu², ¹European Institute of Oncology, Milan, IT, ²Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ³Russian Academy of Medical Sciences, Moscow, RU, ⁴Jiangsu Provincial Tumor Hospital, Jiangsu, CN, ⁵Petrov Research Institute of Oncology, St Petersburg, RU, ⁶Peking University Cancer Hospital & Institute, Beijing, CN, ⁷National Cancer Centre, Singapore, SG, ⁸Tel Aviv University, Tel Aviv, IL, ⁹The University of Hong Kong, Hong Kong, CN, ¹⁰Oncology Centre and Institute, Wasaw, PL, ¹¹Chang Gung Memorial Hospital, 33305, Taoyuan, TW, ¹²HCG Hospital, Bangalore, IN, ¹³S.p.A., Milan, IT, ¹⁴Boehringer Ingelheim Pharmaceuticals, Ridgefield, US, ¹⁵Boehringer Ingelheim Taiwan, Taipei, TW, ¹⁶Boehringer Ingelheim, Vienna, AT, ¹⁷Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁸Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN

- 18:00 - 18:00 **488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)**
K. Kusaka¹, A. Tamura², T. Kozuki³, Y. Koreeda⁴, T. Kita⁵, T. Endo⁶, T. Shibayama⁷, N. Hatakeyama⁸, M. Miura⁹, N. Yamashita¹⁰, M. Takenoyama¹¹, ¹National Hospital Organization - Tokyo National Hospital, Kiyose City, JP, ²National Hospital Organization, Tokyo National Hospital, Tokyo, JP, ³National Hospital Organization Shikoku Cancer Center, matsuyama, JP, ⁴National Hospital Organization Minami-kyushu National Hospital, Aira, JP, ⁵National Hospital Organization Kanazawa Medical Center, Kanazawa, JP, ⁶National Hospital Organization Mito Medical Center, Ibaraki, JP, ⁷National Hospital Organization Okayama Medical Center, Okayama, JP, ⁸National Hospital Organization Kochi Hospital, Kochi, JP, ⁹Akita University Hospital, Akita, JP, ¹⁰National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ¹¹National Hospital Organization Kyusyu Cancer Center, Fukuoka, JP
- 18:00 - 18:00 **495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib**
A. Buder¹, M.J. Hochmair², U. Setinek³, M. Filipits¹, ¹Institute of Cancer Research - Medical University of Vienna, Vienna, AT, ²Otto Wagner Hospital, Sanatoriumstrasse 2, 1140, Vienna, AT, ³Otto Wagner Hospital, Vienna, AT
- 18:00 - 18:00 **520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)**
A. Hata¹, M. Satouchi², S. Morita³, Y. Ota², Y. Urata², Y. Kawa², H. Okada⁴, H. Mayahara⁴, M. Kokubo⁵, Y. Akazawa⁶, T. Uenami⁷, M. Tamiya⁸, K. Kunimasa⁸, K. Nakata⁹, D. Harada¹⁰, A. Nakamura¹¹, N. Takase¹², N. Katakami¹², S. Negoro¹², ¹Institute of Biomedical Research and Innovation, Kobe, JP, ²Hyogo Cancer Center, Akashi, JP, ³Kyoto University, Kyoto, JP, ⁴Kobe Minimally Invasive Cancer Center, Kobe, JP, ⁵Kobe City Medical Center General Hospital, Kobe, JP, ⁶National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, JP, ⁷National Hospital Organization Toneyama Hospital, Toyonaka, JP, ⁸Osaka International Cancer Institute, Osaka, JP, ⁹Japanese Red Cross Kobe Hospital, Kobe, JP, ¹⁰National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ¹¹Kyoto University Graduate School of Medicine, Kyoto, JP, ¹²Takarazuka City Hospital, Takarazuka, JP
- 18:00 - 18:00 **504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours**
P. Song, L. Zhang, PUMCH-Peking Union Medical College Hospital (East), Beijing, CN
- 18:00 - 18:00 **519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia**
C.-H. Kuo¹, K. Yoh², C.-T. Yang¹, C.-C. Wang³, T.-C. Yen⁴, K.-J. Lin⁴, T. Ikeda², Y. Zenke², S. Matsumoto², K. Goto², ¹Chang Gung Memorial Hospital, Linko, Taipei, TW, ²National Cancer Center Hospital East, Kashiwa, JP, ³Chang Gung Memorial Hospital, Kaoshiung, Kaoshiung, TW, ⁴Chang Gung Memorial Hospital, Taipei, TW
- 18:00 - 18:00 **521P - A randomized, phase II study comparing irinotecan versus amrubicin as**

maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)

K. Baba¹, H. Tanaka², Y. Fujita³, A. Nakamura⁴, E. Kikuchi⁵, Y. Kawai⁶, T. Harada⁷, N. Watanabe⁸, H. Yokouchi⁹, K. Usui¹⁰, R. Saito¹¹, H. Watanabe¹², T. Masuda¹³, T. Fukuhara¹⁴, K. Kudo¹⁵, R. Honda¹⁶, S. Oizumi¹⁷, M. Maemondo¹⁸, A. Inoue¹¹, N. Morikawa¹⁸, ¹Hirosaki University - Center for Advanced Medical Research, Hirosaki, JP, ²Hirosaki University, Hirosaki, JP, ³National Hospital Organization Asahikawa Medical Center, Asahikawa, JP, ⁴Sendai Kousei Hospital, Sendai, JP, ⁵Hokkaido University Hospital, Sapporo, JP, ⁶Oji General Hospital, Tomakomai, JP, ⁷JCHO Hokkaido Hospital, Sapporo, JP, ⁸Sunagawa City Medical Center, Sunagawa, JP, ⁹Fukushima Medical University School of Medicine, Fukushima, JP, ¹⁰NTT Medical Center Tokyo, Tokyo, JP, ¹¹Tohoku University School of Medicine, Sendai, JP, ¹²Saka General Hospital, Sendai, JP, ¹³Gunma University, Maebashi, JP, ¹⁴Miyagi Cancer Center, Sendai, JP, ¹⁵National Hospital Organization Osaka Minami Medical Center, Osaka, JP, ¹⁶Asahi General Hospital, Chiba, JP, ¹⁷National Hospital Organization Hokkaido Cancer Center, Sapporo, JP, ¹⁸Iwate Medical University, Morioka, JP

18:00 - 18:00 **526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)**

L. Chu¹, F. Liang², J. Zhang², J. Deng², Y. Chen², Q. Liu², D. Ai², Z. Zhu³, K. Zhao², ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Shanghai Cancer Center Fudan University, Shanghai, CN, ³Fudan University Shanghai Cancer Center, CN

18:00 - 18:00 **499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong**

O.S.H. Chan¹, G. Cheung², M.M.L. Lee³, S. Olsen⁴, ¹Hong Kong Integrated Oncology Centre, Hong Kong, HK, ²The Chinese University of Hong Kong, Shatin, HK, ³Guardant Health AMEA, Singapore, SG, ⁴Guardant Health Pte. Ltd., Singapore, SG

18:00 - 18:00 **489P - Overall survival in patients with EGFRm; NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study**

M.J. Hochmair¹, A. Morabito², D. Hao³, C.-T. Yang⁴, R. Soo⁵, J.C.-H. Yang⁶, R. Gucalp⁷, B. Halmos⁷, L. Wang⁸, A. Märten⁹, T. Cufer¹⁰, ¹Otto Wagner Hospital, Sanatoriumstrasse 2, 1140, Vienna, AT, ²Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS, 80131, Napoli, IT, ³Cummings School of Medicine, University of Calgary, T2N 4N2, Calgary, CA, ⁴Chang Gung Memorial Hospital, 33305, Taoyuan, TW, ⁵National University Hospital, 119047, Singapore, SG, ⁶National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, ⁷Montefiore/Albert Einstein Cancer Center, 10461, Bronx, US, ⁸Taiwan Limited, 104, Taipei City, TW, ⁹International GmbH, 55216, Ingelheim am Rhein, DE, ¹⁰University of Ljubljana, Ljubljana, SI

18:00 - 18:00 **509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial**

A. Camerini¹, A. Morabito², A. Montanino³, R. Bernabe Caro⁴, F. Grossi⁵, R. Ramlau⁶, T.-E. Ciuleanu⁷, G.L. Ceresoli⁸, G. Pasello⁹, F. De Marinis¹⁰, J. Bosch-Barrera¹¹, P. Landreau¹², S. Gautier¹³, C. Ta Thanh Minh¹⁴, D. Kowalski¹⁵, ¹Ospedale "Versilia", Lido di Camaiore, IT, ²Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS, 80131,

Napoli, IT, ³Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁴Hospital Universitario Virgen del Rocio, Sevilla, ES, ⁵IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁶Poznan University of Medical Science, PL, ⁷Ion Chiricuta Oncology Institute-IOCN, Cluj-Napoca, RO, ⁸Humanitas Gavazzeni, Bergamo, IT, ⁹Istituto Oncologico Veneto IRCCS, Padova, IT, ¹⁰Istituto Europeo di Oncologia, Milan, IT, ¹¹ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ¹²Pierre Fabre Oncology, Boulogne-Billancourt, FR, ¹³PIERRE FABRE, Toulouse, FR, ¹⁴Pierre Fabre Oncologie France, Boulogne-Billancourt, FR, ¹⁵Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL

- 18:00 - 18:00 **500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations**
J. Duan¹, H. Bai¹, X. Wang¹, R. Wan¹, H. Cheng², H. Wang², F. Lou², S. Cao², J. Wang¹, ¹National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Beijing, CN, ²Beijing Acornmed Biotechnology Co., Ltd., Beijing, CN
- 18:00 - 18:00 **527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing**
X. Li¹, W. Wang², C. Xu³, X. Pu⁴, S. Fang⁵, X. Cai⁶, Y. Fang⁷, Y. Zhu¹, H. Wang⁸, X. Liang⁹, W. Zhuang³, Y. Zhang¹⁰, L. Wang¹¹, X. Cai¹², J. Li¹³, H. Feng¹⁴, M. Fang², G. Chen³, T. Lv¹⁵, Y. Song¹⁵, ¹Zhejiang Rongjun Hospital, Jiaying, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³Fujian Cancer Hospital, Fuzhou, CN, ⁴Hunan Cancer Hospital, Changsha, CN, ⁵Daping Hospital and Research Institute of Surgery, Army Medical University, Chongqing, CN, ⁶Sun Yat-sen University Cancer Hospital, Guangzhou, CN, ⁷Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, CN, ⁸The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, CN, ⁹The Third People's Hospital of Zhengzhou, Zhengzhou, CN, ¹⁰The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, CN, ¹¹Baotou Cancer Hospital, Baotou, CN, ¹²the First Affiliated Hospital of Dalian Medical University, Dalian, CN, ¹³Xiamen Cancer Hospital, Xiamen, CN, ¹⁴Shanxi Dayi Hospital, Shanxi Academy of Medical Science, Taiyuan, CN, ¹⁵Jinling Hospital, Nanjing, CN
- 18:00 - 18:00 **481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)**
T. Yokoyama¹, H. Yoshioka¹, D. Fujimoto², Y. Demura³, K. Hirano⁴, T. Kawai⁵, R. Kagami⁶, T. Ishida¹, K. Tomii², M. Akai³, M. Hirabayashi⁴, T. Nishimura⁵, Y. Nakahara⁶, Y. Kim⁷, K. Yoshimura⁸, T. Hirai⁷, ¹Kurashiki Central Hospital, Kurashiki, JP, ²Kobe City Medical Center General Hospital, Kobe, JP, ³Japanese Red Cross Fukui Hospital, Hukui, JP, ⁴Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, JP, ⁵Kyoto-Katsura Hospital, Kyoto, JP, ⁶National Hospital Organization Himeji Medical Center, Himeji, JP, ⁷Kyoto University Hospital, Kyoto, JP, ⁸Kanazawa University, Kanazawa, JP
- 18:00 - 18:00 **490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience**
Y. Ang¹, R. Wong¹, C.S. Tan², M.V. Blanco¹, Y. Huang¹, B.C. Goh¹, R. Soo³, ¹NUH-

National University Hospital (S) Pte. Ltd., Singapore, SG, ²OncoCare Cancer Centre, Singapore, SG, ³National University Hospital, 119047, Singapore, SG

- 18:00 - 18:00 **498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study**
S.-G. Wu¹, C.-L. Chiang², C.-Y. Liu³, C.-C. Wang⁴, P.-L. Su⁵, T.-C. Hsia⁶, J.-Y. Shih⁷, G.-C. Chang⁸, ¹National Taiwan University Hospital, Taipei City, TW, ²Taipei Veterans General Hospital, Taipei, TW, ³Linkou Chang Gung Memorial Hospital, New Taipei, TW, ⁴Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, TW, ⁵National Cheng Kung University Hospital, Tainan, TW, ⁶China Medical University Hospital, Taichung, TW, ⁷National Taiwan University Hospital, Taipei, TW, ⁸Taichung Veterans General Hospital, +-- ext., TW
- 18:00 - 18:00 **501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification**
X. Gao¹, X.-W. Wei², Y.-L. Wu³, Q. Zhou², ¹Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences,, Guangzhou, CN, ²Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, GuangZhou, CN, ³Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN
- 18:00 - 18:00 **502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study**
M. Kanazu¹, M. Mori², T. Shiroyama³, I. Nagatomo⁴, S. Ihara⁵, K. Komuta⁵, H. Suzuki⁶, T. Hirashima⁶, M. Kimura⁷, F. Imamura⁷, ¹National Hospital Organization Toneyama Hospital, Toyonaka, JP, ²National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, JP, ³Osaka University Graduate School of Medicine, Suita, JP, ⁴Graduate School of Medicine, Osaka University, Suita Osaka, JP, ⁵Osaka Police Hospital, Osaka, JP, ⁶Osaka Habikino Medical Center, Habikino Osaka, JP, ⁷Osaka International Cancer Institute, Osaka, JP
- 18:00 - 18:00 **482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC**
F. De Marinis¹, K.K. Laktionov², A. Poltoratskiy³, I. Egorova⁴, M. Hochmair⁵, A. Passaro¹, M.R. Migliorino⁶, G. Metro⁷, M. Gottfried⁸, D. Tsoi⁹, G. Ostoros¹⁰, S. Rizzato¹¹, G.Z. Mukhametshina¹², M. Schumacher¹³, S. Novello¹⁴, R. Dziadziuszko¹⁵, W. Tang¹⁶, L. Clementi¹⁷, A. Cseh¹⁸, D. Kowalski¹⁹, ¹European Institute of Oncology, Milan, IT, ²Russian Academy of Medical Sciences, Moscow, RU, ³Petrov Research Institute of Oncology, St Petersburg, RU, ⁴City Clinical Oncological Center (CCOC), Saint Petersburg, RU, ⁵Otto Wagner Hospital, Vienna, AT, ⁶San Camillo-Forlanini Hospital, Rome, IT, ⁷Santa Maria della Misericordia Hospital, Perugia, IT, ⁸Tel Aviv University, Tel Aviv, IL, ⁹St John of God Murdoch Hospital, Murdoch, US, ¹⁰OKTPI-Korányi National Institute for Tuberculosis and Pulmonology, Budapest, HU, ¹¹Azienda Sanitaria-Universitaria Integrata, Udine, IT, ¹²Ministry of Health of the Republic of Tatarstan, Kazan, RU, ¹³Ordensklinikum Elisabethinen, Linz, AT, ¹⁴University of Turin, Turin, IT, ¹⁵Medical University of Gdansk, Gdansk, PL, ¹⁶Boehringer Ingelheim Pharmaceuticals, Ridgefield,

US, ¹⁷S.p.A., Milan, IT, ¹⁸Boehringer Ingelheim, Vienna, AT, ¹⁹Oncology Centre and Institute, Wasaw, PL

- 18:00 - 18:00 **483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis**
R. Rosell¹, A. Poltoratskiy², M. Hochmair³, K.K. Laktionov⁴, R. Ramlau⁵, M. Alonso García⁶, J. Skrickova⁷, P.L. Piovano⁸, S. Rizzato⁹, P. Bidoli¹⁰, D. Kowalski¹¹, L. Clementi¹², A. Cseh¹³, F. De Marinis¹⁴, ¹Catalan Institute of Oncology, Barcelona, ES, ²Petrov Research Institute of Oncology, St Petersburg, RU, ³Otto Wagner Hospital, Vienna, AT, ⁴Russian Academy of Medical Sciences, Moscow, RU, ⁵Poznan University of Medical Sciences, Poznan, PL, ⁶Oncology Hospital del Rocío, Sevilla, ES, ⁷University Hospital Brno, Jihlavská, CZ, ⁸Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ⁹Azienda Sanitaria-Universitaria Integrata, Udine, IT, ¹⁰San Gerardo Hospital, Monza, IT, ¹¹Oncology Centre and Institute, Warsaw, PL, ¹²S.p.A., Milan, IT, ¹³Boehringer Ingelheim, Vienna, AT, ¹⁴European Institute of Oncology, Milan, IT
- 18:00 - 18:00 **484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm⁺) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials**
M. Gottfried¹, F. De Marinis², H. Tu³, K.K. Laktionov⁴, J. Feng⁵, A. Poltoratskiy⁶, J. Zhao⁷, E.-H. Tan⁸, V. Lee⁹, D. Kowalski¹⁰, C.-T. Yang¹¹, B. Srinivasa¹², A. Passaro¹³, L. Clementi¹⁴, W. Tang¹⁵, D.C.-L. Huang¹⁶, A. Cseh¹⁷, K. Park¹⁸, C. Zhou¹⁹, Y.-L. Wu²⁰, ¹Tel Aviv University, Tel Aviv, IL, ²Istituto Europeo di Oncologia, Milan, IT, ³Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ⁴Russian Academy of Medical Sciences, Moscow, RU, ⁵Jiangsu Provincial Tumor Hospital, Jiangsu, CN, ⁶Petrov Research Institute of Oncology, St Petersburg, RU, ⁷Peking University Cancer Hospital & Institute, Beijing, CN, ⁸National Cancer Centre, Singapore, SG, ⁹The University of Hong Kong, Hong Kong, CN, ¹⁰Oncology Centre and Institute, Wasaw, PL, ¹¹Chang Gung Memorial Hospital, 33305, Taoyuan, TW, ¹²HCG Hospital, Bangalore, IN, ¹³European Institute of Oncology, Milan, IT, ¹⁴S.p.A., Milan, IT, ¹⁵Boehringer Ingelheim Pharmaceuticals, Ridgefield, US, ¹⁶Boehringer Ingelheim Taiwan, Taipei, TW, ¹⁷Boehringer Ingelheim, Vienna, AT, ¹⁸Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁹Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ²⁰Guangdong General Hospital and Guangdong Academy of Medical Sciences, Gaungzhou, CN
- 18:00 - 18:00 **491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma**
C.-I. Shen¹, C.-H. Chiu², ¹Taipei Veterans General Hospital, Taipei City, TW, ²Taipei Veterans General Hospital, Taipei, TW
- 18:00 - 18:00 **510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer**
S. Gohar¹, K. Abd El Aziz², N. Abd El Bary², M. Shehata², S. Alhassanin², A. Hegazy², ¹Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG, ²Faculty of Medicine - Menoufia University, Shebin El Kom, EG
- 18:00 - 18:00 **496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs**

T. Ninomaru, A. Hata, C. Kokan, H. Okada, Kobe Minimally Invasive Cancer Center, Kobe, JP

- 18:00 - 18:00 **511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)**
- T. Kubo¹, N. Nogami², A. Bessho³, A. Morita³, S. Ikeo⁴, T. Yokoyama⁴, M. Ishihara⁵, T. Honda⁵, N. Fujimoto⁶, S. Murakami⁷, K. Kaira⁸, T. Harada⁹, K. Nakamura¹⁰, S. Iwasawa¹¹, T. Shimokawa¹², K. Kiura¹, N. Yamashita¹³, H. Okamoto¹², ¹Okayama University Hospital, Okayama, JP, ²Shikoku Cancer Center, Matsuyama, JP, ³Japanese Red Cross Okayama Hospital, Okayama, JP, ⁴Kurashiki Central Hospital, Kurashiki, JP, ⁵Teikyo University School of Medicine, Tokyo, JP, ⁶Okayama Rosai Hospital, Okayama, JP, ⁷Kanagawa Cancer Center, Yokohama, JP, ⁸Gunma University Graduate School of Medicine, Maebashi, JP, ⁹JCHO Hokkaido Hospital, Sapporo, JP, ¹⁰Japanese Red Cross Himeji Hospital, Himeji, JP, ¹¹Chiba University Graduate School of Medicine, Chiba, JP, ¹²Yokohama Municipal Citizen's Hospital, Yokohama, JP, ¹³National Hospital Organization Shikoku Cancer Center, Matsuyama, JP
- 18:00 - 18:00 **485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer**
- S.H. Yoon¹, Y.S. Kim¹, J.H. Chung¹, H.Y. Seol¹, M.H. Kim², ¹Pusan National University Yangsan Hospital, Yangsan, KR, ²Pusan National University Hospital, Busan, KR
- 18:00 - 18:00 **522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer**
- H. Oi¹, Y. Yamano¹, T. Yokoyama¹, T. Matsuda¹, M. Morise², K. Kataoka¹, T. Kimura¹, Y. Kondoh¹, ¹Tosei General Hospital, Seto, JP, ²Nagoya University, Graduate School of Medicine, Nagoya, JP
- 18:00 - 18:00 **512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer**
- H. Imai¹, T. Kasai², K. Mori³, K. Kishi⁴, T. Kaburagi⁵, M. Yomota⁶, T. Sugano⁷, Y. Hosomi⁸, Y. Yamada⁵, S. Moriguchi⁴, K. Minato¹, A. Gemma⁷, ¹Gunma Prefectural Cancer Center, Ota, JP, ²Tochigi Cancer Center, Utsunomiya, JP, ³Jizankai Medical Foundation Tsuboi Cancer Center Hospital, Koriyama, JP, ⁴Toranomon Hospital, Tokyo, JP, ⁵Ibaraki Prefectural Central Hospital, Kasama, JP, ⁶Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, JP, ⁷Graduate School, Nippon Medical School, Tokyo, JP, ⁸Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP
- 18:00 - 18:00 **497P - Real-world efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China**
- X. Ye¹, S. Lu², ¹Shanghai Chest Hospital, Shanghai, CN, ²Shanghai Jiao Tong University, Shanghai, CN
- 18:00 - 18:00 **507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study**

T. Uenami¹, M. Mori², T. Shiroyama³, I. Nagatomo³, S. Ihara⁴, K. Komuta⁴, H. Suzuki⁵, T. Hirashima⁵, M. Kimura⁶, F. Imamura⁶, ¹National Hospital Organization Toneyama Hospital, Toyonaka, JP, ²National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, JP, ³Graduate School of Medicine, Osaka University, Suita Osaka, JP, ⁴Osaka Police Hospital, Osaka, JP, ⁵Osaka Habikino Medical Center, Habikino Osaka, JP, ⁶Osaka International Cancer Institute, Osaka, JP

18:00 - 18:00 **523P - Co-morbidities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection**

W. Xiu, Y. Huang, X. Zhou, L. Zhou, J. Xue, J. Zhu, M. Huang, F. Peng, Y. Liu, Y. Xu, Y. Zhang, M. Yu, Y. Li, Y. Wang, Y. Lu, Y. Gong, West China Hospital of Sichuan University, Chengdu, CN

18:00 - 18:00 **516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan**

M. Shimada¹, M. Kanazu², M. Shimokawa³, R. Saito⁴, M. Mori⁵, A. Tamura¹, Y. Okano⁶, Y. Fujita⁷, T. Endo⁸, M. Motegi⁹, S. Takata¹⁰, T. Kita¹¹, N. Sukoh¹², M. Takenoyama¹³, S. Atagi¹⁴, ¹National Hospital Organization, Tokyo National Hospital, Tokyo, JP, ²National Hospital Organization Toneyama Hospital, Toyonaka, JP, ³National Hospital Organization Kyusyu Cancer Center, Hakata, JP, ⁴National Hospital Organization Shibukawa Medical Center, Shibukawa, JP, ⁵National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, JP, ⁶National Hospital Organization, Kochi National Hospital, Kochi, JP, ⁷National Hospital Organization Asahikawa Medical Center, Asahikawa, JP, ⁸National Hospital Organization Mito Medical Center, Ibaraki, JP, ⁹National Hospital Organization Takasaki General Medical Center, Takasaki, JP, ¹⁰National Hospital Organization Fukuoka-Higashi Medical Center, Koga, JP, ¹¹National Hospital Organization Kanazawa Medical Center, Kanazawa, JP, ¹²National Hospital Organization Hokkaido Medical Center, Sapporo, JP, ¹³National Hospital Organization Kyusyu Cancer Center, Fukuoka, JP, ¹⁴National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, JP

18:00 - 18:00 **486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)**

M. Morita¹, A. Nakamura², H. Tanaka³, R. Saito⁴, S. Inoue⁵, T. Harada⁶, T. Yamada⁷, T. Nakagawa⁸, D. Jingu⁹, S. Sugawara², ¹Miyagi Cancer Center, Natori, JP, ²Sendai Kousei Hospital, Sendai, JP, ³Hirosaki University, Hirosaki, JP, ⁴Tohoku University Hospital, Sendai, JP, ⁵Yamagata University Faculty of Medicine, Yamagata, JP, ⁶JCHO Hokkaido Hospital, Sapporo, JP, ⁷Toyama University Hospital, Toyama, JP, ⁸Omagari Kosei Medical Center, Omagari, JP, ⁹Saka General Hospital, Shiogama, JP

18:00 - 18:00 **515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors**

T. Hakozaiki, R. Kitadai, Y. Hosomi, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP

18:00 - 18:00 **518P - Real world prospective clinical impact of finding actionable genomic**

alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer

B.C. Ahn¹, S. Lee², Y.J. Chun¹, M.H. Hong², H.R. Kim³, B.C. Cho⁴, ¹Severance Hospital, Seoul, KR, ²Yonsei Cancer Center Yonsei University, Seoul, KR, ³Yonsei University Severance Hospital, Seoul, KR, ⁴Yonsei University, Seoul, KR

- 18:00 - 18:00 **508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study**
- J. Wang¹, Z. Zhang², F. Zhang¹, Q. Song¹, L. Zhang¹, Z. Liu², J. Ma², X. Yan², L. Wang², H. Tao², S. Zhang², X. Li², X. Zhi², Y. Hu², S. Jiao², ¹Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, ²The First Medical Center of Chinese PLA General Hospital, Beijing, CN
- 18:00 - 18:00 **525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma**
- A. Fukuda¹, M. Yomota², Y. Hosomi¹, ¹Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, ²Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, JP
- 18:00 - 18:00 **524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital**
- L. Moharana, D. Lokanatha, L. Jacob, M. Sureshbabu, K. Lokesh, A. Rudresha, L. Rajeev, S. Smitha, Kidwai Cancer Institute, Bangalore, IN
- 18:00 - 18:00 **505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?**
- A. B P¹, M. Sharma¹, P. Jain¹, S. Joga¹, S. Bothra², A. Jajodia¹, R. Sood³, S. Pasricha¹, U. Batra¹, ¹Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, ²Rajiv Gandhi Cancer Institute & Research Centre, Delhi, IN, ³Rajiv Gandhi Cancer Institute and Research Centre, ROHINI, IN
- 18:00 - 18:00 **487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma**
- C.S. Chai¹, C.K. Liam², O. Po Lin³, Y.K. Pang⁴, G.F. Ho⁴, A. Alip⁵, C.K. Wong², M.E. Poh², J.L. Tan², ¹Faculty of Medicine and Health Science, University Malaysia Sarawak, Kota Samarahan, MY, ²University Malaya Medical Centre (UMMC), Kuala Lumpur, MY, ³UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, ⁴University Malaya Medical Center, Kuala Lumpur, MY, ⁵University of Malaya Faculty of Medicine, Kuala Lumpur, MY
- 18:00 - 18:00 **492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer**
- H. Ahn¹, Y. Kim², E.Y. Kim³, K.W. Kim³, K.H. Sung³, E.K. Cho⁴, S.M. Kang³, ¹Gachon University Gil Hospital, Incheon, KR, ²Gachon University Gil Medical Center, Incheon, KR, ³Gachon University Gil Medical Center, Incheon, KR, ⁴Gachon University, Incheon, KR
- 18:00 - 18:00 **513P - Phase II study of vitamin B12 and folate supplementation for patients**

undergoing chemotherapy with pemetrexed

S. Kitagawa¹, K. Watanabe², Y. Takagi³, Y. Hosomi², ¹tokyo metropolitan komagome hospital, Tokyo, JP, ²Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, ³Teikyo University School of Medicine, Tokyo, JP

- 18:00 - 18:00 **493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience**
S. Shrivastva, B. Stalin, S. Gundeti, Nizam's Institute of Medical Sciences, Hyderabad, IN
- 18:00 - 18:00 **494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib**
C.S. Chai¹, O. Po Lin², C.K. Liam³, Y.K. Pang⁴, G.F. Ho⁴, A. Alip⁵, C.K. Wong³, M.E. Poh³, J.L. Tan³, ¹Faculty of Medicine and Health Science, University Malaysia Sarawak, Kota Samarahan, MY, ²UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, ³University Malaya Medical Centre (UMMC), Kuala Lumpur, MY, ⁴University Malaya Medical Center, Kuala Lumpur, MY, ⁵University of Malaya Faculty of Medicine, Kuala Lumpur, MY
- 18:00 - 18:00 **517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses**
F. Guo, Y. Zhang, Z. Li, L. Tu, J. He, Y. Huang, K. Liu, F. Luo, West China Hospital of Sichuan University, Chengdu, CN
- 18:00 - 18:00 **528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis**
Q. Zhuang¹, F. Lin², X. Lin², J. Li³, W. Junxin², ¹Fujian Medical University Cancer Hospital, Fuzhou, CN, ²Fujian Cancer Hospital, Fuzhou, CN, ³Xiamen Cancer Hospital, Xiamen, CN
- 18:00 - 18:00 **530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis**
C.E. Barbon¹, R. Velasco, Jr.¹, D.B. Sacdalan², R.R. Angeles¹, ¹University of the Philippines - Philippine General Hospital, Manila, PH, ²Philippine General Hospital, Manila, PH
- 18:00 - 18:00 **531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC**
B.C. Cho¹, G.-C. Chang², Y.-C. Kim³, S. Geater⁴, S. Saeteng⁵, C.-T. Yang⁶, Y. Goto⁷, S. Lu⁸, A. Ardizzoni⁹, F. Barlesi¹⁰, P. De Marchi¹¹, L. Paz-Ares¹², D.R. Spigel¹³, M. Thomas¹⁴, E. Garon¹⁵, M. Leung¹⁶, J. Baum¹⁷, Z. Zewen¹⁸, B. Mookerjee¹⁸, J.C.-H. Yang¹⁹, ¹Yonsei University, Seoul, KR, ²Taichung Veterans General Hospital, +- ext., TW, ³Chonnam National University Medical School, and CNU Hwasun Hospital, Jeonnam, KR, ⁴Prince of Songkla University, Songkhla, TH, ⁵Chiang Mai University, Chiang Mai, TH, ⁶Chang Gung Memorial Hospital, Taoyuan, TW, ⁷National Cancer Center Hospital, Tokyo, JP, ⁸Shanghai Jiao Tong University, Shanghai, CN, ⁹S.Orsola-Malpighi University Polyclinic, Bologna, IT,

¹⁰Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ¹¹Barretos Cancer Hospital, Barretos, BR, ¹²University Hospital 12 De Octubre, Madrid, ES, ¹³Sarah Cannon Research Institute, Nashville, TN, US, ¹⁴Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg, Heidelberg, DE, ¹⁵UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ¹⁶Novartis, East Hanover, US, ¹⁷Novartis Pharmaceuticals Corporation, Cambridge, US, ¹⁸Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁹National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW

18:00 - 18:00

532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC

D.S.W. Tan¹, T.M. Kim², B.J. Solomon³, W.L. Tan⁴, C.-J. Yu⁵, S. Geater⁶, G. De Castro Jr.⁷, A. Greystoke⁸, E. Felip⁹, B.E. Johnson¹⁰, S. Deudon¹¹, A.-L. Louveau¹², V.Q. Passos¹³, B.C. Cho¹⁴, ¹National Cancer Center Singapore, Singapore, SG, ²Seoul National University Hospital, Seoul, KR, ³Peter MacCallum Cancer Centre, Melbourne, AU, ⁴National Cancer Centre, Singapore, Singapore, SG, ⁵National Taiwan University Hospital, Taipei, TW, ⁶Songklanagarind Hospital, Songkla, TH, ⁷ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, ⁸Newcastle upon Tyne Hospitals, Newcastle upon Tyne, GB, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Dana-Farber Cancer Institute, Boston, US, ¹¹Novartis Pharma AG, Basel, CH, ¹²Novartis Pharma SAS, Rueil-Malmaison, FR, ¹³Novartis Pharmaceuticals Corporation, East Hanover, NJ, US, ¹⁴Yonsei University, Seoul, KR

18:00 - 18:00

533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)

D. Lim¹, Y. Goto², B.C. Cho³, H. Kaneda⁴, J.-H. Kang⁵, S.-W. Kim⁶, C.-H. Chiu⁷, J.C.-H. Yang⁸, W.-C. Su⁹, K. Obyrne¹⁰, V. Papadimitrakopoulou¹¹, M. Reck¹², I. Malet¹³, B. Mookerjee¹⁴, Z. Zewen¹⁴, L. Paz-Ares Rodriguez¹⁵, ¹National Cancer Centre Singapore, Singapore, SG, ²National Cancer Center Hospital, Tokyo, JP, ³Yonsei University, Seoul, KR, ⁴Osaka City University Graduate School of Medicine, Osaka, JP, ⁵Seoul St Marys Hospital, Seoul, KR, ⁶Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁷Taipei Veterans General Hospital, Taipei, TW, ⁸National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, ⁹National Cheng Kung University Hospital, Tainan, TW, ¹⁰Greenslopes Private Hospital, Greenslopes, AU, ¹¹UT/MD Anderson Cancer Center, Houston, US, ¹²LungenClinic Grosshansdorf GmbH, Grosshansdorf, DE, ¹³Novartis Pharma AG, Basel, CH, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁵University Hospital Doce de Octubre, Madrid, ES

18:00 - 18:00

534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)

K. Otsubo¹, J. Kishimoto², H. Kenmotsu³, Y. Minegishi⁴, H. Horinouchi⁵, T. Kato⁶, E. Ichihara⁷, A. Shiraki⁸, S. Atagi⁹, M. Ando¹⁰, N. Yamamoto¹¹, I. Okamoto¹², ¹Kitakyushu Municipal Medical Center, Kitakyushu, JP, ²Kyushu University, Fukuoka, JP, ³Shizuoka Cancer Center, Shizuoka, JP, ⁴Nippon Medical School Main Hospital, Tokyo, JP, ⁵National Cancer Center Hospital, Tokyo, JP, ⁶Kanagawa Cancer Center, Yokohama, JP, ⁷Okayama

University Hospital, Okayama, JP, ⁸Ogaki Municipal Hospital, Ogaki, JP, ⁹National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, JP, ¹⁰Nagoya University Hospital, Nagoya, JP, ¹¹Wakayama Medical University, Wakayama, JP, ¹²Kyushu University Hospital, Fukuoka, JP

- 18:00 - 18:00 **535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)**
S. Ikeda¹, T. Kato², H. Kenmotsu³, T. Ogura¹, S. Iwasawa⁴, T. Iwasawa¹, R. Kasajima², Y. Miyagi², T. Misumi⁵, T. Yamanaka⁵, H. Okamoto⁶, ¹Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, ²Kanagawa Cancer Center, Yokohama, JP, ³Shizuoka Cancer Center, Shizuoka, JP, ⁴Chiba University Graduate School of Medicine, Chiba, JP, ⁵Yokohama City University School of Medicine, Yokohama, JP, ⁶Yokohama Municipal Citizen's Hospital, Yokohama, JP
- 18:00 - 18:00 **536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study**
J.C.-H. Yang¹, B. Ellers-Lenz², J. Straub³, A. Johne³, Y.-L. Wu⁴, ¹National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, ²Merck Healthcare KGaA, Darmstadt, DE, ³Merck KGaA - Germany, Darmstadt, DE, ⁴Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN
- 18:00 - 18:00 **Young Oncologist Patient Case (Presenter must be under 40 years of age)**
- 18:00 - 18:00 **YO8 - Carcinosarcoma of the Breast in a Filipino Female: A Case Report**
M.A.L. Dantes, Jose R. Reyes Memorial Medical Center, Manila, PH
- 18:00 - 18:00 **YO9 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone**
G. Harti¹, I. Wijaya², ¹RSUP Dr Hasan Sadikin Hospital Bandung, Bandung, ID, ²Hasan Sadikin General Hospital, Bandung, ID
- 18:00 - 18:00 **YO10 - Rectal Follicular Dendritic Cell Sarcoma**
K. Bajaj, Tata Memorial Hospital, Mumbai, IN
- 18:00 - 18:00 **YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer**
L. Tao¹, D. Xiu², D. Li³, ¹Henan Province Hospital of TCM, Zhengzhou, CN, ²Peking university third hospital, Beijing, CN, ³Henan Provincial People's Hospital, Zhengzhou, CN
- 18:00 - 18:00 **YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient**
G. Kerkarchachai, Vajira Hospital Centre, Bangkok, TH

- 18:00 - 18:00 **YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy**
W. Mahaparn¹, J. Surintrspanont², A. Sanpawat², K. Sasiwimonphan², P. Sitthideatphaiboon², ¹King Chulalongkorn Memorial Hospital - Thai Red Cross Society, Bangkok, TH, ²King Chulalongkorn Memorial Hospital, Bangkok, TH
- 18:00 - 18:00 **YO14 - Urachal Adenocarcinoma: Case Report**
M.J. Alcantara, C. Gorospe, St. Luke's Medical Center, Quezon City, PH
- 18:00 - 18:00 **YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report**
M.A.L. Dantes, Jose R. Reyes Memorial Medical Center, Manila, PH
- 18:00 - 18:00 **YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation**
P. Cheewasathianchai, Khon Kaen University - Faculty of Veterinary Medicine, Khon Kaen, TH
- 18:00 - 18:00 **YO17 - Serous ovarian cancer treated with palbociclib and letrozole**
D.W. Lee¹, G.F. Ho², ¹University Malaya Medical Centre (UMMC), Kuala Lumpur, MY, ²University Malaya Medical Center, Kuala Lumpur, MY
- 18:00 - 18:00 **YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report**
P. Pimsa¹, N. Ngamphaiboon², K. Paiwattanupant³, ¹Sappasit Prasong Hospital, Ubon Ratchathani, TH, ²ramathibodi, prayathia, TH, ³Ramathibodi, prayathai, TH
- 18:00 - 18:00 **YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?**
Y. Chen, J. Lu, J. Wang, C. Xu, G. Chen, Fujian Cancer Hospital, Fuzhou, CN
- 18:00 - 18:00 **YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?**
A. Luchinin, V. Ovsepyan, Kirov Scientific Research Institute of Hematology and Blood Transfusion, Kirov, RU
- 18:00 - 18:00 **YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.**
I. Madabhavi, Gujarat Cancer and Research Institute, Ahmedabad, IN
- 18:00 - 18:00 **YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma**
M.V. Cruz-Ordinario¹, E.C. Cuaresma², M. Guevarra², E. Lim², M.S. Imasa², ¹St. Luke's Medical Center - Quezon City, Quezon City, PH, ²St. Luke's Medical Center - Quezon City, Quezon City, PH

- 18:00 - 18:00 **YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report**
E. Buenacosa-Nepucpan, Jose R. Reyes Memorial Medical Center, Manila, PH
- 18:00 - 18:00 **YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.**
I. Rosli¹, C.T. Chong², G.F. Ho², ¹UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, ²University Malaya Medical Center, Kuala Lumpur, MY
- 18:00 - 18:00 **YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.**
M. Nishio, T. Otsuka, K. Asai, Y. Okita, S. Otozai, T. Fujii, H. Yoshizawa, S. Nakatsuka, T. Kumagai, F. Imamura, Osaka International Cancer Institute, Osaka, JP
- 18:00 - 18:00 **YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis**
P. Bhandari, NAMS, Bir Hospital, Kathmandu, NP
- 18:00 - 18:00 **YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)**
N.F. Ab Muin¹, G.F. Ho², ¹Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, MY, ²University Malaya Medical Center, Kuala Lumpur, MY
- 18:00 - 18:00 **YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report**
R. Ibusuki¹, T. Harada¹, A. Shimauchi¹, T. Kayukawa¹, D. Etoh², Y. Okamatsu¹, K. Tsubouchi¹, K. Inoue¹, ¹JCHO Kyusyu Hospital, Kitakyushu, JP, ²Japan Community Healthcare Organization, Kyushu Hospital, Kitakyushu, JP
- 18:00 - 18:00 **YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach**
R.E. King¹, A. Villaruel², J.P. Magno¹, S.P. De Guzman¹, L.I. Catedral¹, K.A. Mondragon¹, F.I. Ting¹, R. Velasco, Jr.¹, F. Gracieux Jr.², ¹University of the Philippines - Philippine General Hospital, Manila, PH, ²Philippine General Hospital, Manila, PH
- 18:00 - 18:00 **YO31 - Primary pulmonary sarcoma**
K. Ubaydullaeva, National Cancer Research Center of Uzbekistan, Tashkent, UZ
- 18:00 - 18:00 **YO32 - prostatic rhabdomyosarcoma in an adult patient: A case study**
M.R. Islam, M. Islam, National Institute of Cancer Research & Hospital, Dhaka, BD
- 18:00 - 18:00 **YO33 - Hyponatremia - slaying the dragon or chasing a mirage- a Case report**
R. D. Arora, All India Institute of Medical Sciences, Delhi, IN
- 18:00 - 18:00 **YO34 - A rare endocrinological syndrome presenting with weakness in Soft tissue sarcoma - a Case report**
R. D. Arora, All India Institute of Medical Sciences, Delhi, IN

- 18:00 - 18:00 **YO35 - Gefitinib induced movement disorder - a Case report**
R. D. Arora, All India Institute of Medical Sciences, Delhi, IN
- 18:00 - 18:00 **YO36 - A case of BRAF V600E mutated non-small-cell lung cancer with pleomorphic features**
R. Matsuzawa, M. Morise, I. Tanaka, T. Hase, K. Wakahara, N. Hashimoto, Nagoya University, Graduate School of Medicine, Nagoya, JP
- 18:00 - 18:00 **YO37 - Intraventricular metastasis as the first presentation of non-small cell lung cancer**
S. Putraveephong, K. Wirasorn, J. Chindaprasirt, A. Sookprasert, P. Chadbunchachai, Khon Kaen University - Faculty of Medicine - Srinagarind Hospital, Khon Kaen, TH
- 18:00 - 18:00 **YO38 - Cerebral metastases from a thymic malignancy: a case report**
M. Nik Eezamuddeen¹, M. Amir², N. Bakar², M. Krea², ¹University technology Mara, Sungai buloh, Sungai Buloh, MY, ²university teknologi mara, sungai buloh, MY
- 18:00 - 18:00 **YO39 - Primary Follicular Thyroid Carcinoma Metastatic to the Kidney Mimicking Renal Cell Carcinoma: A Case Report**
J. Aranilla, National Kidney and Transplant Institute, Quezon City, PH
- 18:00 - 18:00 **YO40 - A Rare Case of Primary Malignant Giant Cell Tumor of Tibia**
G. Venugopal, M. Malik, Nizam Institute of Medical Sciences, Hyderabad, IN

24-11-2019

09:15 - 10:45 **Type: Educational session** **Hall 405**
Title: Adjuvant treatment in gastrointestinal cancer
 Chair: Alberto Sobrero, IT; Eiji Oki, JP

09:15 - 09:15 **Session DOI**

09:15 - 09:30 **Minimal residual disease (overview lecture)**
J. Tie, Peter MacCallum Cancer Centre, Melbourne, AU

09:30 - 09:45 **Colorectal cancer**
A. Sobrero, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

09:45 - 10:00 **Pancreatic cancer**
M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

10:00 - 10:15 **Gastric cancer**
Y. Kodera, Nagoya University, Graduate School of Medicine, Nagoya, JP

10:15 - 10:45 **Discussion**

09:15 - 10:45	Type: Multidisciplinary tumour board Title: Challenges in the management of clinical stage N2 disease Chair: Sanjay Popat, GB	Hall 404
09:15 - 09:15	Session DOI	
09:15 - 09:20	Presentation of case/condition <u>S. Popat</u> , Royal Marsden Hospital NHS Foundation Trust, London, GB	
09:20 - 09:40	Medical oncologist's perspective <u>E. Felip</u> , Vall d'Hebron University Hospital, Barcelona, ES	
09:40 - 10:00	Radiation oncologist's perspective <u>Y.C. Ahn</u> , Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR	
10:00 - 10:20	Thoracic surgeon's perspective <u>T. Mitsudomi</u> , Kindai University - Faculty of Medicine, Osaka, JP	
10:20 - 10:45	Discussion	

09:15 - 10:45 **Type: Multidisciplinary tumour board** **Hall 407**
Title: Advanced prostate cancer (hormone-naïve case)
 Chair: Ravindran Kanesvaran, SG

09:15 - 09:15 **Session DOI**

09:15 - 09:20 **Presentation of case/condition**

R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

09:20 - 09:40 **Medical oncology perspective**

S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

09:40 - 09:55 **Surgery perspective**

L.S. Lee, SGH-Singapore General Hospital/Singhealth-Academia, Singapore, SG

09:55 - 10:15 **Radiation oncology perspective**

D. Poon, Prince of Wales Hospital, Shatin, HK

10:15 - 10:45 **Discussion**

09:15 - 10:45 **Type: Proffered Paper session** **Room 324**
Title: Proffered paper session - Gynaecological cancers
 Chair: Sudeep Gupta, IN; Mansoor Raza Mirza, DK

09:15 - 09:15 **Session DOI**

09:15 - 09:25 **2240 - Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)**

M. Friedlander¹, K. Moore², N. Colombo³, G. Scambia⁴, B.-G. Kim⁵, A. Oaknin⁶, A. Lisyanskaya⁷, A. Floquet⁸, A. Leary⁹, G. Sonke¹⁰, C. Gourley¹¹, S. Banerjee¹², A. Oza¹³, A. González-Martín¹⁴, C. Aghajanian¹⁵, W. Bradley¹⁶, E. Lowe¹⁷, R. Hettle¹⁸, E. Flood¹⁷, P. Disilvestro¹⁹, ¹Prince of Wales Hospital, Randwick, AU, ²Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ³Istituto Europeo di Oncologia, Milan, IT, ⁴Policlinico Universitario A. Gemelli, Roma, IT, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁶Vall d'Hebron University Hospital, Barcelona, ES, ⁷St Petersburg City Oncology Dispensary, St Petersburg, RU, ⁸Institute Bergonié, Bordeaux, FR, ⁹Institut Gustave Roussy, Villejuif, FR, ¹⁰The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹¹Edinburgh Cancer Research UK Centre, Edinburgh, GB, ¹²Royal Marsden Hospital NHS Foundation Trust, London, GB, ¹³Princess Margaret Cancer Centre, Toronto, CA,

¹⁴Clínica Universidad de Navarra, Madrid, ES, ¹⁵Memorial Sloan-Kettering Cancer Center, New York, US, ¹⁶Froedtert and the Medical College of Wisconsin, Milwaukee, US, ¹⁷AstraZeneca, Gaithersburg, US, ¹⁸PAREXEL Access, London, GB, ¹⁹Women & Infants Hospital, Providence, US

- 09:25 - 09:35 **2250 - Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy**
M. Friedlander¹, R. Hettle², E. Parkhomenko³, ¹Prince of Wales Hospital, Randwick, AU, ²PAREXEL Access, London, GB, ³PAREXEL, London, GB
- 09:35 - 09:50 **LBA10 - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev**
K. Fujiwara¹, P. Harter², A. Leary³, D. Perol⁴, S. Pignata⁵, A. González-Martín⁶, E. Petru⁷, E. Van Nieuwenhuysen⁸, N. Colombo⁹, J. Mäenpää¹⁰, F. Selle¹¹, N. De Gregorio¹², D. Lorusso¹³, E.M. Guerra Alia¹⁴, C. Lefeuvre-Plesse¹⁵, P. Buderath¹⁶, A. Lortholary¹⁷, A. Burges¹⁸, E. Pujade-Lauraine¹⁹, I. Ray-Coquard⁴, ¹Saitama Medical University Internatl Medical Centre, Saitama, JP, ²Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, ³Institut Gustave Roussy, Villejuif, FR, ⁴Centre Léon Bérard, Lyon, FR, ⁵Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁶Clínica Universidad de Navarra, Madrid, ES, ⁷Medical University of Graz, Graz, AT, ⁸Leuven Cancer Institute, Leuven, BE, ⁹Istituto Europeo di Oncologia, Milan, IT, ¹⁰Tampere University and University Hospital, Tampere, FI, ¹¹Hôpital Tenon, Paris, FR, ¹²Universitätsklinikum Ulm, Ulm, DE, ¹³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹⁴Hospital Universitario Ramón y Cajal, Madrid, ES, ¹⁵Centre Eugène Marquis, Rennes, FR, ¹⁶University Hospital of Essen, Essen, DE, ¹⁷Centre Catherine de Sienne, Nantes, FR, ¹⁸Klinikum der Universität München, Munich, DE, ¹⁹Groupe hospitalier Hôtel Dieu (AP-HP), Paris, FR
- 09:50 - 10:05 **Invited Discussant 2240, 2250 and LBA10**
C. Sessa, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH
- 10:05 - 10:17 **LBA11 - Mainstreaming genetic counselling for genetic testing of BRCA1/2 in ovarian cancer patients in Malaysia (MaGIC study)**
S.Y. Yoon¹, S.W. Wong¹, N.S. Ahmad¹, S. Mariapun¹, T. Hassan¹, H. Padmanabhan¹, J. Lim¹, A. George², M.K. Thong³, G.S. Chng⁴, S.H. Teo¹, E. Bleiker⁵, Y.L. Woo³, ¹Cancer Research Malaysia, Subang Jaya, MY, ²Institute of Cancer Research, London, GB, ³University Malaya Medical Centre, Kuala Lumpur, MY, ⁴Hospital Kuala Lumpur, Kuala Lumpur, MY, ⁵Netherlands Cancer Institute, Amsterdam, NL
- 10:17 - 10:29 **2260 - Prevalence of germline BRCA1 and BRCA2 mutations and variants among ovarian, primary peritoneal and fallopian tube cancer patients: A multicentre Indian study**
S. Gupta¹, S. Rajappa², S. Advani³, A. Agarwal⁴, S. Aggarwal⁵, C. Goswami⁶, S. Dattatreya Palanki⁷, D. Arya⁸, S. Patil⁹, R. Kodagali¹⁰, ¹Tata Memorial Hospital Centre,

Mumbai, IN, ²Basavatkaram Indo American Cancer Hospital, Hyderabad, IN, ³Sushrut Hospital, Mumbai, IN, ⁴BLK Superspeciality Hospital, New Delhi, IN, ⁵Sir Gangaram Hospital, New Delhi, IN, ⁶Medica Superspeciality Hospital, New delhi, IN, ⁷Omega Hospitals, Hyderabad, IN, ⁸Max Saket,, New Delhi, IN, ⁹HCG Cancer Hospital, Bengaluru, IN, ¹⁰AstraZeneca India, Bangalore, IN

10:29 - 10:44 **Invited Discussant One LBA11 and 2260**

M.R. Mirza, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK

09:15 - 10:45 **Type: Educational session** **Summit 2**
Title: Perspective of liquid biomarkers for cancer care
 Chair: Kohei Shitara, JP; Noboru Yamamoto, JP

09:15 - 09:15 **Session DOI**

09:15 - 09:35 **Methodology of liquid biopsy**

I. Tan, National Cancer Centre Singapore, Singapore, SG

09:35 - 09:55 **Liquid biomarkers for NSCLC**

Y. Goto, National Cancer Center Hospital, Tokyo, JP

09:55 - 10:15 **Liquid biomarkers for advanced GI cancer**

K. Shitara, National Cancer Center Hospital East, Kashiwa, JP

10:15 - 10:35 **Liquid biomarkers for immunotherapy**

F.C. Bidard, Institut Curie, Paris, FR

10:35 - 10:45 **Discussion**

09:15 - 10:15 **Type: Mini Oral session** **Room 311**
Title: Mini Oral session - Immunotherapy of cancer
 Chair: Daniel Shao Weng Tan, SG; Michele Teng, AU; Anders Skanderup, SG

09:15 - 09:15 **Session DOI**

09:15 - 09:20 **LBA14 - Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy**

A. Abed¹, A. Khattak², M. Millward³, A. Chopra⁴, E. Gray⁵, ¹Fiona Stanley Hospital, Perth, AU, ²Fiona Stanley Hospital, Murdoch, AU, ³Sir Charles Gairdner Hospital, Nedlands, AU, ⁴Institute for Immunology and Infectious Diseases (IIID), Murdoch, AU, ⁵Edith Cowan University, Joondalup, AU

- 09:20 - 09:25 **Discussion led by moderators**
D.S.W. Tan¹, M. Teng², A. Skanderup³, ¹National Cancer Center Singapore, Singapore, SG, ²QIMR Berghofer Medical Research Institute, Brisbane, AU, ³A*STAR - Genome Institute of Singapore (GIS), Singapore, SG
- 09:25 - 09:30 **3170 - Association of survival and blood-based genomic signature with atezolizumab for patients with second-line and third-line EGFR wild-type non-small cell lung cancer: Pooled analysis of individual patient data from the POPLAR and OAK trials**
Y. Yu¹, A. Li², Y. Chen³, Q. Li³, Q. Ou³, D. Lin³, W. Zhang³, Z. Li³, H. Hu³, H. Yao³, ¹2nd Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ²Guangdong Medical University, Zhanjiang, CN, ³Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN
- 09:30 - 09:35 **3180 - Both low and high blood tumour mutational burden are favourable predictors with atezolizumab**
W. Nie, B. Han, Shanghai Chest Hospital, Shanghai, CN
- 09:35 - 09:40 **3190 - Combined model of frameshift mutations and TMB in predicting response to immunotherapy in NSCLC**
H. Zhou, J. Liu, Y. Zhang, W. Fang, L. Zhang, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 09:40 - 09:55 **Discussion led by moderators**
D.S.W. Tan¹, M. Teng², A. Skanderup³, ¹National Cancer Center Singapore, Singapore, SG, ²QIMR Berghofer Medical Research Institute, Brisbane, AU, ³A*STAR - Genome Institute of Singapore (GIS), Singapore, SG
- 09:55 - 10:00 **3200 - PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC**
J. Liu, H. Zhou, Y. Zhang, Y. Huang, Y. Yang, W. Fang, L. Zhang, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 10:00 - 10:05 **3210 - Data-driven miRNA classifier as response predictor for immune checkpoint inhibitor treatment in advanced-stage cancer patients**
C.-H. Hsieh¹, S.-T. Kang², W.-M. Chen², Y.-C. Lin¹, H.-M. Wang¹, J.-S. Chen¹, Y.-S. Hsieh², E. Yang², ¹Chang Gung Memorial Hospital, Taoyuan, TW, ²Quark Biosciences, Inc., Hsinchu City, TW
- 10:05 - 10:15 **Discussion led by moderators**
D.S.W. Tan¹, M. Teng², A. Skanderup³, ¹National Cancer Center Singapore, Singapore, SG, ²QIMR Berghofer Medical Research Institute, Brisbane, AU, ³A*STAR - Genome Institute of Singapore (GIS), Singapore, SG

11:00 - 12:30	<p>Type: Industry Satellite Symposium Title: Eisai Co., Ltd. - New paradigm of treatment strategy for intermediate and advanced HCC Chair: David Tai, SG; Yi-Hsiang Huang, TW</p>	Hall 405
11:00 - 11:05	<p>Introduction <u>D. Tai</u>¹, <u>Y.-H. Huang</u>², ¹National Cancer Centre Singapore (NCCS), Singapore, SG, ²Taipei Veterans General Hospital, Taipei City, TW</p>	
11:05 - 11:25	<p>Changing paradigm of treatment strategy for intermediate and advanced HCC <u>M. Ikeda</u>, National Cancer Center Hospital East, Kashiwa, JP</p>	
11:25 - 11:35	<p>Adopting new paradigm of treatment strategy into clinical practice: Multidisciplinary approach (from loco-regional interventionist perspective) <u>S.-M. Lin</u>, Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW</p>	
11:35 - 11:45	<p>Adopting new paradigm of treatment strategy into clinical practice: Multidisciplinary approach (from hepatologist perspective) <u>D.Y. Kim</u>, Pusan National University Hospital, Busan, KR</p>	
11:45 - 11:55	<p>Adopting new paradigm of treatment strategy into clinical practice: Multidisciplinary approach (from medical oncologist perspective) <u>S.P. Choo</u>, NCCS - National Cancer Centre Singapore, Singapore, SG</p>	
11:55 - 12:25	<p>Panel discussion <u>M. Ikeda</u>¹, <u>S.-M. Lin</u>², <u>D.Y. Kim</u>³, <u>S.P. Choo</u>⁴, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, ³Pusan National University Hospital, Busan, KR, ⁴NCCS - National Cancer Centre Singapore, Singapore, SG</p>	
12:25 - 12:30	<p>Conclusions <u>D. Tai</u>¹, <u>Y.-H. Huang</u>², ¹National Cancer Centre Singapore (NCCS), Singapore, SG, ²Taipei Veterans General Hospital, Taipei City, TW</p>	

11:00 - 12:30	Type: Industry Satellite Symposium Title: Roche - Cancer immunotherapy in HCC: The combination revolution Chair: Pierce Chow, SG	Hall 404
11:00 - 11:05	Welcome and introductions <u>P. Chow</u> , National Cancer Centre Singapore, Singapore, SG	
11:05 - 11:25	Review of phase III data in advanced HCC <u>A.-L. Cheng</u> , National Taiwan University, Taipei, TW	
11:25 - 11:45	Navigating HCC treatment decisions: What are the clinical implications for patients? <u>H.C. Toh</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
11:45 - 12:00	Cancer immunotherapy in intermediate or early HCC <u>D. Pinato</u> , Imperial College London - Hammersmith Hospital, London, GB	
12:00 - 12:20	The patient perspective: Awareness and involvement in clinical decision making <u>J. Tsai</u> , Formosa Cancer Foundation, Taipei City, TW	
12:20 - 12:30	Q&A and meeting close	

11:00 - 12:30 **Type: Industry Satellite Symposium** **Hall 407**
Title: Takeda - Redefining ALK+ NSCLC management
 Chair: Tony S.K. Mok, CN

11:00 - 11:20 **All Presentations**

11:20 - 11:25 **Welcome**
T.S.K. Mok, Prince of Wales Hospital, Hong Kong, CN

11:25 - 11:40 **Present and future of molecular testing in lung cancer**
T.S.K. Mok, Prince of Wales Hospital, Hong Kong, CN

11:40 - 12:20 **Evolving ALK + NSCLC paradigm**
R. Camidge, University Of Colorado Hospital, Aurora, US

12:20 - 12:40 **Optimal sequencing strategies in second line and beyond**
M.-J. Ahn, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

12:40 - 12:50 **Conclusion**
T.S.K. Mok, Prince of Wales Hospital, Hong Kong, CN

11:00 - 12:30	Type: Industry Satellite Symposium Title: Merck - The new continuum of care in mCRC Chair: Takayuki Yoshino, JP	Room 324
11:00 - 11:05	Welcome <u>T. Yoshino</u> , National Cancer Center Hospital East, Kashiwa, JP	
11:05 - 11:20	Tumor location is a key decision factor for 1st-line mCRC treatment <u>Y. Deng</u> , The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN	
11:20 - 11:50	Choosing the best 1st-line treatment for RAS wt mCRC patients <u>D. Aderka</u> , Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL	
11:50 - 12:05	Cetuximab rechallenge in 3rd line mCRC can provide a new standard of care <u>M. Scartozzi</u> , AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT	
12:05 - 12:25	Panel discussion: Asian hot topics <u>J.Y. Wang</u> ¹ , <u>T. Yoshino</u> ² , ¹ Chung-Ho Memorial Hospital, Kaohsiung Medical University Hospital, Kaohsiung City, TW, ² National Cancer Center Hospital East, Kashiwa, JP	
12:25 - 12:30	Conclusions <u>T. Yoshino</u> , National Cancer Center Hospital East, Kashiwa, JP	

11:00 - 12:30	Type: ESMO Colloquium Title: ESMO Colloquium supported by Astellas - State of the art management of mCRPC Chair: Ravindran Kanesvaran, SG; Arun Azad, AU	Summit 2
11:00 - 11:00	Session DOI	
11:00 - 11:05	Introduction <u>A. Azad</u> , Monash Medical Centre, Clayton, AU	
11:05 - 11:15	mCRPC definition and benefits of treatment <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
11:15 - 11:30	Optimal first-line treatment in mCRPC after either chemo or ARI in mHSPC <u>C. Sternberg</u> , Weill Cornell Medicine - The Blenis Lab, New York, US	
11:30 - 11:45	Changing treatment algorithms in mCRPC: Role of PARP inhibitors <u>A. Azad</u> , Monash Medical Centre, Clayton, AU	
11:45 - 12:00	Is there an optimal sequencing strategy in mCRPC? <u>B. Tran</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
12:00 - 12:15	Immunotherapy in mCRPC management <u>A. Azad</u> , Monash Medical Centre, Clayton, AU	
12:15 - 12:30	Conclusion and wrap up <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	

11:00 - 12:30	Type: ESMO Colloquium Title: ESMO Colloquium supported by Guardant Health: Liquid biopsy in the management of solid tumours Chair: Byoung Chul Cho, KR	Room 311
11:00 - 11:00	Session DOI	
11:00 - 11:05	Introduction <u>B.C. Cho</u> , Yonsei University, Seoul, KR	
11:05 - 11:30	What does liquid biopsy mean? <u>F.C. Bidard</u> , Institut Curie, Paris, FR	
11:30 - 11:55	Use of liquid biopsies in colorectal cancers <u>T. Yoshino</u> , National Cancer Center Hospital East, Kashiwa, JP	
11:55 - 12:10	Use of liquid biopsy in breast cancer <u>P. Mainwaring</u> , ICON Cancer Care, Brisbane, AU	
12:10 - 12:25	Use of liquid biopsy in non-small cell lung cancer <u>J.C.-H. Yang</u> , National Taiwan University Hospital, Taipei city, TW	
12:25 - 12:30	Conclusion <u>B.C. Cho</u> , Yonsei University, Seoul, KR	
11:00 - 11:45	Type: Young Oncologist session Title: Vesalius talk: The role of the Mentor in shaping oncology career paths Chair: Guillem Argiles Martinez, ES; Fabrice André, FR; Daniel Shao Weng Tan, SG	Exhibition area

12:45 - 14:15	Type: Multidisciplinary tumour board Title: Current controversies in the management of primary and secondary liver cancer Chair: Sylvie Lorenzen, DE; Eiji Oki, JP	Hall 405
12:45 - 12:45	Session DOI	
12:45 - 12:50	Presentation of case/condition <u>E. Oki</u> , National Kyushu Cancer Center, Fukuoka, JP	
12:50 - 13:10	The viewpoint of a Medical oncologist <u>T. Yoshino</u> , National Cancer Center Hospital East, Kashiwa, JP	
13:10 - 13:30	The viewpoint of a Surgical oncologist <u>J. Xu</u> , Zhongshan Hospital, Fudan University, Shanghai, CN	
13:30 - 13:50	The viewpoint of an Interventional radiologist <u>T. De Baere</u> , Institut Gustave Roussy, Villejuif, FR	
13:50 - 14:15	Discussion	

12:45 - 14:15 **Type: Educational session** **Hall 404**
Title: Melanoma treatment today and tomorrow
 Chair: Caroline Robert, FR; Atsushi Otsuka, JP

12:45 - 12:45 **Session DOI**

12:45 - 13:05 **Adjuvant vs neoadjuvant therapy**
R. Dummer, Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH

13:05 - 13:25 **New combinations in metastatic disease**
C. Robert, Institut Gustave Roussy, Villejuif, FR

13:25 - 13:45 **Update on mucosal melanoma**
L. Si, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN

13:45 - 14:05 **Management of acral melanoma**
A. Otsuka, Kyoto University-Graduate school of medicine, Kyoto, JP

14:05 - 14:15 **Discussion**

12:45 - 14:15 **Type: Educational session** **Hall 407**
Title: Early integration of palliative care
 Chair: Lalit Krishna, SG

12:45 - 12:45 **Session DOI**

12:45 - 13:15 **Current status and future directions of ESMO Designated Centers: A global perspective**
S. Kaasa¹, Y. Matsumoto², ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ²National Cancer Center Hospital East, Kashiwa, JP

13:15 - 13:45 **Focus on the top 4 symptoms and guidelines**
M. Mori¹, P. Stone², ¹Seirei Christopher University, Hamamatsu, JP, ²University College London, London, GB

13:45 - 14:00 **ESMO supportive and palliative care Guidelines**
K. Jordan, University of Heidelberg, Heidelberg, DE

14:00 - 14:15 **Discussion**

12:45 - 13:35	Type: Mini Oral session Title: Mini Oral session - Gynaecological cancers Chair: Amita Maheshwari, IN; Sandro Pignata, IT	Room 324
12:45 - 12:45	Session DOI	
12:45 - 12:50	2270 - Laparoscopic radical hysterectomy leads to poorer prognosis compared with abdominal radical hysterectomy in patients with locally advanced cervical cancer <u>T.W.Y. Hu</u> , West China Second Hospital,, Chengdu, CN	
12:50 - 12:55	2280 - Comparison of long-term oncologic outcomes between laparoscopy and laparotomy for stage Ia1-Ib3 cervical cancer: A matched cohort study <u>D. Dai</u> , H. Huang, J. Liu, Sun Yat-sen University Cancer Center, Guangzhou, CN	
12:55 - 13:05	Discussion led by moderator <u>S. Pignata</u> , Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT	
13:05 - 13:10	LBA12 - Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601) <u>Y. Antill</u> ¹ , P.S. Kok ² , M. Stockler ³ , K. Robledo ² , S. Yip ² , M. Parry ² , D. Smith ⁴ , A. Spurdle ⁵ , E. Barnes ² , M. Friedlander ⁶ , S. Baron-Hay ⁷ , C. Shannon ⁴ , J. Coward ⁸ , P. Beale ⁹ , G. Goss ¹⁰ , T. Meniawy ¹¹ , J. Andrews ² , M. Kelly ² , L. Mileskin ¹² , ¹ Cabrini Health, Malvern, AU, ² NHMRC Clinical Trials Centre, Camperdown, AU, ³ Chris O'Brien Lifehouse, Camperdown, AU, ⁴ Mater Adult Hospital, Brisbane, AU, ⁵ QIMR Berghofer Medical Research Institute, Brisbane, AU, ⁶ Prince of Wales Hospital, Randwick, AU, ⁷ Royal North Shore Hospital, St Leonards, AU, ⁸ ICON Cancer Care, Brisbane, AU, ⁹ Sydney Local Health District, Concord Cancer Centre, Sydney, AU, ¹⁰ Box Hill Hospital-Eastern health, Box Hill, AU, ¹¹ School of Medicine and Pharmacology Sir Charles Gairdner Hospital, Nedlands, AU, ¹² Peter MacCallum Cancer Center, Melbourne, AU	
13:10 - 13:15	Discussion led by moderator <u>S. Pignata</u> , Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT	
13:15 - 13:20	2290 - Application of hysterectomy in treatment of trophoblastic neoplasia <u>Y. Liu</u> ¹ , Y. He ² , Y. Long ² , ¹ West China Second Hospital,, Chengdu, CN, ² West China Second University Hospital, Sichuan University, Chengdu, CN	
13:20 - 13:35	Discussion led by moderator <u>A. Maheshwari</u> , Tata Memorial Hospital Centre, Mumbai, IN	

12:45 - 14:15 **Type: Collaborative session** **Summit 2**
Title: ESMO - AACR Collaborative Session: CAR-T cells / NK cells
 Chair: John Haanen, NL; Shannon Maude, US

12:45 - 12:45 **Session DOI**

12:45 - 12:50 **Introduction**

S. Maude, The Children's Hospital of Philadelphia, Philadelphia, US

12:50 - 13:10 **New directions in CAR-T therapy**

F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB

13:10 - 13:30 **CAR-T for solid tumours**

S. Maude, The Children's Hospital of Philadelphia, Philadelphia, US

13:30 - 13:50 **Targeting BCMA with CAR-T**

B. Wang, The Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Sheng, CN

13:50 - 14:10 **Using NK cells for immunotherapy**

D. Lee, Nationwide Children's Hospital, Columbus, US

14:10 - 14:15 **Conclusions and clinical perspectives**

F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB

12:45 - 13:45 **Type: Mini Oral session** **Room 311**
Title: Mini Oral session - Haematological malignancies
 Chair: Soon Thye Lim, SG; Martin Dreyling, DE; Marco Ladetto, IT; Won Seog Kim, KR

12:45 - 12:45 **Session DOI**

12:45 - 12:50 **LBA13 - Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis**

J.H. Yi¹, W.S. Kim², S.J. Kim³, D.H. Yoon⁴, C. Suh⁵, M.H. Chang⁶, D.H. Yang⁷, J.-C. Jo⁸, S.Y. Hyun⁹, H.-S. Eom¹⁰, J.-O. Lee¹¹, J.H. Kwon¹², S.H. Han¹³, S.-S. Lee¹⁴, J.-Y. Kwak¹⁵, S.H. Kim¹⁶, ¹Chung-Ang University Hospital, Seoul, KR, ²Samsung Medical Center (SMC), Seoul, KR, ³Samsung Medical Center, Seoul, KR, ⁴University of Ulsan College of Medicine, Seoul, KR, ⁵Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁶National Health Insurance Corporation Ilsan Hospital, Ilsan, KR, ⁷Chonnam National University Hwasun Hospital, Gwangju, KR, ⁸Ulsan University Hospital, Ulsan, KR, ⁹Yonsei University Wonju College of Medicine, Wonju, KR, ¹⁰National Cancer Center, Goyang, KR, ¹¹Seoul National University Bundang Hospital, Seongnam, KR, ¹²ChungBuk National University Hospital, Cheongju, KR, ¹³Jeju National University Hospital, Jeju, KR,

¹⁴Wonkwang University Hospital, Iksan, KR, ¹⁵Chonbuk National University Medical School, Jeonju, KR, ¹⁶Soonchunhyang University, College of Medicine, Busheon, KR

- 12:50 - 12:55 **2660 - A population pharmacokinetic model: Assessment of pharmacokinetic similarity of HLX01 and rituximab in diffuse large B-cell lymphoma**
Y. Shi¹, Y. Qin², S. Zhao³, P. Hu⁴, X. Zeng⁴, X. Zhang⁵, W. Jiang⁵, S. Liu⁵, E. Liu⁵, K. Chai⁵, A. Luk⁵, D. Yao⁵, ¹Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, CN, ²National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ³Certara Strategic Consulting China, Shanghai, CN, ⁴Peking Union Medical College Hospital, Beijing, CN, ⁵Shanghai Henlius Biopharm, Shanghai, CN
- 12:55 - 13:05 **Discussion led by moderators**
S.T. Lim¹, M. Dreyling², M. Ladetto³, W.S. Kim⁴, ¹National Cancer Center Singapore, Singapore, SG, ²Ludwig Maximilians University - Grosshadern, Munich, DE, ³Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ⁴Samsung Medical Center (SMC), Seoul, KR
- 13:05 - 13:10 **2690 - Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup analysis of ICARIA-MM study**
T. Ikeda¹, K. Sunami², S.-Y. Huang³, M.-C. Wang⁴, Y.I. Koh⁵, C.G. Min⁶, S.-P. Yeh⁷, M. Matsumoto⁸, M. Uchiyama⁹, S. Iyama¹⁰, C. Shimazaki¹¹, J.H. Lee¹², K.H. Kim¹³, H. Kaneko¹⁴, J.S. Kim¹⁵, T.-L. Lin¹⁶, F. Campana¹⁷, K. Tada¹⁸, S. Iida¹⁹, K. Suzuki²⁰, ¹Shizuoka Cancer Center, Shizuoka, JP, ²National Hospital Organization Okayama Medical Center, Okayama, JP, ³National Taiwan University Hospital, Taipei, TW, ⁴Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TW, ⁵Seoul National University, Seoul, KR, ⁶Seoul St. Mary's Hospital, Seoul, KR, ⁷China Medical University Hospital, Taichung, TW, ⁸National Hospital Organization Shibukawa Medical Center, Shibukawa, JP, ⁹Japanese Red Cross Society Suwa Hospital, Nagano, JP, ¹⁰Sapporo Medical University School of Medicine, Sapporo, JP, ¹¹Japan Community Health care Organization Kyoto Kuramaguchi Medical Center, Kyoto, JP, ¹²Gil Gacheon Hospital, Incheon, KR, ¹³Samsung Medical Center, Seoul, KR, ¹⁴Japanese Red Cross Osaka Hospital, Osaka, JP, ¹⁵Sevrance Hospital, Seoul, KR, ¹⁶Chang Gung Memorial Hospital, Linkou, Taoyuan, TW, ¹⁷Sanofi, CAMBRIDGE, US, ¹⁸Sanofi, Tokyo, JP, ¹⁹Nagoya City University Graduate School of Medical Sciences, Nagoya, JP, ²⁰Japanese Red Cross Medical Center, Tokyo, JP
- 13:10 - 13:15 **Discussion led by moderators**
S.T. Lim¹, M. Dreyling², M. Ladetto³, W.S. Kim⁴, ¹National Cancer Center Singapore, Singapore, SG, ²Ludwig Maximilians University - Grosshadern, Munich, DE, ³Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ⁴Samsung Medical Center (SMC), Seoul, KR
- 13:15 - 13:20 **2700 - Imatinib induced toxicity and its influence on cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia**
H. Natarajan¹, L. Kumar², S. Bakhshi², A. Sharma², T. Velpandian², M. Kabra², A. Gogia², N.R. Biswas², Y.K. Gupta², ¹JIPMER - Jawaharlal Institute of Postgraduate Medical

Education and Research, Puducherry, IN, ²All India Institute of Medical Sciences (AIIMS), New Delhi, New Delhi, IN

13:20 - 13:25 **Discussion led by moderators**

S.T. Lim¹, M. Dreyling², M. Ladetto³, W.S. Kim⁴, ¹National Cancer Center Singapore, Singapore, SG, ²Ludwig Maximilians University - Grosshadern, Munich, DE, ³Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ⁴Samsung Medical Center (SMC), Seoul, KR

14:30 - 15:40 Type: Mini Oral session

Hall 405

Title: Mini Oral session - Breast cancer

Chair: Alexandru Eniu, RO; Peter Dubsy, CH; Boon Chua, AU

14:30 - 14:30 **Session DOI**

14:30 - 14:35 **LBA5 - The role of radiation therapy in clinically node-positive, pathological negative nodes after neoadjuvant chemotherapy in breast cancer patients: In sentinel node biopsy and trastuzumab era**

J.H. Joo¹, Y. Ki², S.S. Kim³, ¹Pusan National University Yangsan Hospital, Yangsan, KR, ²Pusan National University Yangsan Hospital, Yangsan-si, KR, ³Asan Medical Center, Seoul, KR

14:35 - 14:40 **260 - De-escalating axillary surgery according to neoadjuvant single or dual HER2 blockade in clinically node-positive, HER2-positive breast cancer**

C. Cha¹, D. Kim¹, J. Lee¹, S. Park¹, S.J. Bae¹, J.Y. Kim², S.G. Ahn¹, H.S. Park², S. Park², S.I. Kim², Y.U. Cho², J. Jeong¹, ¹Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, ²Severance Hospital, Yonsei University College of Medicine, Seoul, KR

14:40 - 14:50 **Discussion led by moderators**

P. Dubsy¹, B. Chua², ¹Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH, ²Peter MacCallum Cancer Center, Melbourne, AU

14:50 - 14:55 **390 - Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET)**

S.-A. Im¹, Y.-S. Yap², J. Sohn³, K.S. Lee⁴, K.H. Jung⁵, L.M. Tseng⁶, S.C. Lee⁷, K.G. Babu⁸, Y.H. Park⁹, I. Gounaris¹⁰, M. Sondhi¹¹, A. Ridolfi¹¹, J.P. Zarate¹¹, Y.-S. Lu¹², ¹Seoul National University Hospital, Seoul, KR, ²National Cancer Centre Singapore, Singapore, SG, ³Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ⁴National Cancer Center, Gyeonggi-d, KR, ⁵Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁶Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, TW, ⁷NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ⁸Curie Centre Of Oncology-Hcg Hospital Koramangala, Bangalore, IN, ⁹Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁰Novartis Pharma AG, Basel, CH, ¹¹Novartis Pharmaceutical

Corporation, East Hanover, US, ¹²National Taiwan University Hospital, Taipei, TW

- 14:55 - 15:00 **400 - Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with advanced breast cancer (ABC): Final results from EVEREXES**
Y.-H. Im¹, B. Karabulut², K.S. Lee³, A. Adhav⁴, B.-W. Park⁵, H. Yesil Cinkir⁶, J. Bowles⁷, T. Delgar Alfaro⁸, H.L. Xue⁹, S.-B. Kim¹⁰, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ²Ege University Medical Faculty, Izmir, TR, ³National Cancer Center, Korea, Seoul, KP, ⁴HCG Manavata Cancer Centre, Nashik, IN, ⁵Yonsei University Hospital, Seoul, KR, ⁶Gaziantep University Medical Faculty, Şehitkamil, TR, ⁷Novartis pharmaceutical AG, Basel, CH, ⁸Novartis, Basel, CH, ⁹Novartis, Mapletree Business City, SG, ¹⁰Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR
- 15:00 - 15:05 **20 - Protective effects of bisoprolol against acute anthracycline-induced cardiotoxicity: A randomized control study**
S. Sandoughdaran, M. Malekzadeh Moghani, N. Tabatabai, Shahid Beheshti University of Medical Sciences, Tehran, IR
- 15:05 - 15:10 **30 - Integrative analysis of metabolic subtypes in triple-negative breast cancer reveals new therapeutic strategies**
Y. Gong, P. Ji, Y. Xiao, D. Ma, M.-L. Jin, X. Hu, Y.-Z. Jiang, Z.-M. Shao, Fudan University Shanghai Cancer Center, Shanghai, CN
- 15:10 - 15:30 **Discussion led by moderators**
A. Eniu, The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO

14:30 - 16:00	Type: Multidisciplinary tumour board Title: Multidisciplinary tumour board on salivary glands and unknown primary cancers Chair: Christian Simon, CH	Hall 404
14:30 - 14:30	Session DOI	
14:30 - 14:35	Paranasal sinus: Case presentation <u>R. Nagadia</u> , SGH-Singapore General Hospital/Singhealth-Academia, Singapore, SG	
14:35 - 15:00	Paranasal sinus <u>M.L.K. Chua</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
15:00 - 15:05	Salivary glands: Case presentation <u>C.K.H. Wong</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
15:05 - 15:30	The role of chemotherapy for salivary gland cancer: Recent updates <u>B. Keam</u> , Seoul National University Hospital, Seoul, KR	
15:30 - 15:35	Unknown primary cancers: Case presentation <u>M.T.L. Tan</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
15:35 - 16:00	Unknown primary cancers <u>C. Simon</u> , Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH	

14:30 - 16:00 **Type: Collaborative session** **Hall 407**
Title: ESMO- SIOG Collaborative session: Early and advanced Colorectal Cancer in Older Adults
 Chair: Ravindran Kanesvaran, SG; Demetris Papamichael, CY

14:30 - 14:30 **Session DOI**

14:30 - 14:30 **Factors affecting decision making for the use of adjuvant therapy in older adults**

14:30 - 14:40 **Case presentation**

J. Lee, NCCS - National Cancer Centre Singapore, Singapore, SG

14:40 - 14:50 **Discussion - European perspective**

D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY

14:50 - 15:00 **Discussion - Asian perspective**

I. Tan, National Cancer Centre Singapore, Singapore, SG

15:00 - 15:15 **Q&A**

15:15 - 15:15 **Metastatic colon cancer: managing older patients and individuals with co-morbidities**

15:15 - 15:25 **Case presentation**

J. Lee, NCCS - National Cancer Centre Singapore, Singapore, SG

15:25 - 15:35 **Discussion - European perspective**

D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY

15:35 - 15:45 **Discussion - Asian perspective**

I. Tan, National Cancer Centre Singapore, Singapore, SG

15:45 - 16:00 **Q&A**

14:30 - 16:00 **Type: Mixed Proffered paper and Mini oral session** **Room 324**
Title: Mixed session - Melanoma
 Chair: Reinhard Dummer, CH

14:30 - 14:30 **Session DOI**

- 14:30 - 14:42 **3410 - Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC)**
A. Weppler¹, P. Bhave², P. De Ieso³, M. Chua³, J. Raleigh³, A. Hatzimihalis³, A. Gill⁴, S. Balachander⁵, J. Callahan³, A. Pattison⁵, A. Caneborg⁵, G. Au Yeung³, G. McArthur³, R. Hicks³, R. Tohill⁵, S. Sandhu³, ¹Peter MacCallum Cancer Center, Melbourne, AU, ²Alfred Hospital, Melbourne, AU, ³Peter MacCallum Cancer Centre, Melbourne, AU, ⁴Royal North Shore Hospital, Sydney, AU, ⁵University of Melbourne, Melbourne, AU
- 14:42 - 14:54 **3420 - Response of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: Interim analysis of prospective observational study (CREATIVE study)**
N. Yamazaki¹, A. Takahashi¹, K. Namikawa¹, T. Takenouchi², Y. Nakamura³, S. Kitano¹, T. Fujita⁴, K. Kubota⁵, T. Yamanaka⁵, Y. Kawakami⁴, ¹National Cancer Center Hospital, Tokyo, JP, ²Niigata Cancer Center Hospital, Niigata, JP, ³Saitama Medical University International Medical Center, Saitama, JP, ⁴Keio University School of Medicine, Tokyo, JP, ⁵Yokohama City University School of Medicine, Yokohama, JP
- 14:54 - 15:06 **Invited Discussant 3410 and 3420**
M.F. Harunal Rashid, NCCS - National Cancer Centre Singapore, Singapore, SG
- 15:06 - 15:16 **3430 - Global patterns in the incidence of acral melanoma: Systematic review and meta-analysis**
K. Cho¹, A. Cust², Y.M. Foo³, G. Eslick⁴, ¹University of Sydney - Nepean Clinical School, Kingswood, AU, ²University of Sydney, Sydney, AU, ³Western Sydney University, Campbelltown, AU, ⁴University of Sydney, Kingswood, AU
- 15:16 - 15:26 **3440 - Metastatic acral melanoma treatment outcomes: A systematic review and meta-analysis**
K. Cho¹, A. Cust², Y.M. Foo³, G. Eslick⁴, ¹University of Sydney - Nepean Clinical School, Kingswood, AU, ²University of Sydney, Sydney, AU, ³Western Sydney University, Campbelltown, AU, ⁴University of Sydney, Kingswood, AU
- 15:26 - 15:38 **Invited Discussant 3430 and 3440**
L. Si, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN
- 15:38 - 15:43 **3450 - Melanomas and stress patterns on the plantar surface of the foot: A systematic review and meta-analysis**
Y.M. Foo¹, K. Cho², A. Cust³, G. Eslick⁴, ¹Western Sydney University, Campbelltown, AU, ²University of Sydney - Nepean Clinical School, Kingswood, AU, ³University of Sydney, Sydney, AU, ⁴University of Sydney, Kingswood, AU
- 15:43 - 15:48 **3460 - Association of BAP1 with ATR protein and their clinical significance with patient outcome in uveal melanoma**

J. Jha¹, N. Pushker¹, M. Singh¹, L. Singh², S. Sen¹, J. Kaur¹, S. Kashyap³, ¹AIIMS - All India Institute of Medical Sciences, Delhi, IN, ²Jamia Millia Islamia, Delhi, IN, ³AIIMS - All India Institute of Medical Sciences, NEW DELHI, IN

15:48 - 15:58 **Discussion led by moderators**

C. Robert¹, P. Lorigan², ¹Institut Gustave Roussy, Villejuif, FR, ²The Christie NHS Foundation Trust, Manchester, GB

14:30 - 16:00 **Type: Educational session** **Summit 2**
Title: New advances in the management of challenging lymphomas
 Chair: Marco Ladetto, IT; Won Seog Kim, KR; Yok-Lam Kwong, HK

14:30 - 14:30 **Session DOI**

14:30 - 14:50 **Checkpoint inhibition in lymphoma management**

Y.-L. Kwong, Queen Mary Hospital, Hong Kong, HK

14:50 - 15:10 **What is the best regiment and sequencing for treatment of mantle cell lymphoma**

M. Dreyling, Ludwig Maximilians University - Grosshadern, Munich, DE

15:10 - 15:30 **New genetic insights to peripheral t cell lymphoma with a focus on angioimmunoblastic T cell lymphoma**

M. Sakata-Yanagimoto, University of Tsukuba, Tsukuba, JP

15:30 - 15:50 **Current and novel treatment options for peripheral t cell Lymphoma on genetic insights**

S.T. Lim, National Cancer Center Singapore, Singapore, SG

15:50 - 16:00 **Discussion**

14:30 - 15:30	Type: Special Session Title: What did you learn from the rad-onc session? Chair: Kevin Chua, SG; Françoise Mornex, FR	Room 311
14:30 - 14:30	Session DOI	
14:30 - 14:30	Breast cancer	
14:30 - 14:40	Clinical case <u>G. Kusumawidjaja</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
14:40 - 15:00	Discussion of the case <u>F.L. Lim</u> , Singapore, SG	
15:00 - 15:00	Lung SARB-IO	
15:00 - 15:10	Clinical case <u>F. Mornex</u> , Centre Hospitalier Lyon Sud, Pierre Bénite, FR	
15:10 - 15:30	Discussion <u>F. Hegi-Johnson</u> , Gosford Hospital, Gosford, AU	

15:45 - 16:45	Type: Special Session Title: What did you learn from the rad-onc session? Chair: Kevin Chua, SG; Françoise Mornex, FR	Room 311
15:45 - 15:45	Session DOI	
15:45 - 15:45	Oligometastatic disease (case1)	
15:45 - 15:55	Clinical case <u>K. Chua</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
15:55 - 16:15	Discussion <u>Y.Y. Soon</u> , National University of Singapore, Singapore, SG	
16:15 - 16:15	Oligometastatic disease (case2)	
16:15 - 16:25	Clinical case <u>J. Miao</u> , Sun Yat-sen University Cancer Center, Guangzhou, CN	
16:25 - 16:45	Discussion <u>C. Yip</u> , National Cancer Center Singapore, Singapore, SG	